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Cancer is the second leading cause of death in the United States. Inhibitors that
target key enzymes involved in epigenetic alterations, particularly histone deacetylases
(HDACs), are garnering interest in cancer research because of their unique ability to
reversibly induce terminal differentiation of transformed cells by influencing chromatin
structure. Through an in-house collaborative effort, derivatives of hinokitiol, a troplonerelated non-benzenoid aromatic compound, are being synthesized and characterized by
the Wright and Anderson laboratories as HDAC inhibitors (HDACi). Given the novelty of
these tropolones as antineoplastic agents, a number of biochemical and functional
studies were conducted in order to develop tropolones as isoform-selective HDACi with
potent antitumor properties. These studies include: (1) Elucidation of HDAC enzymatic
activity and inhibition, (2) Comparative analyses of antiproliferative effects in a panel of
normal dermal fibroblasts, solid tumor and hematological cell lines, (3) Evaluation of
induction and mechanisms of cell death by apoptosis, (4) Assessment of histone and
tubulin modulation, and (5) Investigation of specific gene expression. Ultimately, the
knowledge garnered from these studies will be used to develop a new library of isoformselective HDAC inhibitors with a wider therapeutic index for the treatment of both solid
tumors and hematological malignancies.
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Chapter 1
Cancer: A Global Disease Burden

A. Introduction
Cancer, alternatively known as malignant tumors or malignant
neoplasms, is a generic term that refers to a large group of more than 100
diseases that are generally characterized by uncontrolled growth and spread
of abnormal cells (1-5). Colloquially, cancer is used to describe malignant
tumors that are typically invasive and metastatic but tumors can also be
benign in which the abnormal cell growth is localized and noninvasive (1).
Globally, cancer accounted for 7.6 million deaths (approximately 13% of all
deaths) in 2008 with 70% of these cancer deaths occurring in low- and
middle-income countries (4). The World Health Organization (WHO) projects
a continuous increase in cancer deaths worldwide with an estimated 13.1
million deaths in 2030 primarily due to late detection and treatment of most
cancers in developing countries (3, 4).
There are six important factors, known as the hallmarks of cancer that
are required for cancer development and tumor progression: limitless
replicative potential, blocking of apoptosis and differentiation as well as the
stimulation of angiogenesis, proliferation, and metastasis (1, 6, 7). These
cancer hallmarks are regulated by epigenetic mechanisms including histone
acetylation which will be discussed in detail in subsequent chapters.
1

However, it should be noted that the primary cause of cancer deaths is the
process of metastasis by which abnormal cells in malignant tumors rapidly
invade and spread to other organs (1, 7).

B. Classification of cancers
Most tumors can be classified according to their origin into four major
groups: epithelial, mesenchymal, neuroectodermal and mesenchymal (1).
However, it should be noted that not all tumors fall neatly into these four
categories. Examples include melanomas which are derived from pigmented
skin cells known as melanocytes and small-cell lung carcinomas (SCLCs).
Yet, more than 80% of all cancers are carcinomas that arise from the
epithelial cell layers of the skin, lungs, gastrointestinal (GI) tract, mammary
glands, and other organs (1). Most carcinomas fall into two major groups,
squamous cell carcinomas and adenocarcinomas. Squamous cell carcinomas
refer to tumors that arise from epithelial cells forming the protective cell layers
such as in the skin and the esophagus. Conversely, many epithelia that
contain specialized cells that secrete substances into the cavities they line
such as the lung, stomach & colon generate adenocarcinomas. The
remainders of malignant tumors arise from nonepithelial tissues throughout
the body and are divided into 3 major groups: sarcomas, neuroectodermal
tumors, and hematopoietic cancers. Sarcomas, including osteosarcomas and
liposarcomas, are derived from mesenchymal cells and constitute only about
2

1% of all tumors (1). Tumors that arise from the central & peripheral nervous
systems are known as neuroectodermal tumors and include gliomas,
glioblastomas and neuroblastomas. While comprising only about 1% of
cancers, they make up 2.5% of cancer-related deaths (1).
Cancers that make up the hematopoietic or blood-forming tissues
include leukemias and lymphomas, a focal point of this dissertation.
Leukemias refer to malignant derivatives of hematopoietic cell lineages that
move freely through the circulation and unlike red blood cells are
nonpigmented. Alternatively, lymphomas refer to tumors of the lymphoid
lineages which yield B and T lymphocytes that aggregate to form solid
masses instead of the dispersed, single-cell populations of tumor cells
typically associated with leukemias. In 2008, the International Agency for
Research on Cancer (IARC), a part of the WHO, developed a new
classification of tumors of hematopoietic and lymphoid tissues into five broad
categories (8, 9): mature B-cell neoplasms, mature T-cell and NK-cell (natural
killer) neoplasms, Hodgkin lymphoma, histiocytic and dendritic cell
neoplasms, and posttransplantation lymphoproliferative disorders (PTLDs).
Mycosis fungoides (MF) is the most common form of about 15 sub-types of
skin tumors collectively known as cutaneous T-cell lymphoma (CTCL), a
mature T-cell neoplasm that will be discussed at length in this dissertation
(10).
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Each cancer type is further described by a numerical staging system
that describes the severity of a patient’s cancer based on the extent of the
primary tumor (11). The TNM system, arguably the most widely used staging
system for cancer combines a numerical staging system (0-IV) to describe the
extent of a tumor (T), the extent of spread to the lymph nodes (N), and the
presence of distant metastasis (M). A number is added to each letter to
indicate the size or extent of the primary tumor and the extent of cancer
spread. Stage 0 [Carcinoma in situ (CIS)], stage I-III (higher numbers indicate
more extensive disease) and stage IV (the cancer has spread to another
organ(s)). It should be noted that CIS are considered precursors of cancer
that may, if left untreated for a long duration, transform into a malignant
neoplasm. Alternatively, many cancer registries, such as the NCI’s-National
Cancer Institute-Surveillance, Epidemiology, and End Results Program
(SEER), use summary staging for all types of cancer into five main categories
(11):

1.
2.
3.
4.
5.

In situ: Abnormal cells are present only in the layer of cells in which they
developed.
Localized: Cancer is limited to the organ in which it began, without
evidence of spread.
Regional: Cancer has spread beyond the primary site to nearby lymph
nodes or organs and tissues.
Distant: Cancer has spread from the primary site to distant organs or
lymph nodes.
Unknown: Insufficient information for accurate stage determination.

4

C. Epidemiology of cancer
Cancer is the second leading cause of death in the United States and
a major cause of death worldwide (2-5). According to IARC reports (3), 5.6
million (44%) of the 12.7 million new cases of cancer worldwide in 2008
occurred in economically developed countries whereas 7.1 million (56%)
occurred in economically developed countries; however, of the 7.6 million
cancer deaths in 2008, 2.8 million (37%) were in developed countries
whereas 4.8 million (63%) were in developing countries. Globally, the three
leading causes of cancer deaths in men are lung, liver and stomach cancers
and concurrently breast, lung and colorectal cancers for women. In
developing countries, the three leading causes of cancer-related deaths in
men are lung, liver and stomach cancers whereas the three leading causes of
cancer-related deaths in women are breast, cervical and lung cancers.
Alternatively, in developed countries, the three leading causes of cancerrelated deaths in men are lung, colorectal and prostate cancers whereas the
three leading causes of cancer-related deaths in women are breast, lung and
colorectal cancers.
Cancer mortality rates for the US mirrors that of other developed
countries. In 2012, the estimated US cancer deaths in men were attributed to
lung cancer (29%), prostate cancer (9%) and colorectal cancers (9%)
whereas in women, lung cancer (26%), breast cancer (14%) and colorectal
(9%) were the top three causes of cancer deaths. Moreover, the American
5

Cancer Society (ACS) predicts that there will be a total of 1,660,290 new
cancer cases almost evenly divided among men (51%) and women (49%) in
2013. Furthermore, a total of 580,350 deaths from cancer, 53% in men and
47% in women, are projected to occur in the US in 2013.
The ACS further reports that cancer deaths in the US have reduced
between 1991 and 2009 by 20% overall, 24% in men and 16% in women
(12). This reduction is most likely as a result of lower smoking rates for lung
cancers, and earlier detection and treatment for prostate, colon and breast
cancers (12). While the etiology of most cancers is unknown, it is generally
agreed that heredity and environmental exposures play key roles in the onset
and progression of many cancers. For example, many Japanese immigrants
are typically at a lower risk of developing stomach cancers caused by the
bacteria, H. pylori, when compared to indigenous populations (1). Lifestyle
cancers account for almost 80% of total cancers in the US (1, 12); these
lifestyle cancers are primarily linked to tobacco consumption (example, lung
cancer) and high fat diets (example, pancreatic cancer). Furthermore, the
National Institutes of Health (NIH) estimates that the overall costs of cancer in
2007 were over $226.8 billion (2): $103.8 billion for direct medical costs (total
of all health expenditures) and $123.0 billion for indirect mortality costs (cost
of lost productivity due to premature death).

6

D. Clinical manifestations and prevention of cancer
Researchers at Keele University in the United Kingdom have shown
eight clinical features that have a higher predictive value for cancer onset and
progression particularly in older adults (13): rectal bleeding, iron deficiency
anemia, rectal examination that gives cause for concern, hematuria (blood in
the urine), hemoptysis (coughing up blood), a breast lump, postmenopausal
bleeding, and dysphagia (difficulty in swallowing). Early screening and
detection of cancers in addition to lifestyle choices such as reduction in
tobacco consumption and high fat diets are regarded as preventive measures
for cancer onset and progression. However, the risk of cancer incidence also
increases with age as a result of prolonged damage to the body’s immune
system and DNA repair systems.

E. Current trends in cancer treatment
Invasion and metastasis of malignant cells can result in death if the
spread is not controlled; however treatment methods are dependent on the
stage and type of cancer and include radiation, surgery, chemotherapy,
hormone therapy, biological therapy, targeted therapy and complementary
and alternative medicine (CAM) (14). Depending on the stage, many nonhematological cancers can be terminated by surgical exclusion whereas
radiation therapy can be used to treat virtually any type of cancer. CAM refers
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to non-standard medical practices used in the treatment of cancer including
acupuncture and yoga.
There are three broad categories of drugs for treatment of cancers and
these are cytotoxic chemotherapy, hormone therapies and targeted therapies
(14). Cytotoxic chemotherapy refer to drugs that kill rapidly diving cells in
general and constitutes the most conventional class of drugs for cancer
treatment. Cytotoxic chemotherapy drugs are subdivided into six major
classes. The first are alkylating agents that directly damage DNA by crosslinking DNA strands via the addition of alkyl groups directly to guanine bases
in DNA thus preventing DNA replication and concurrently RNA transcription.
Alkylating agents, particularly the nitrogen mustards, were the first reported
chemotherapy drug but are no longer widely used due to toxicity issues.
However, the FDA approved Treanda (generically known as bendamustine) a
nitrogen mustard, for the treatment of chronic lymphocytic leukemias and
lymphomas in 2008 (15). It should be noted that alkylating agents do not
selectively damage malignant cells and as such are associated with a broad
range of local and systemic toxic effects; long term use is associated with
damage to the bone marrow and onset of second cancers particularly bladder
cancer and acute leukemia. Platinum-containing drugs, particularly cisplatin
used in the treatment of testicular cancer, are often grouped with alkylating
agents because they exert a similar mechanism of action but are less likely to
cause leukemias (16).
8

Antimetabolites are a second class of antineoplastic drugs that function
as cytostatics because they interfere with DNA and RNA production and
concurrently cell division and tumor growth. For example, Efudex (generically
known as 5-Fluorouracil or 5-FU) is a pyrimidine analog that is classified as a
suicide inhibitor because it works through an irreversible inhibition of
thymidylate synthase, an enzyme that plays a key role in DNA synthesis and
repair (17). 5-FU is an established form of treatment for colorectal and
pancreatic cancer; But 5-FU is also associated with toxicity and a range of
side effects including myelosuppression and diarrhea.
Anti-tumor antibiotics are a third class of cancer chemotherapy drugs
that consist of five major drug groups: anthracyclines, dactinomycin,
plicamycin, mitomycin, and bleomycin. The anthracyclines are by far the most
popular anti-tumor antibiotics and have been shown to be effective against
more types of cancer than any other class of chemotherapeutic agents (18,
19). The prototypical anthracyclines, Daunomycin cerebudine
(daunorubicin)—the first reported anthracycline—and Adriamycin
(doxorubicin), are both isolated from the bacterium, Streptomyces peucetius
but there are currently over 2,000 known analogs of doxorubicin (18).
Anthracyclines work by intercalating DNA thus interfering with enzymes
involved in DNA replication. Anthracyclines are used in the treatment of a
wide variety of cancers including leukemias, lymphomas, breast, uterine and
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lung cancers. However, the biggest limitation to their use is cardiotoxicity
(19).
Topoisomerase (ToP) inhibitors constitute the fourth class of
antineoplastic drugs; as the same suggests, these inhibitors interfere with the
action of topoisomerases, which are ubiquitous enzymes that control DNA
supercoiling and entanglements structure by catalyzing the breaking and
rejoining of DNA strands (20). The mechanism of action (MOA) of ToP
inhibitors also classifies them as pharmacological inhibitors of poly (ADPribose) polymerase (PARP) used for the therapy of many diseases including
cancer (20, 21). There are two major classes of topoisomerases (I and II) and
ToP inhibitors are typically classified based on the class of topoisomerase
that is inhibited (20). For example, Camptosar (irinotecan) is a topoisomerase
I inhibitor that is typically combined with 5 F-U for the treatment of colon
cancers. Alternatively, Etopophos (Etoposide, etoposide phosphate or VP-16)
is a topoisomerase II inhibitor that is often used in combination with other
chemotherapy drugs to treat many cancers including lung cancer and
testicular cancer. However, it should be noted that treatment with
topoisomerase II inhibitors is associated with an increased risk of a second
cancer — acute myelogenous leukemia (AML) (14).
Mitotic inhibitors are a fifth class of cancer chemotherapeutic drugs
that are typically plant alkaloids and other natural product derivatives. Mitotic
10

inhibitors prevent the process of mitosis through microtubule polymerization
thus preventing cancerous growth. Mitotic inhibitors are used in the treatment
of many cancers including breast, lung and myelomas. For example, the
taxanes, Taxol (paclitaxel) and Taxotere (docetaxel) are commonly used for
the treatment of breast and lung cancers (22). However, these mitotic
inhibitors are known for their potential to induce peripheral nerve damage
which can be a dose-limiting side effect (14).
Corticosteroids constitute the sixth class of cancer chemotherapy
drugs and refer to natural steroidal hormones and steroidal-like drugs that are
used to destroy malignant neoplasms, particularly lymphomas, leukemias and
lymphomas. Corticosteroids are also widely used for their anti-emetic
properties to prevent nausea and vomiting caused by chemotherapy.
Corticosteroids such as prednisone can also be used to prevent
hypersensitivity prior to administering chemotherapy (14).
There are many other drugs, such as differentiating agents, used in the
treatment of cancer that are not classically cytotoxic chemotherapeutic drugs.
Differentiating agents are based on the concept that cancer cells are
immature and as a result less differentiated than normal cells thus these
differentiating agents are therapies that induce cancer cell to resume the
process of maturation. Even though differentiation therapies do not destroy
cancerous cells, they restrain cell growth thus allowing for the use of more
11

conventional chemotherapy drugs. For example, retinoids have been
successfully used in the treatment of acute promyelocytic leukemia (23, 24).
Hormonal therapies constitute the second broad classification of drugs
used in the treatment of cancer. Hormone therapy include sex hormones or
hormone-like drugs that change the action or production of specific
hormones, particularly steroid hormones, or drugs that inhibit the production
or activity of such hormones known as hormone antagonists. Hormone
therapies are used to slow the growth of breast, prostate, and endometrial
(uterine) cancers because these sex hormones are powerful drivers of gene
expression in these cancers; therefore the drugs work by preventing
cancerous cells from using the hormones needed for growth or by preventing
the body from making the hormones (14). Hormonal therapies are largely
subdivided into inhibitors of hormone synthesis, hormone receptor
antagonists and hormone supplements. Aromatase inhibitors and
Gonadotropin-releasing hormone (GnRH) analogs are considered inhibitors of
hormone synthesis (25-27). Aromatase inhibitors are used primarily in the
treatment of breast cancer in post-menopausal women and include Arimidex
(anastrozole) (25). Analogs or agonists of GnRH, also known as luteinizing
hormone-releasing hormone (LHRH), induce a chemical castration that
involves complete suppression of testosterone production from the male
testes or complete suppression of the production of estrogen and
progesterone from the female ovaries (26, 27). For example, Lupron
12

(leuprolide) and Zoladex (goserelin) are used in the treatment of hormoneresponsive cancers: breast, prostate, and estrogen-dependent conditions
such as endometriosis and uterine fibroids (27).
Hormone receptor antagonists include antiandrogens and selective
estrogen receptor modulators (SERMs). Antiandrogens like Eulexin
(flutamide) work by blocking the androgen receptor (28) whereas SERMs
work by blocking the estrogen receptor (29, 30). However, some SERMs like
tamoxifen are only partial agonists that can actually increase estrogen
receptor signaling in some tissues, such as the endometrium (29, 30).
Tamoxifen is currently first-line treatment for nearly all pre-menopausal
women with hormone receptor-positive breast cancer (29, 30). Hormone
supplementations include androgens like Halotestin (fluoxymesterone) that is
used in the treatment of breast cancers (31).
Targeted therapies are becoming increasingly more popular in cancer
treatment as a result of a better understanding of proteins through major
discoveries in the field of molecular oncology (1, 14). Targeted therapies can
be used as part of the main treatment, or they may be used after treatment to
maintain remission or decrease the chance of recurrence. Targeted therapies
work by blocking the growth of cancer cells by interfering with specific protein
targets that are needed for carcinogenesis and tumor growth. For example,
Gleevec (Imatinib Mesylate) is a tyrosine kinase inhibitor that was rapidly
13

approved by the FDA in 2001 for the treatment of a specific abnormality
associated with chronic myelogenous leukemia (CML) known as the
Philadelphia chromosome-positive CML (32, 33). Gleevec has also been
approved for the treatment of gastrointestinal stromal tumors (GIST) and for
use in children with acute lymphoblastic leukemia (ALL) (34, 35).
Targeted therapies can either be small molecule inhibitors like Gleevec
or imunotherapies such as vaccines and monoclonal antibodies. Cancer
immunotherapies employ the use of the immune system to reject cancer by
stimulating a patient’s immune system to attack the malignant tumor cells.
Compared to other types of cancer treatments, immunotherapies are
relatively new and are typically classified as either active or passive (14).
Active immunotherapies stimulate the body’s own immune system to fight
cancers. Active immunotherapies are usually administered via immunization,
such as the prostate cancer vaccine, Provenge (generically known as
sipuleucel-T) that was the first FDA therapeutic cancer vaccine that was
approved in 2010 (36). Alternatively, passive immunotherapies utilize
therapeutic antibodies as drugs, in which case the patient's immune system is
recruited to destroy tumor cells by the therapeutic antibodies For example,
Herceptin (trastuzumab) is a monoclonal antibody that selectively binds with
high affinity to the extracellular domain of the human epidermal growth factor
receptor 2 protein (HER2) that is implicated in many breast cancers (14).
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F. Conclusions
Cancers are complex diseases that present significant financial and
emotional burden due to high prevalence worldwide and concomitantly high
mortality rates particularly in developing countries. While efforts are currently
in place for more effective prevention and treatment of cancer, there are
many limitations that have reduced cancer survival including late stage
screening, expensive treatment costs, toxicity and debilitating side effects.
Reductions in cancer mortality rates in the US are attributed to lower smoking
rates and earlier screening and treatments. Targeted therapies are becoming
more popular because of improved efficacy particularly when compared to
cytotoxic chemotherapeutic agents that show poor selectivity between
proliferating cells in cancerous and normal tissues.
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Chapter 2
Biological and clinical significance of histone deacetylases (HDACs)

A. Introduction
Epigenetic alterations of chromatin structure are implicated in
carcinogenesis and malignant transformations and refer to heritable changes
in gene expression that are not accompanied by changes in DNA sequence
(1, 2). The fact that histone acetylation is a key component in the regulation of
gene expression has inspired the study of enzymes known as histone
deacetylases (HDAC) because of their role in changing the accessibility of
DNA to regulatory proteins (3-11). HDACs possess complex, multifunctional
roles including transcriptional regulation, regulation of tubulin and cytoskeletal
function, control of cardiac growth, regulation of thymocyte development and
facilitation of DNA repair (12-16). In this chapter, we will discuss the biological
and clinical relevance of HDACs as targets for the treatment of cancer and
other key therapeutic areas.

B. HDACs are key players in the regulation of gene expression
The precise organization of chromatin is essential for many cellular
processes, including transcription, replication, repair, recombination and
chromosome segregation (3, 10, 16-19). Dynamic changes in chromatin
structure are directly modulated by post-translational modifications of the
amino-terminal tails (3); these covalent modifications typically alter the
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interaction of the highly basic histone tails with the negatively charged DNA
backbone or with other chromatin-associated proteins that may be required
for different downstream cellular processes (3). Post-translational
modifications of histones include phosphorylation, methylation, ubiquitylation,
sumoylation, and acetylation (3, 6, 17-21).
Histone acetylation is considered to be the most studied posttranslational modulation of nucleosomes (21, 22). Histone acetylation is
regulated by histone acetyltransferases (HATs) and results in an open
chromatin configuration and gene transcription whereas histone deacetylation
is regulated by HDACs and results in gene silencing (3, 20, 23). Hypoacetylated histones increase the positive charge of histone and condense the
chromatin while hyperacetylated histones neutralize the electrostatic charge
thus resulting in chromatin relaxation (20, 23). Moreover, many transcription
activators such as the p300/CBP complex and transcription repressors like
the retinoblastoma protein (pRb) have been associated with HATs and
HDACs respectively (20,25 ). Furthermore, the balance between acetylated
and nonacetylated proteins is controlled by the activity of HDACs and HATs
(3, 17, 20, 21, 23-25).
Many recent studies have shown that inhibition of HDACs elicits
anticancer effects in several tumor cells by inhibition of cell growth and
inducing cell differentiation (6, 10, 19, 22, 23, 24, 26-29). HDAC inhibition is
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also associated with neuroprotective effects in both in vivo and in vitro models
of brain disorders (11, 25, 27-29). Furthermore, HDACs are also garnering
interest in stem cell research since HDAC inhibition results in a two- to
fivefold increase in the efficiency of reprogramming of somatic cells to a
pluripotent state (12, 27-29). Inhibition of HDAC enzymes also results in the
alteration of the response to ischemic injury in the heart and reduces infarct
size which suggests novel therapeutic approaches for acute coronary
syndromes (13, 27). HDAC inhibitors (HDACi) have also found applications
as anti-inflammatory agents (27-29) and in the treatment of autoimmune
disorders including colitis (27, 30).

C. Classification and distribution of HDACs
HDACs, also known as lysine deacetylases (KDACs) that more aptly
describes their function instead of their targets, are a family of enzymes that
catalyze the reversible removal of acetyl groups on lysine residues of
proteins, including the core nucleosomal histones H2A, H2B, H3, and H4 (6,
24). There are 18 known HDAC isozymes classified into four groups on the
basis of phylogenetic and functional analysis (4, 15, 17-20, 22, 24,26, 31-40).
The most studied HDACs are the classical HDACs (Table 1) that are zincdependent amidohydrolases and consist of 11 enzymes sub-divided into
class I (HDAC-1,-2,-3, &-8), IIa (HDAC-4,-5, -7 & -9), IIb (HDAC-6 & -10) and
IV (HDAC11). The Class III HDACs require nicotinamide adenine
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dinucleotide (NAD+) as a co-substrate and consist of the silent information
regulator 2 (SIR2)-related-proteins (Sirtuins; SIRT) SIRT 1-7 (7, 15, 16, 26,
31, 32).
Class I HDACs are approximately 400-500 residues long, and consist of
HDAC1, -2, -3, and -8; class II HDACs are approximately 1,000 residues long
and are subdivided into class IIa and IIb HDAC enzymes.

Table 1: Biological functions of class I and class II HDACs(1,8).
HDAC
Isoform
Biological Functions
Class
HDAC1
Proliferation; gene regulation; apoptosis
Class I
HDAC2
Proliferation; cardiac morphogenesis
HDAC3
Proliferation; regulation of Interferon expression
HDAC8
Proliferation; regulation of contractile capacity;
telomerase activity
HDAC4
Skeletogenesis; chondrocyte hypertrophy;
Class IIa
mediator of neuronal death; repression of retinoid
signaling; stabilization of Hypoxia-inducible factor-1
(HIF-1)
HDAC5
Suppression of cardiac stress; cardiac
development
HDAC7
Regulation of apoptosis in developing
thymocytes
HDAC9
Cardiac development
Class IIb
HDAC6
Proliferation; regulation of tubulin acetylation;
heat shock protein (Hsp90) acetylation

Class IIa HDACs consists of HDAC4, -5, -7, and -9; HDAC6 and
HDAC10 constitute the class IIb HDACs and are the only HDACs that have
two catalytic sites that are believed to work independently (33). HDAC11, the
lone member of class IV, is made up of 347 amino acids and shares
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conserved residues in its catalytic site with class I and II HDACs (7, 15, 16,
28, 19, 26).
HDACs as well as HATs are recruited to transcription factor protein
complexes without directly binding to DNA (3, 7). In fact, with the exception of
HDAC8, HDACs exist as multiprotein complexes that include co-repressors
such as Sin3, nuclear receptor co-repressor (N-CoR), silencing mediator for
retinoic acid and thyroid hormone receptor (SMRT), activators, chromatinremodelling proteins and HATs (7, 26, 38, 40-42). For example, the
enzymatic activity of HDAC3 is greatly enhanced through interaction with the
SMRT/N-CoR repressor complex (38, 42) whereas HDAC1 and HDAC2 are
recruited together into three main transcriptional complexes: Sin3A, NuRD
and CoREST (40, 41).
With the exception of HDAC8, class I HDACs are ubiquitously
expressed in various human tissues, located in the nucleus, and function as
transcription corepressors (6, 7, 19, 20, 39). However, HDAC8 expression is
restricted to primary cells that show smooth muscle differentiation and
possibly shifts between the nucleus and cytoplasm potentially implying a
different biological function for HDAC8 (19, 26, 32, 35, 36). Class II HDACs
are selectively distributed in human tissues; class IIa enzymes shuttle
between the cytoplasm and the nucleus whereas class IIb HDACs are
primarily located in the cytoplasm. Three of the class III sirtuins (SIRT1,
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SIRT6-7) are localized in the nucleus, SIRT3-5 are localized in the
mitochondria and SIRT2 is a cytoplasmic protein (14). HDAC11, the unique
member of class IV, resides in the nucleus and is found primarily in the brain,
heart, skeletal muscle and kidney (7).

D. HDAC8 as a model for the elucidation of target-ligand interactions
HDAC8 is a 377 residue class I enzyme that lies close to the
phylogenetic boundary between class I and class II HDACs, and maps to the
X chromosome (16, 18, 19, 26, 35). The three dimensional crystal structure of
human HDAC8 (Figure 1) complexed with structurally diverse hydroxamic
acid HDAC inhibitors was first solved in 2004 by two independent groups
(PDB ID: 1W22 and 1T64; 16, 19). Since then, the HDAC2 foot pocket and
catalytic domains of HDAC4 and HDAC7 have been solved (26).
Furthermore, the crystal structure of the tetrameric oligomerization domain of
HDAC3 complexed with transducin (beta)-like 1-linked protein (TBL1), SMRT,
and G protein pathway suppressor 2 (GPS2) was recently solved (38, 42).
However, with the exception of HDAC8, functional HDACs are not found as
single polypeptides, but as high-molecular weight multiprotein complexes (6,
7, 19, 20, 39); therefore, from a structural biology perspective, HDAC8 is the
best model for the study of catalysis and inhibition of HDAC enzymes (19,
26).
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Figure 1: Ribbon diagram of the HDAC8:TSA complex showing the HDAC8 fold,
the TSA molecules (blue and pink) and the zinc ion (orange) (PDB ID 1T64; 16).

X-ray crystallographic studies of HDAC8 have revealed that the
architecture of the HDAC8 active site, likely to be common to all zincdependent HDACs, shares a 30% sequence identity (Figure 2) with the
archeobacterial homolog of eukaryotic deacetylases (HDLP) (16,19, 37).
HDAC8 also has a distinct inhibition pattern that differs from that of
HDAC1 and -3, which both share 43% sequence identity with HDAC8
(19). Evaluation of HDAC inhibition by a diverse class of HDACi including
TSA shows greater than a 300-fold difference between inhibition of either
HDAC1 or HDAC3 when compared to HDAC8 inhibition (19).
Furthermore, sequence alignments of HDAC8 with other class I HDACs
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suggest that the other isozymes possess longer L1 loops that may result
in more conformationally static active sites for HDAC-1, -2, and -3 when
compared to HDAC8 (16). The structure of HDAC8 consists of a compact
α/β-domain composed of a central eight-stranded parallel β-sheet (Figure
1) flanked by 13 α-helices (19, 26).

Figure 2: Stereo diagram (16) depicting superposition of the HDAC8:TSA
structure (cyan) and the L1 loops of HDAC8 (green) and HDLP (yellow).

The asymmetric unit of HDAC8 (Figure 1) consists of two molecules
packed as a head-to-head dimer (19). Each molecule binds one Zn2+ ion
and two K+ ions and the presence of K+ ion is hypothesized to stabilize the
oxyanion formed in the transition state of the deacetylation reaction (19,
26). The dimeric arrangement in the HDAC8 crystal is mediated by the two
capping groups (pyridine and thiophene) of each hydroxamic acid inhibitor
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molecule stacking against each other (19). This phenomenon explains
why initial attempts to crystallize the enzyme without a bound ligand,
otherwise known as the apoprotein, was unsuccessful (16, 18-19); this is
because each capping group interacts with protein residues, Pro-273 and
Tyr-306, of the opposite molecule, forming an extensive hydrophobic
sandwich and giving rise to the twofold axis relating the two molecules in
the asymmetric unit (19).
The HDAC8 active site displays characteristics of both serine and
zinc proteases, and contains two histidine-to-aspartate (His–Asp) dyads
with both histidine residues apparently acting as a general acid–base
catalytic pair (Figure 3; 18, 19, 26, 35, 37). It is hypothesized that the
catalytic metal ion (zinc) and a general base (Histidine142; H142)
activates the water molecule in the HDAC active site (Figure 3) for a
nucleophilic attack on the carbonyl group of the susbstrate (17, 26). The
tetrahedral intermediate is stabilized by the formation of a hydrogen bond
with Y306 (Phenylalanine306), and a general acid (H143) protonates the
lysine leaving group and catalyzes the formation of the products from the
tetrahedral intermediate (17).
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Figure 3: Molecular surface representation and architecture of the HDAC8 active site
(19). Stick representations are used to depict residues important in catalysis and
inhibitor binding as well as the inhibitor and the modeled acetyllysine substrate. Oxygen
(red); nitrogen (blue); sulfur (orange); and carbon (gray).

The crystal structure of HDAC8 has led to a firmer understanding of how
catalysis occurs within the HDAC family of enzymes but also revealed unique
features of HDAC8, including conformational flexibility proximal to the binding
site pocket mediated by the L1 active site loop (Figure 2) and the absence of a
50-111 amino acid C-terminal domain that extends from catalytic domain (16,
18, 19).
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E. Diverse application of HDACi in several therapeutic areas
In recent years, many HDAC inhibitors (HDACi) have either been
approved by the FDA or are in clinical development for cancer treatment
particularly due to the fact that these HDACi exert minimally drastic side
effects when compared to conventional chemotherapy (5-9, 14, 23, 27-29, 31,
34, 39, 43-45). However, an increasing number of structurally diverse HDACi
have also been identified for the treatment of many other diseases, including,
neurodegeneration, metabolic, inflammatory and autoimmune disorders,
infectious diseases, and cardiovascular diseases (25, 27-29). Yet, the
mechanisms of action of these HDACi for the treatment of most diseases
remain poorly understood thus limiting advancement in clinical development
and therapeutic administration (6, 28, 46, 47)
There are four major classes of HDAC inhibitors (Table 2) currently in
clinical development: hydroxamic acids, short chain fatty acids, cyclic
tetrapeptides and benzamides (4, 15). They all share a common
pharmacophore pattern consisting of: a metal binding domain that complexes
zinc; a linker domain that mimics the substrate and occupies the active site
channel; a connecting unit, and a surface domain that makes contact with the
rim of the catalytic pocket (15). All HDAC inhibitors (HDACi) inhibit HDAC
enzymes in a reversible fashion, except for the epoxides (trapoxin and
depudesin), which inhibit HDACs irreversibly via covalent binding to the
epoxyketone group (4). Most HDACi, including the FDA-approved vorinostat,
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are relatively nonselective inhibitors of all or most HDAC enzymes but are
permeable to the blood-brain barrier (BBB) (25); this permeability to the BBB
is an attractive feature particularly for the treatment of neurodegenerative
diseases (25).
The largest class of HDAC inhibitors with the most promising
therapeutic potential is the hydroxamic acids (4, 6, 7). In fact, seven of the
twelve HDACi including currently undergoing clinical trials for the treatment of
cancer, including panobinostat and belinostat are hydroxamic acids (6, 9, 23).
Zolinza, (generically known as vorinostat and suberoylanilide bishydroxamide
(SAHA); Table 3), a hydroxamic acid HDACi was approved by the U.S. Food
and Drug Administration (FDA) in 2006 for the treatment of cutaneous T-cell
lymphoma (6-9, 23, 48). Vorinostat is currently in clinical trials as
monotherapy or in combination therapy for the treatment of both solid and
hematological cancers (6, 48).
The use of the potent, antifungal hydroxamic acid HDACi, Trichostatin
A (TSA) and its analog, vorinostat, in the treatment of colitis in mice results in
an increase in the expression of thymic-derived Foxp3+ T regulatory cells
(Tregs) presumably as a result of HDAC9 inhibition (44). Administration of
TSA in a middle cerebral artery occlusion model of brain ischemia resulted in
a forty eight percent (48%) reduction in injury volume in treated animals when
compared to non-treated models (13).
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Table 2: Classification, potency and clinical application of key HDACi

Group

Hydroxamic
acids

Structure

HDAC
Inhibition

In vitro
IC50
range

Clinical Application

Class I & II:
TSA, SAHA

nM





HDAC6 only
(class IIb):
Tubacin
Short-chain
fatty acids

Cyclic
tetrapeptides/
[4]
epoxides





Class I & IIa:
Butyrate,
VPA

mM

HDAC-1 &-2
(class I):
Romidepsin

nM

HDAC-2& -3
(class I):
Apicidin

Benzamides

HDAC1: MS275

31

μM








Neurodegenerative
Neurological
Gastroentereology
(colitis)
Cardiovascular
HIV
Cancer



Neurodegenerative
Neurological
Anti-epileptic
Bipolar disorders
HIV
Stem cell research
(lupus)
Cancer



Cancer



Cancer

Treatment of wild-type mice as well as of mouse models of
neurodegenerative diseases show that the inhibition of HDAC2 by vorinostat
restored learning ability and promoted the retrieval of long-term memory more
potently than the fatty acid HDACi, sodium butyrate (11). However, studies have
shown that TSA, like many HDACi, have basal toxicity and prolonged treatment
at high doses often leads to neuronal death thus limiting their neuroprotective
effects (25, 49, 50).
Sodium phenylbutyrate (PB), a fatty acid HDACi, has also been shown to
promote cytostasis and differentiation in myelodysplastic syndrome and acute
myeloid leukemia (AML; 44). These effects may possibly be as a result of
HDAC8 inhibition since HDAC8 has been shown to associate specifically with the
inv(16) fusion protein found in AML(19, 51); besides, TSA has already been
shown to impair inv(16)-mediated repression (19, 51). The fatty acid HDACi,
valproic acid (VPA), is a pan-HDACi used in the treatment of epilepsy and bipolar
disorders and shows promise in the treatment of both solid tumors and
hematological malignancies (7, 25, 45, 48). VPA has also been shown to
possess neuroprotective effects, presumably as a result of reducing
excitotoxicity, in cultured primary neurons that are induced by exposure to
glutamate (25, 48-50); glutamate-induced excitotoxicity is implicated in the
pathophysiology of many neurodegenerative diseases such as Parkinson’s
disease suggesting a promising therapeutic application for VPA (11, 25, 48-50).

32

Moreover, HDAC2 inhibition has been shown to facilitate learning and
memory in wild-type mice as well as in mouse models of neurodegeneration
(11). Thus, the neuroprotective effects of VPA may be attributed to HDAC2
inhibition. VPA is also currently in clinical studies for the treatment of HIV and
retinitis pigmentosa (45, 48, 52, 53). VPA has been shown to be more potent
than the hydroxamates, TSA and vorinostat, in the reprogramming of somatic
cells to a pleuripotent state possibly by the collective effects of upregulation of
embryonic stem (ES)-specific genes and the downregulation of mouse
embryonic fibroblasts (MEF) as a result of HDAC inhibition (12).
The bicyclic peptide, Istodax (generically known as Romidepsin; Table
3) was the second HDACi to be approved by the FDA in 2009 for the
treatment of CTCL (6, 47). MS-275, a benzamide derivative, is in Phase I
clinical trials in the treatment of several forms of cancer but no full report has
been published to date (7). Entinostat, a synthetic benzamide derivative, has
been shown to selectively inhibit two class I HDAC enzymes, HDAC1 and
HDAC3 (6). Entinostat and mocetinostat are isoform-selective, synthetic
benzamide derivatives that are currently in clinical trials for the treatment of
both solid and hematological cancers (2, 6, 48). Entinostat is also in clinical
trials for the treatment of relapsed or refractory Hodgkin lymphoma (6).
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Table 3: Comparative analysis of the two FDA-approved HDACi
Category

HDACi

Brand name

Zolinza (Merck & Co., Inc.)

Generic names (s)

Vorinostat; SAHA

Approval Date:

October 2006

Structural Class
Structure

Istodax (Gloucester Pharma)
Romidepsin
November 2009

Hydroxamic acid

Cyclic tetrapeptide

[4]

HDAC inhibition
Source

Clinical Indication

Mode of Action

Adverse effects

Broad-spectrum

Class I-specific

Trichostatin A (TSA ) Analog
Note: TSA isolated from the
bacterium Streptomyces
hygroscopius
CTCL (progressive or recurrent
or following 2 systemic therapies;
based on 2 clinical trials with 107
patients total)
Not fully characterized but shown
to:
1. Cause accumulation of
acetylated histones in vitro.
2. Induce cell cycle arrest and/or
apoptosis of some transformed
cells.

Isolated from the bacterium
Chromobacterium violaceum

1. Gastrointestinal symptoms:
diarrhea, nausea, anorexia,
weight decrease, vomiting,
constipation.
2. Constitutional symptoms:
fatigue, chills.
3. Hematologic abnormalities:
thrombocytopenia (low platelet
count), anemia.
4. Taste disorders: dysgeusia, dry
mouth.

1. Gastrointestinal symptoms:
nausea, vomiting, anorexia.
2. Constitutional symptoms:
fatigue.
3. Hematologic abnormalities:
anemia, thrombocytopenia,
neutropenia (low white blood
cells), and lymphopenia.
4. Other adverse effects:
electrocardiogram (ECG)
changes.
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CTCL (in patients who have
received at least 1 prior systemic
therapy; based on 2 clinical trials
with 167 patients total)
Not fully characterized but shown
to:
1. Induce cell differentiation, cellcycle arrest and apoptosis.
2. Inhibit hypoxia-induced
angiogenesis and depletes
several oncoproteins.

F. HDACs are validated targets for the treatment of cancer
The increased focus on HDAC inhibitors (HDACi) for cancer treatment
stems from their ability to alter several cellular functions known to be
important in cancer cells (4, 6, 8, 14, 15, 19, 26). HDACi have demonstrated
anticancer efficacy across a range of malignancies, especially in the
hematological cancers resulting in the approval of two HDACi for CTCL
treatment (16). The mechanisms of the antiproliferative effects of HDACi is
not fully elucidated but generally involves the accumulation of acetylated
histones and non-histone protein substrates that are involved in the regulation
of gene expression, cell proliferation and cell death (7).
HDACs have been shown to play a significant role in transcriptional
regulation and regulation of tubulin and cytoskeletal function (54-56). HDAC1,
HDAC2, HDAC3, and HDAC9 have been shown to coimmunoprecipitate with
the ATP-dependent heat shock protein-70 (Hsp-70) resulting in inhibition of
the chaperone activity of the protein (9, 30). HDAC6 has been shown to
deacetylate the structural protein, α-tubulin, resulting in a modulation of cell
motility (9, 56). HDACs are known to associate with a number of well
characterized cellular oncogenes and tumor-suppressor genes such as the
retinoblastoma protein, leading to an aberrant recruitment of HDAC activity,
which in turn results in changes in gene expression (4). Overexpression of
HDACs has also been observed in different tumor types including gastric,
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colorectal, breast and prostate cancers as well as hematological cancers like
leukemias and lymphomas (9, 19, 31, 35, 39, 57-60).
Gene knockout experiments have shown that class 1 HDACs are
important in cell survival and proliferation whereas class II HDACs have
tissue-specific roles (15, 19, 36). Class I enzymes, especially HDACS -1, -2
and -3, are the most frequently expressed in cancers including lymphoid cell
lines and primary tumors (4, 7, 14, 26, 32, 56). Evidence for increased
expression of the class I HDACs, HDAC-1, -2 and -3, have also been
reported in colon cancer (58, 59). Overexpression of HDAC1 has been
reported in approximately 70% of all prostate cancer lesions (57, 60);
whereas, overexpression of HDAC8 has been observed in a common form of
acute myeloid leukemia (16, 19). Overexpression of the class II enzyme,
HDAC10 has also been reported in gastric cancer (56).

G. Therapeutic limitations of broad-spectrum HDACi
It has been demonstrated that broad-spectrum inhibition of several
HDAC isoforms disrupt multiple cellular processes that depend on protein
acetylation (55); however, some of these processes may not be involved in
the maintenance of tumor progression thus broad-spectrum HDAC inhibition
increases the potential for toxicity (23, 55). A recent high-throughput profiling
of the potency of a panel of structurally diverse small HDACi against all class
I and II HDAC enzymes showed an apparent redundancy of these HDACi
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such as vorinostat towards inhibition of toward HDAC-1, -2, and -3 but the class
IIa enzymes are not targeted by most HDACi tested (6).
Furthermore, most HDACi, especially the hydroxamic acids, bind the
zinc ion in the HDAC active site and show limited isoform selectivity within or
between class I, II and IV HDACs (19). The two FDA-approved HDACi,
vorinostat and romidepsin, like most HDACi currently in clinical development,
are nonselective inhibitors of all or most of class 1 and class II HDACs
resulting in significant adverse side-effects that become dose-limiting in
clinical trials (6, 9, 19).

H. Current trends in pre-clinical and clinical development of HDACi:
Isoform-selective HDACi and combination therapies
We have recently reported increased development of isoform-selective
HDACi presumably as a result of superiority in the reduction of toxic effects
as well as improved efficacy (48). However, seven of the twelve HDAC
inhibitors currently in clinical development are hydroxamic acids (15); this
hydroxamic acid functionality binds to a zinc ion in the active site displaying
little isoform selectivity between class I, II and IV HDACs (16). Furthermore,
the presence of the strong metal chelating group in hydroxamic acids can
result in inhibition of other metalloenzymes or sequestration of metal ions
(16).
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Isoform-selective HDAC inhibitors (HDACi) offer the ability to alter
distinct pathways, which are more specifically involved in the tumor
phenotype and could therefore provide a wider therapeutic index compared
with the broad spectrum HDACi currently in clinical development (4, 23, 37).
There are several factors that have hindered the development of potent
isoform-selective HDAC inhibitors (HDACi); these factors include similarity
between the catalytic sites of HDAC enzymes, and until recently, lack of X-ray
crystal structures (7, 19). A ranking of the substrate selectivity of HDACs
using a library of fluorogenic tetrapeptide substrates suggests that HDAC8
has the highest substrate selectivity followed by HDAC-1, -3 and -6 (37, 61).
Differences in catalytic activity and even substrate selectivity can be exploited
in developing isoform-selective class I and possibly class II HDACi with a
wider therapeutic index against more aggressive and more common forms of
cancer (10, 37, 61).
Three-dimensional models for four class I histone deacetylases (HDAC1, -2, -3, and -8), built using homology modeling and docked to three widely
studied hydroxamic acid HDACi (TSA, CG-1521, and SK683) shows small
differences in the shape and charge distribution around the opening of the
active site of the enzymes (10). These observations indicate that it is
possible to develop HDAC8-selective inhibitors, whereas development of
isoform-selective inhibitors between HDACs that show more sequence
homology, such as HDAC1 and -3, may be more challenging (10). However,
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Arqule Inc. has reported a series of aliphatic hydroxamic acids that show
selectivity towards HDAC1 (48). Furthermore, screens of large compound
libraries have yielded selective inhibitors of HDACs 1, 4, 6, and 8 but
structural determinants of selective HDAC inhibition remain unknown (7, 9,
45, 48).
It is generally agreed that combination of chemotherapy or
chemoradiotherapy is preferable over single-agent therapy in order to
maximize treatment efficacy and concurrently reducing toxicity (6, 7, 9).
Various preclinical and clinical studies have shown that HDACi can improve
the efficacy of several chemotherapeutic and radiotherapeutic treatments
including targeted anticancer drugs, cytotoxic agents, antiangiogenesis drugs,
or radiation therapy (6). This improvement in efficacy may be attributed to
synergistic or additive effects particularly given that these HDACi exert
relatively minor side effects when compared to conventional chemotherapy
(6, 28). Furthermore, combination therapies may also help to overcome
potential mechanisms of drug resistance to HDACi possibly by inducing
caspase-independent cell death rather than autophagic cell death as has
been reported for combination of the FDA-approved anti-estrogen drug,
tamoxifen, with vorinostat in tamoxifen-resistant MCF-7 (TAMR-MCF-7) cells
xenograft model (6, 62). Combination of vorinostat with tamoxifen has been
shown to reverse hormone resistance in a phase II study of patients with
hormone therapy-resistant breast cancer (63). Combination of tamoxifen with
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vorinostat, MS-275 and valproic acid has also been shown to improve
apoptosis in breast cell lines (64).
Several preclinical studies of vorinostat in combination with other
anticancer agents have shown remarkable synergistic or additive effects in
multiple solid tumor cell lines as well as hematological malignancies such as
multiple myeloma, non-Hodgkin lymphoma and leukemia (6). Mocetinostat
has been evaluated in single-agent and combination therapies in several
phase I and phase II clinical trials in both solid and hematological
malignancies. Various panobinostat-based combination studies are currently
being conducted, including a phase I/II trial of panobinostat with the FDAapproved kinase inhibitor, immunosuppressant and anti-cancer agent,
everolimus, in patients with relapsed Hodgkin lymphoma and non-Hodgkin
lymphoma (6).

I. Conclusions
HDACs are a family of 18 enzymes that play key roles in regulation of
gene expression. X-ray crystallographic structures of HDAC8 have led to a
better understanding of catalysis and inhibition of HDAC enzymes. Structures
of the foot pocket of HDAC2, catalytic domains of HDAC4 and HDAC7, and
the crystal structure of the tetrameric domain of HDAC3 complexed with
TBL1, SMRT, and GPS2 have been solved. These structural studies have
also been pivotal in understanding target-ligand interactions. HDAC inhibitors
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show promise in the treatment of cancer, neurodegenerative diseases and
other key therapeutic areas. Two pan-HDACi, vorinostat and romidepsin,
have been approved by the FDA for CTCL treatment but broad spectrum
HDAC inhibition has been associated with increased toxicity. Therefore,
current trends favor the development of isoform-selective inhibitors that could
provide better pharmacokinetic profiles while maintaining efficacy as a result
of selective targeting of HDAC enzymes.
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Chapter 3
Discovery and Development of Tropolone natural product derivatives as HDAC
inhibitors

A. Introduction
Natural products have found diverse applications as antimicrobial,
antifungal, and anticancer agents as well as in the treatment of neurological
disorders (1-6). Several HDACi are either natural products or derivatives of
natural products (Figure 1; 7-14); examples include the hydroxamate, TSA,
that is isolated from the actinomycete Streptomyces hygroscopius; SAHA, a
synthetic derivative of TSA, that was approved by the FDA in 2006 for CTCL
treatment; the bicyclic depsipeptide antibiotic, romidepsin, that is isolated
from Chromobacterium violaceum and approved by the FDA in 2009 for
CTCL treatment. However, preclinical development of natural products is
often limited by structural complexity and high molecular weight.
β-thujaplicin, otherwise known as hinokitiol, is a tropolone-related
compound and natural product that is isolated from the woods of Thujopsis
dolabrata and Chamaecyparis obtusa (6,15-19 ); hinokitiol is associated with
a range of biochemical and pharmacological activities including antifungal and
antimicrobial activities as well as antiproliferative activities in multiple cell lines
including malignant melanomas, stomach and prostate cancers. Tropolones
are non-benzenoid aromatic compounds characterized by a seven-membered
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ring and an alpha-hydroxyl ketone (Figure 1). The presence of the alphahydroxyl ketone on the tropolone ring in hinokitiol has been shown to chelate
metal ions and to inhibit metalloenzymes (6). However, to the best of our
knowledge, this is the first comprehensive study dedicated to the
development of tropolone natural product derivatives as isoform-selective
histone deacetylases inhibitors (HDACi). Therefore, in this chapter we will
discuss the history of the development of tropolones as (HDACi) and our
efforts to elucidate target-ligand interactions via in silico docking studies and
biochemical assays.
a)

c)

b)

d)

e)

Figure 1: Structures of (a) TSA; b) SAHA; c) Romidepsin (10); d) tropolone scaffold;
e) β-thujaplicin.
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B. Development of the tropolone library
We hypothesize that the lead-like nature of the simple tropolone
scaffold will allow for zinc metal binding, a lipophillic seven-membered ring to
interact with the hydrophobic pocket surrounding the zinc ion and three
unique positions (α, β, γ) available for substitution to reach essential pockets
in HDAC isozymes. Therefore, a library of tropolone natural product
derivatives are currently being synthesized and characterized in-house by the
Wright and Anderson laboratories with the goal of evaluating structure-activity
relationships (SAR) via the addition of structurally-diverse substituents at the
alpha, beta, and possibly gamma positions of the tropolone ring.
These structurally-diverse substituents involve the addition of alkyl and
aryl groups to the tropolone ring in order to evaluate SAR via biochemical and
functional studies. We expect that structure-guided substitutions to the
tropolone scaffold will be used to elucidate potency and selectivity, not only
for HDAC enzymes relative to other metalloenzymes, but within individual
HDAC isozymes. There are currently fourteen compounds in the tropolone
library (Table 1). The structures of compound 1, an unsubstituted tropolone,
and compound 10—β-thujaplicin—are shown in Figure 1.
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Table 1: Tropolone library
Structure

Structure

Alpha-substituted tropolones

Beta-substituted tropolones

Compound 2

Compound 7

Compound 3

Compound 8

Compound 4

Compound 9

Compound 5

Compound 11

Compound 6

Compound 12

Compound 13

Compound 14
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C. Prospective in silico docking studies
As previously discussed in Chapter 2, HDAC8 is the best model for the
study of HDAC catalysis and inhibition because it is the only isozyme that
does not exist as a multiprotein complex (20-24). The HDAC8 active site
consists of a long, 12-Å-deep, narrow tunnel with a zinc ion positioned near
the bottom of the enzyme active site (Figure 2) that accommodates the
acetylated lysine during the catalytic reaction (20-24).

Figure 2: Mesh diagram depicting the binding of the hydroxamate moiety of
SAHA to the zinc atom (pink) in the cavity of HDAC8 (20, 21).

Computational studies of a tropolone docked in the HDAC8 crystal
structure (PDB ID1T64; 22) show that the tropolone ring sits in a
hydrophobic pocket that consists of Phe208, Tyr306, Met274 and Phe152
(Figure 3). Mutational studies have shown that the catalytic tyrosine
residue (Tyr306) is essential for enzymatic activity (24). Tyr306 is also
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conserved in all HDACs except for class IIa enzymes where it is replaced
by a histidine (25). Hence, this position will be very important in
determining isoform selectivity among HDAC enzymes. The tropolone ring
is also within van der Waals distance of Phe208, His143 and Gly151
which should provide stabilizing interactions for the ligand-target complex.

Figure 3: A tropolone, analog 5 (compound 10 in table 1) modeled in the active
site of HDAC8

To date, nine crystal structures of human HDAC8 complexed with
various inhibitors have been solved (26). All crystal structures contain a
Zn2+ ion in the HDAC8 active site, two K+ ions bound to structural sites,
and conformational variability in the L1 and L2 loop segments (Figure 4a)
that may be responsible for the polymorphism observed for HDAC8inhibitor complexes (22, 26). In fact, a comparison of the crystal structure
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of HDAC8 (22) complexed with four structurally diverse hydroxamates
(TSA, SAHA, MS-344 and CRA-A) also reveals remarkable malleability
and structural differences in the protein surface in the vicinity of the
opening of the active site (Figure 4b). Our docking studies of a tropolone
modeled in the active site of HDAC8 (Figure 4c) also revealed similar
trends in the flexibility of the HDAC8 active site. Therefore, from a
physiological perspective, this flexibility shows that HDAC8 might be able
to bind acetylated lysines that are presented in a variety of structural
contexts. These observations indicate that is possible to develop HDAC8selective inhibitors (22, 27-29). Indeed, several hydroxamate HDAC8selective inhibitors have been reported to be in preclinical development
today particularly for cancer treatment by Pharmacyclics Inc., Gladstone
Institutes and Ithaca College (29).
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Figure 4: a) Simplified illustration with the aid of of Cα traces show movement of
the L1 loop between the HDAC8:MS-344 and HDAC8:TSA complexes (11); b)
Solvent accessible surfaces (11) of the active site regions of the HDAC8:TSA,
HDAC8:MS-344, HDAC8:SAHA, and HDAC8:CRA-A complexes; c) Space-filled
structure of a tropolone (Compound 9) superimposed with TSA docked into the
active site of HDAC8 (PDB ID: 1T64; 22).

a)

b)
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c)

D. Cloning, expression and purification of HDAC8
The strength of structure-based drug design (SBDD) as a tool in
medicinal chemistry relies primarily on high-resolution three-dimensional Xray crystal structures of a target-ligand complex (30, 31). Our in silico docking
studies suggest that tropolones are promising HDACi and have prompted
interest towards the co-crystallization of an HDAC8:tropolone complex with
the goal of generating a focused library, evaluating structure activity
relationships (SAR) and designing new compounds that show selectivity and
potency towards HDAC isozymes. We herein describe our efforts to clone,
express and purify HDAC8.
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We cloned HDAC8 based on modifications of previously reported
conditions (22, 23, 26, 32). HDAC8 (Open Biosystems: clone ID
LIFESEQ257457) was expressed in Escherichia coli using a T7 Lac
promoter-driven vector, pET41b (EMD4 Biosciences, USA). The HDAC8
coding sequence was PCR-amplified using the following primer sequences
(forward , 5’- GTGTC TCTAGA TGGAGGA GCCGGAGGAA CCG – 3’;
reverse, 5’- GTGTC CTCGAG GAC CACATGCTTC AGATTCCCTT
TGATGTAGTT G 3') with XhoI and XbaI restriction endonuclease sites,
respectively. The PCR product was digested with XhoI and XbaI and
subcloned into the multiple cloning region of pET41b. The inserted gene
sequence was confirmed on both strands by automated dideoxynucleotide
sequencing using the T7 promoter primers (UCONN DNA Biotechnology
Facility). The resultant HDAC8 expression plasmid was then transferred to
the lysogenic BL21 DE3 E. coli strain containing a chromosomal copy of T7
RNA polymerase under lacUV5 promoter control.
Subsequent expression and purification was performed essentially as
described by the Vannini group in reference 23 and is described in Section A
of the Materials and Methods chapter. Efforts are currently in place by the
Anderson laboratory to solve the crystal structure of our HDAC8 protein
(ACA-HDAC8) bound to a tropolone. The use of structure-based drug design
(SBDD) will allow for modifications at the unique positions (α, β and γ) of the
seven-membered tropolone ring, provide a more distinct appraisal of the
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structure-activity relationships (SAR), and produce leads for the development
of tropolones as isoform-selective HDAC inhibitors.

E. Evaluation of HDAC enzyme kinetic parameters
We evaluated key enzyme kinetic parameters for three class I HDACs
(HDAC1, HDAC2 and HDAC8), two class IIa HDACs (HDAC4 and HDAC5),
and one class IIb HDAC (HDAC6) using fluorogenic assays that correlate
HDAC activity to fluorescence (Table 2). Experimental methods are
highlighted in Section B of the Materials and Methods chapter (33). With the
aid of non-linear regression analysis (GraphPad Prism Software, Inc., CA),
we were able to determine best fit values for the Michaelis-Menten (KM)
constant and maximum enzyme velocity (Vmax) and concurrently determine
values for the enzyme turnover number (kcat) as well as the catalytic efficiency
(kcat /KM). We compared our results to published data for HDAC enzyme
kinetics (34, 35). Standard error values are reported in Section 1 of the
Appendix. Corresponding histograms are in the Appendix, Section 2.
There were some notable differences within and between HDAC
isozymes (Table 2). For example, the KM for HDAC4 was 43 µM whereas the
KM for HDAC5 was 116.6 µM but kcat /KM values for HDAC4 and HDAC5 were
52,308 M-1 s-1 and 947 M-1 s-1 respectively. These values indicate that HDAC4
has a better catalytic efficiency than HDAC5. Conversely, HDAC8 had a KM
value of 56.82 µM and kcat /KM value of 29,224 M-1 s-1 whereas HDAC6, the
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only assayed isozyme with two catalytic active sites, had a KM value of 23.42
µM and kcat /KM value of 123,641 M-1 s-1, the highest value for any isozyme.
But this observation is not surprising particularly given that the two catalytic
domains in HDAC6 contribute independently to the overall activity of the
enzyme (36, 37). These observations are promising and validate the use of
the fluorogenic assays for evaluation of HDAC enzyme inhibition by our
tropolone library.

Table 2: Kinetics and comparative reactivity analysis

Class I HDAC

Class IIa HDAC

Class IIb
HDAC

Kinetic
Parameter

HDAC1

HDAC2

HDAC8

HDAC4

HDAC5

HDAC6

KM (μM)

29.09

39.05

56.82

43.00

116.6

23.42

Vmax (μM)

437.40

599.50

5,661.00 5803.00

772.5

4,069

kcat (s-1)

0.25

0.26

1.70

2.25

0.10

2.90

kcat /KM (M-1 s-1)

8,615

6,552

29,224

52,308

947

123,641
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F. Elucidation of HDAC inhibition
Our initial assessment of HDAC inhibition was evaluated using the
natural product (compound 10), a commercially available human recombinant
HDAC2 enzyme (BPS Bioscience, San Diego, CA), and a fluorogenic HDAC
assay kit (Active Motif, Carlsbad, CA). Experimental methods are highlighted
in Section C of the Materials and Methods chapter. We compared our results
to reported data for HDAC enzyme inhibition (34, 35, 38). Standard error
values are reported in Section 3 of the Appendix. Assay data are highlighted
in Figure 5a and Figure 5b. Our data show that the fluorogenic assay is highly
reproducible and allowed us to subsequently conduct a comprehensive
analysis of the tropolone library in a panel of HDAC enzymes.
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Figure 5: a) Single time-point analysis of HDAC2 inhibition by compound 10; b)
Histogram summarizing comprehensive analysis of HDAC2 inhibition by compound 10.
Note that graph and histogram represent non-linear regression analysis (GraphPad
Prism) of HDAC2 inhibition by compound 10 (Log C = Log Concentration).
a)

b)
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We evaluated inhibition constant (Ki) values for our tropolone library for
three class I HDACs (HDAC1, HDAC2 and HDAC8), two class IIa HDACs
(HDAC4 and HDAC5), and one class IIb HDAC (HDAC6) using fluorogenic
assays that correlate HDAC activity to fluorescence. Detailed assay methods are
highlighted in Section C of the Materials and Methods Chapter. We compared
our data to reported values for HDAC inhibition (28, 34, 35, 38). Assay data
indicated that our compounds showed high potency and selectivity towards
HDAC2 and HDAC8 relative to the other evaluated HDAC isozymes. Standard
error values for IC50 analysis of HDAC2 and HDAC8 are reported in the Appendix,
Section 4. With the aid of non-linear regression analysis (GraphPad Prism), we

were able to determine IC50 values and convert them to Ki values using methods
described by Cheng and Prusoff (39).
There were significant differences in inhibition within and between HDAC
isozymes; between TSA and the tropolones; as well as between the alphasubstituted and beta-substituted tropolones (Table 3). The tropolones showed
preferential inhibition of the class I HDACs when compared to either class IIa or
class IIb HDACs. For example, the tropolones were not active in HDAC5 at the
tested concentrations (0.0002-20 µM) whereas TSA had a Ki value of 5 µM. With
the exception of compound 2 (Ki =527 nM), the tropolones were not active in
HDAC6 whereas TSA had a Ki value of 3.02 nM. However, in a similar manner
as TSA, the tropolones inhibited HDAC4 relatively poorly with Ki values greater
than 8 µM. Yet this discovery is not surprising since most HDACi show poor
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selectivity towards inhibition of class IIa HDACs possibly due to difficulty in
establishing accurate methods for evaluation of HDAC activity and inhibition (35,
40). HDAC2 and HDAC8 share 43% sequence identity (22) and inhibition of
these two isozymes by the tropolones were by far more promising than any of the
other HDAC isozymes.
With the exception of the natural product, (compound 10; Ki = 15. 44 nM)
and the methylated tropolone (compound 11) that was inactive even at 2500 nM,
the tropolones exhibited notable potency in the inhibition of HDAC2 with values
that were even more potent than that of TSA (Ki =1.06 nM). Inhibition of HDAC2
by both the alpha-substituted and beta-substituted tropolones was similar; for
example, compounds 5 and 9 with dimethoxyphenyl groups at the alpha and beta
positions respectively had corresponding Ki values of 0.42 nM and 0.51 nM for
HDAC2.
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Table 3: Inhibition constants for class I and class II HDACs
Note: For all HDAC isozymes except HDAC4 & HDAC5; Not Active
(N.A.) refers to Ki values >2500 nM, the upper limit of assayed inhibitor
concentrations; for HDAC4 & HDAC5, N.A. refers to Ki values >20,000
nM, the upper limit of the assay.
Compound

Ki ( nM)
Class I HDAC
HDAC1

HDAC2

Class II HDAC
HDAC8

69.65

HDAC4

HDAC5

HDAC6

14,547.00

5,000

3.02

TSA

0.87

1.06

1

N.A.

0.04

N.A.

N.A.

N.A.

N.A.

2

N.A.

0.26

1.09

N.A.

N.A.

527.00

3

N.A.

0.25

186.30

N.A.

N.A.

N.A.

4

N.A.

0.81

83.80

N.A.

N.A.

N.A.

5

N.A.

0.42

811.50

N.A.

N.A.

N.A.

6

N.A.

0.23

123.65

N.A.

N.A.

N.A.

7

N.A.

0.06

1.47

10,860.00

N.A.

N.A.

8

N.A.

0.12

2.38

8,361.00

N.A.

N.A.

9

N.A.

0.51

266.30

11,204.00

N.A.

N.A.

10

N.A.

15.44

177.95

N.A.

N.A.

N.A.

11

N.A.

N.A.

7.87

11,641.00

N.A.

N.A.

12

N.A.

0.13

12.81

806.13

N.A.

N.A.

13

N.A.

0.22

2.27

6115.00

N.A.

N.A.

14

N.A.

0.04

122.70

990.23

N.A.

N.A.
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With the exception of the unsubstituted tropolone (compound 1) that
was inactive even at 2500 nM, the tropolones had submicromolar Ki values
for HDAC8 that were comparable to TSA (Ki =69.65 nM). However, the betasubstituted tropolones seemed to be more potent than the alpha-substituted
tropolones. For example, compound 5 had a Ki value of 811.50 nM whereas
compound 9 had a Ki value of 266.30 nM. Furthermore, the tropolones show
some selectivity towards HDAC2 when compared to HDAC8. For example,
compound 9 exhibits greater than 500-fold selectivity towards HDAC2 relative
to HDAC8. This observation is highly promising and shows that it is possible
to develop these tropolones as HDAC2-selective inhibitors. This discovery is
groundbreaking particularly given the fact that there are no reported HDAC2selective inhibitors in pre-clinical and clinical development presumably due to
the high degree of similarity in the catalytic sites of HDAC1, HDAC2 and HDAC3 (29, 41).
Furthermore, hinokitiol (compound 10) has also been shown to
possess neuroprotective activity in HT22 mouse hippocampal cells (42).
Published reports have shown that treatment with HDACi such as TSA,
sodium butyrate, or vorinostat protected against glutathione depletion-induced
oxidative stress, a mechanism that is implicated in many neurodegenerative
diseases including strokes and Alzheimer’s disease (43, 44). Concurrently,
HDAC2 inhibition has been shown to facilitate learning and memory in wildtype mice as well as in mouse models of neurodegeneration (46). Our studies
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may have shown that the neuroprotective effects of hinokitiol may be as a
result of HDAC2 inhibition. However, we cannot rule out the possibility that
other protein substrates and HDAC isoforms might be implicated by the
tropolones (42). Yet, our data suggests that it is indeed possible to explore
the use of tropolones in the treatment of neurodegenerative diseases.
Interestingly, the tropolones did not inhibit HDAC1 whereas TSA had a
Ki value of 0.87 nM. This observation is quite significant particularly given that
HDAC1 and HDAC2 share 80% sequence identity, exhibit functional
redundancy in many cell types, and are recruited together into three main
transcriptional complexes: Sin3A, NuRD and CoREST (46). However, our
studies may be limited by difficulty in standardizing data obtained from
different HDAC fluorogenic substrates particularly given high batch to batch
variability in substrate properties (47). Yet, as previously stated, our data
indicates that it may be possible to develop these tropolones as HDAC2selective inhibitors, and explore potential therapeutic uses for the treatment of
cancers and possibly neurodegenerative diseases.

G. Investigation of the mechanism of action of tropolones in HDAC8
Based on enzyme inhibition data, compound 2 was chosen to evaluate
the mechanism of action of tropolones in HDAC8. Experimental methods are
described in section D of the Materials and Methods chapter. Assay data
(Figure 6) were analyzed via non-linear regression analysis (GraphPad
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Prism). Standard error values for Ki and alpha are reported in section 5 of the
Appendix.
The parameter, alpha, (Ki‘/Ki) is used to determine the degree to which
binding of an inhibitor changes the affinity of the enzyme for the substrate
(48). The alpha value obtained for Compound 2 in HDAC8 was 4.5 indicating
competitive binding since alpha is statistically greater than 1 (48, 49).
Furthermore, the measured Ki for compound 2 is 0.53 nM, which correlates
well with the calculated Cheng and Prusoff Ki of 1.09 nM. Therefore, the
competitive mode of inhibition as well as relatively poor binding by the
methylated tropolone (compound 11) highly suggests that the tropolones
inhibit HDAC activity by targeting the bound Zn2+ metal at the active site.
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Figure 6: Analysis of mode of binding of compound 2 against HDAC8
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H. Optimizing the tropolone scaffold to explore the HDAC hydrophobic
pocket
We are currenty working on the development of a second generation
library of tropolones that will potentially maintain isoform selectivity in HDAC
inhibition while exerting a more robust therapeutic application particularly for
the treatment of solid tumors and hematological malignancies. The proposed
scaffold for second-generation tropolones (Figure 7) will now include a linker
domain (the alkyl chain) that is presumed to mimic the natural HDAC
substrate and occupy the active site channel thus allowing for exploration for
isozyme selectivity (41, 50). R groups will either be hydrogen atoms, alkyl
groups, or aryl groups. The same substitutions will also be evaluated in the
alpha and possibly the gamma positions in order to elucidate structure-activity
relationships (SAR).

Figure 7: Proposed scaffold for 2nd generation tropolones
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Moreover, virtually all HDACi currently in clinical development for the
treatment of cancer share this common pharmacophore pattern (28-30, 41, 50)
consisting of: a metal binding domain which complexes zinc; a linker domain
and a surface domain or cap group that makes contact with the rim of the
catalytic pocket. In our case, the tropolone ring with the alpha-hydroxyl ketone
serves as the metal-binding domain, the alkyl chain will serve as the linker
domain and the secondary aryl moiety will serve as the cap group. It is
expected that modification of the tropolone scaffold may also lead to
improvements in pharmacokinetic properties that may improve in vitro potency
& possibly in vivo efficacy (51, 52). Knowledge garnered from the work
presentated in this dissertation as well as the proposed studies is crucial
towards further development of tropolones as isoform-selective HDAC
inhibitors with enhanced antitumor properties.

I. Conclusions
Many HDACi, including the two FDA-approved HDACi, are natural
products or derivatives of natural products. Our tropolone natural product
derivatives are highly promising competitive HDACi that show preferential
inhibition of class I HDACs, particularly HDAC2 and HDAC8. In silico docking
studies have provided visual insights on HDAC8 binding by the tropolones;
efforts are currently in place to co-crystallize a tropolone with our purified
HDAC8 protein (ACA-HDAC8) in order to more aptly evaluate target-ligand
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interactions and use this knowledge to guide substitutions to the tropolone
scaffold. Furthermore, our biochemical analyses indicate that it is possible to
develop tropolones as HDAC2-selective inhibitors and exploit their
therapeutic potential particularly for the treatment of neurodegenerative
diseases; this observation is groundbreaking since there are no reported
HDAC2-selective inhibitors either in preclinical or clinical development. We
are also developing new compounds potentially for the treatment of cancer
that is based on a modified scaffold that will allow us to further probe the
HDAC hydrophobic pocket and explore isozyme selectivity.
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Chapter 4
Analysis of cancer cell line selective cytotoxicity

A. Introduction
The ability of established HDACi to induce cell death alone and/or in
combination with other anticancer agents has been previously reported for
both solid tumors and hematological malignancies (1-49). Evidence for the
antiproliferative properties of β-thujaplicin has been previously reported in
multiple cell lines including malignant melanoma, stomach cancer, and
prostate cancer at micromolar levels (50-55). The cellular reduction of the
yellow tetrazolium compound, MTS, into soluble purple formazan is
accomplished by dehydrogenase enzymes found only in metabolically active
cells (56, 57). Thus, we employed this MTS assay to evaluate cancer cell line
selective cytotoxicity in ten human cell lines: HT29 and HCT116 colon cancer
cell lines; BXPC3 pancreatic cell line; MCF-7 and MCF-10A breast cell lines;
Jurkat acute T-cell leukemia cell line; HuT-78 cutaneous T-cell lymphocytes
(CTCL); U87 glioblastoma cell line; A549 lung cancer cell line; and normal
adult human dermal fibroblasts (hdF).
The focus of this chapter is to comprehensively evaluate cytotoxicity in
multiple cell lines and determine the cell lines that are the most sensitive to
inhibition by the tropolones. Assays were performed in triplicate and assay
data werecompared to published data for the experimental control, SAHA,
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when possible (1-5). Detailed experimental methods for cell culturing and cell
viability assays are in sections E and F respectively of the Materials and
Methods Chapter. Standard errors values are reported in Sections 6 and 7 of
the Appendix.

B. Evaluation of cancer cell line selective cytotoxicity in solid tumors
It is well established that HDACi are able to inhibit a diverse panel of
solid tumor cell lines as well as hematological cell lines (1-49). Inhibition of
solid tumors by SAHA and TSA has been reported for the primary breast
adenocarcinoma cell line, MCF-7 (1, 14-17), and two primary colon
adenocarcinoma cell lines, HCT-116 (3, 18-25), and HT-3, 22, 24).
Overexpression of HDAC1, -2, and -3 has been reported in colorectal
carcinomas (56-58). Increased expression of class IIa HDACs has been
correlated with reduced survival in estrogen receptor-positive (ER+) breast
cancer patients (26). Aberrant expression of HDAC1, HDAC2, and HDAC7
has been observed in pancreatic cancer cells (27). TSA has been shown to
inhibit the BXPC3 pancreatic cancer cell line in the submicromolar levels (28).
Glioblastomas are the most common, most aggressive, and most
chemoresistant type of brain tumors (31). TSA has also been shown to inhibit
the growth of U87 cells presumably by altering the HDAC1 levels (31). MCF10A cells are spontaneously immortalized ‘normal’ breast epithelial cell lines
that have been shown to exhibit no signs of terminal differentiation or
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senescence (59). The antiproliferative effects of SAHA on the MCF-10A cell
line have been reported (1, 16). Structurally diverse HDACi, including SAHA,
have been shown to inhibit the growth of the A549 lung cancer cell line (32,
34-36).
We performed cytotoxicity studies in these seven human solid tumor
cell lines: HT29, HCT116, BXPC3, MCF-7, MCF-10A, U87, and A549. The
cancer cell growth inhibitory results was proportional to HDAC inhibition data
particularly given that the unsubstituted tropolone, compound 1, and the
methylated tropolone, compound 11, exhibited poor inhibition of all solid
tumor cell lines (Table 1). The alpha-substituted tropolones were generally
more potent than the beta-substituted tropolones in all seven solid tumor cell
lines. Surprisingly, the tropolones and SAHA were more active in the MCF10A cell line than the more differentiated MCF-7 breast cell line; perhaps
indicating a better prognosis for early onset treatment of breast cancer versus
treatment at a more advanced stage (60). However, given recent trends in
cell line contamination and cell-specific genomic alterations associated with
breast cell lines, we cannot rule out the possibility that the integrity of the
MCF-10A cells may be compromised (61-63).
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Table 1: Evaluation of cancer cell line selective cytotoxicity in solid tumors
GI50 (μM), 72h

Compound

Solid Tumors
HCT116

HT-29 BXPC-3 A549 U87

MCF-7 MCF-10A

SAHA

2.50

5.17

5.56

43.66

39.12

29.45

2.70

1

63.73

>100

>100

>100

>100

85.28

3.31

2

15.24

>100

29.39

>100

>100

91.48

33.17

3

32.06

75.40

17.13

>100

>100

>100

17.50

4

56.99

56.99

35.93

85.53

>100

>100

26.50

5

46.65

46.70

14.06

57.60

>100

>100

21.70

6

34.98

35.00

21.16

75.00

>100

>100

34.00

7

53.44

>100

18.49

69.20

>100

>100

2.90

8

43.67

43.70

91.57

52.40

>100

>100

13.30

9

>100

>100

34.79

53.44

>100

>100

38.81

10

6.92

92.00

18.50

52.00

>100

>100

1.90

11

>100

>100

>100

>100

>100

>100

85.38

12

62.61

>100

43.02

38.00

>100

>100

4.44

13

26.86

>100

>100

25.68

>100

84.62

5.07

14

>100

>100

>100

36.00

>100

>100

21.00
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Alternatively, the tropolones showed relatively poor inhibition of the
A549 cells and had half maximal growth inhibition (GI50) values in U87 cells
that were greater than 100 micromolar. The gastrointestinal cancer cell lines,
BXPC3, HCT116 and HT-29, seemed to be the most sensitive to inhibition by
the tropolones. The tropolones were particularly cytotoxic in the BXPC3 and
HCT116 cell lines with mean GI50 values of 32 µM and 40 µM respectively.
These observations have prompted further investigation on the
antiproliferative effects on cell cycle progression in BXPC3 and HCT116 cell
lines by the tropolones which will be discussed in subsequent chapters.

Figure 1: Evaluation of cancer cell line selective cytotoxicity in solid tumors
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C. Evaluation of cancer cell line selective cytotoxicity in hematological
cell lines and normal dermal fibroblasts
The benefits of HDAC inhibitors (HDACi) in the treatment of
hematological malignancies are supported by the fact that both SAHA and
Romidepsin were approved by the FDA for the treatment of cutaneous T-cell
lymphoma (CTCL) (2, 4, 8-10, 33, 39, 42, 45-47). Overexpression of HDAC-1,
-2 and -6 has also been reported in CTCL (33). Inhibition of the growth of
Jurkat T-leukemia and HuT-78 cells by SAHA and other HDACi has been
reported (2, 4, 5, 28). We have previously reported that the beta-substituted
tropolones show selective inhibition of proliferating cells in cancerous tissues
versus normal adult human dermal fibroblasts (hDF) (50). Therefore, we
further explored the cytotoxicity of the tropolone library in the normal
fibroblasts, hDF, and the two hematological cell lines, Jurkat and HuT-78. The
cell growth inhibitory results was proportional to HDAC inhibition data
particularly given that the methylated tropolone, compound 11, exhibited poor
inhibition of both the Jurkat and HuT-78 cell lines (Table 2).
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Table 2: Evaluation of cancer cell line selective cytotoxicity in hematological cell
lines and normal fibroblasts.
Compound
GI50 (μM), 72h
Hematological

Normal

Jurkat

HuT-78

hDF

SAHA

0.90

2.10

18.95

1

12.21

43.02

>100

2

3.33

7.83

96.46

3

1.15

4.11

93.07

4

0.62

2.87

>100

5

0.76

3.05

>100

6

1.86

4.74

>100

7

0.67

4.14

12.40

8

4.62

8.95

>100

9

5.89

17.09

>100

10

1.10

4.99

>100

11

>100

>100

>100

12

4.45

13.11

>100

13

0.59

3.25

>100

14

6.30

11.36

>100
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Tropolones, like many HDACi, show preferential inhibition of the
hematological malignancies, as evidenced by the fact that most of the
tropolones had GI50 values in the very low micromolar range (Figure 2).

Growth inhibition was more pronounced in the Jurkat cells but the GI 50
values were still relatively potent in the HuT-78 cells particularly when compared
to the solid tumor cell lines or the dermal fibroblasts (Figure 3). For example,
compound 2 showed a 12-fold selectivity towards HuT-78 cells and a 30-fold
selectivity towards Jurkat cells when compared to hDF cells. The alphasubstituted tropolones were slightly more potent than the beta-substituted
compounds in both hematological cell lines. For example, compounds 5 and 9
have a dimethoxyl phenyl functional group substituted at the alpha and beta
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positions respectively; but compound 5 had lower GI50 values of 0.76 µM and
3.05 µM in Jurkat and HuT-78 cells respectively whereas compound 9 had GI50
values of 5.89 µM and 17.09 µM respectively in the two hematological cell lines.
Interestingly, SAHA and compound 7 were the only compounds to
significantly inhibit growth of the hDF cells with GI50 values of 18.95 µM and
12.40 µM respectively. This observation is promising in the pre-clinical
development of tropolones since many anticancer drugs currently in clinical
development are cytotoxic agents with low therapeutic index acting nonselectively against proliferative cells of both cancerous and normal tissues (37).
Furthermore, it may be inferred that SAHA and other broad-spectrum HDACi
can modulate the acetylation status of a wide range of protein targets leading to
undesired toxic effects (8-10, 39, 44-47). Therefore, the development of more
selective isoform-selective HDACi, like the tropolones, could result in improved
therapeutic efficacy in cancer treatment as well as improved pharmacokinetic
profiles.
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Figure 3: Evaluation of cancer cell line selective cytotoxicity in hematological cell
lines and normal human adult dermal fibroblasts
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D. Conclusions
The benefits of HDACi as anticancer agents have been widely explored
resulting in FDA approval of vorinostat and romidepsin for the treatment of
CTCL. Many HDACi are currently in preclinical and clinical development for the
treatment of cancer. Given these developments, we explored cell line selective
cytotoxicity of tropolones presumably as a result of HDAC inhibition. We
observed a correlation between HDAC inhibition and cancer cell line growth
inhibition particularly given that the methylated tropolone, compound 11 inhibited
all of the cell lines relatively poorly when compared to the rest of the library.
Tropolones also display cancer cell line selective cytotoxicity as evidenced by
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preferential inhibition of the two hematological cell lines, Jurkat and HuT-78. The
nature and position of substituents on the tropolone ring seems to be critical in
inducing growth inhibition since the unsubstituted tropolone, compound 1,
inhibited all of the cell lines relatively poorly when compared to the rest of the
library. There was also a correlation between increased hydrophobicity and
more potent cytotoxicity; furthermore, the alpha-substituted tropolones seemed
to be slightly more potent than the beta-substituted compounds in all cell lines.
Additionally, it seems that selective HDAC inhibition may result in reduced
toxicity profiles as evidenced by the fact that with the exception of compound 7,
none of the tropolones showed significant inhibition of the normal dermal
fibroblasts unlike the pan HDAC inhibitor, SAHA (GI50 = 18.95 µM). It may be
deduced that SAHA and other broad-spectrum HDACi can modulate the
acetylation status of a wide range of protein targets leading to undesired toxic
effects. Thus, the development of more selective isoform-selective HDACi, like
the tropolones, could result in improved therapeutic efficacy while reducing toxic
effects.
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Chapter 5
Assessment of histone and tubulin modulation

A. Introduction
Modulation of chromatin structure is critical in the regulation of
transcription (1-21). The amino terminal tails of the core histones (H2A, H2B,
H3 and H4) undergo various post-transcriptional modifications, including
methylation, acetylation and phosphorylation (3-4; 8-14). Histone acetylation
is considered to be the most studied posttranslation modification of
nucleosomes (2, 3). In fact, a recent global proteomic analysis has revealed
more than 1700 protein substrates of HDACs including histones and
structural proteins like tubulin (Figure 1; 13-14). Furthermore, accumulation of
acetylated histones has been demonstrated as one of the molecular
mechanisms for HDAC inhibition (3, 14-18). Therefore in this chapter, we will
explore the modulation of histones and tubulins as a result of HDAC inhibition
by the tropolones.
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Figure 1: Illustration of the multiple roles of HDACs in cells (14).

B. Initial assessment of histone hyperacetylation in HT-29 colon cancer
cells
In collaboration with Dr. Cassandra Godman, a former member of the
Giardina laboratory here at the University of Connecticut, our preliminary
assessment of histone hyperacetylation was conducted in HT-20 colon
cancer cells after a 24h treatment with 40 µM compound 9 (DWI) via Western
blot analysis. Four millimolar of the broad spectrum fatty acid HDACi, butyric
acid (BA), served as experimental control. Following treatment, a 3-part
protein extraction was performed and the nucleolar fraction was run on a
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12.5% SDS gel, transferred overnight, and probed for acetyl-specific histones.
Compound 9 showed some specificity to certain acetyl marks since no
differences were observed in either the acetylated Histone H4 Lysine 12
(H4K12Ac) or H3K18Ac but the results showed hyperacetylation of H3K9 and
H3K23 (Figure 2). Moreover, it has been demonstrated that the deacetylation
of H3K9 is required for proper chromosome condensation and H3K9 levels
are reduced in mitotic cells (4, 16-18). These results show that the tropolones
display selectivity towards acetyl-specific histones and may not be pan
HDACi like many HDACi including BA and SAHA.

Figure 2: Western blot analysis of Compound 9 (DW-I) and butyric acid (BA).
The graphs represent the quantification of the triplicate gel using ImageJ
software.
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C. Investigation of histone modulation in Jurkat cells
Based on the fact that Jurkat and HuT-78 cells were the most sensitive
to treatment by tropolones, we investigated hyperacetylation of key lysine
residues on histones in these two hematological cell lines. Acetylation of
histone H3 at lysine9 (K9) has been shown to be essential for histone
deposition and chromatin assembly (4, 18). Hyperacetylation of H3K9 is also
associated with an increase in the expression of the cyclin-dependent kinase
inhibitors (CDK), p21 & p27 that play important roles in cell cycle progression
(20). Acetylation of histone H4 particularly at lysine12 (K12) has been
correlated with HDAC2 inhibition in CTCL and regulation of telomeric
hereochromatin plasticity in yeast cells (3, 21). Furthermore, it has been
reported that in vivo HDAC8 inhibition leads to hyperacetylation of histones
H3 and H4 (19). Given these observations and our biochemical data that
shows that tropolones selectively target HDAC2 and HDAC8, we decided to
conduct a comprehensive analysis of the hyperacetylation of specific lysine
residues on histones H3 and H4.
Our initial assessment of histone hyperacetylation in the hematological
cell lines was conducted in Jurkat cells after a 12h treatment via flow
cytometric analyses by sequentially incubating treated cells with primary
antibodies for histone H4 and H4K12Ac followed by treatment with secondary
antibodies conjugated with a fluorescein isothiocyanate (FITC). Flow
cytometry has been shown to be a convenient method for evaluating
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epigenetic alterations (22-25). We determined geometric mean fluorescence
intensities (GMFI), equivalent to the median cell population, for each
treatment with the aid of the FlowJo Workstation (26-28). Epigenetic
alterations were measured at multiple time points and/or multiple
concentrations when possible. We also compared our data for our
experimental control, SAHA, to published values for histone hyperacetylation
when possible (3, 20). Detailed methods for flow cytometric analyses are in
Section G of the Materials and Methods chapter. We compared global
hyperacetylation of histone H4 to specific hyperacetylation of histone H4
lysine12 (K12) for a more quantitative analysis of the modulation of specific
histone hyperacetylation (Table 1). Histograms for the modification of H4 and
additional histograms for H4K12Ac evaluation are in the Appendix, Section 8.
Modulation of histone H4 by the tropolones and SAHA were within the
same range as the untreated control (Table 1). However, modulation of the
specific lysine residue on histone H4K12, varied between the untreated
control and the HDACi (Table 1; Figure 2). In fact, SAHA exerted more than
10-fold increase in the modulation of H4K12Ac. The tropolones exhibited at
least a 2-fold increase in hyperacetylation of H4K12 with the alpha
dimethoxyphenyl tropolone (compound 5) and the natural product (compound
10) inducing a corresponding 6-fold increase in H4K12 hyperacetylation, the
highest among the tropolones.
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Table 1: Evaluation of histone hyperacetylation in Jurkat and HuT-78 cells after a 12h
treatment with 10 µM HDACi
Treatment

Jurkat, GMFI
H4

H4K12Ac

H4K12/H4 ratio

Control

1.50

7.13

4.8

SAHA

2.04

100.00

49.0

Compound 2

1.88

33.50

17.8

Compound 5

1.75

42.20

24.1

Compound 7

2.17

13.10

6.0

Compound 9

1.88

25.70

13.7

Compound 10

2.04

45.40

22.3

Compound 11

1.87

25.20

13.5

Compound 13

2.08

34.00

16.4

Compound 14

1.86

34.90

18.8

Furthermore, we investigated global (H4 acetylation) and specific
(H4K12Ac) hyperacetylation for more quantitative comparative analysis.
Similar to our observations on H4K12Ac modulation alone, we found that the
H4K12Ac/H4 ratio was the highest in cells treated with SAHA followed by
compound 5 and compound 10. Interestingly, the beta-phenyl (compound 7)
and the methylated tropolone (compound 11) exhibited the lowest
H4K12Ac/H4 ratio indicating that the tropolones show selectivity towards
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acetyl marks depending on the nature and position of the substituents on the
tropolone ring.

Figure 2: Evaluation of the modulation of H4K12Ac in Jurkat cells. Note that
histograms represent the untreated control (red) superimposed with the HDACi
treatment (blue) for comparative analysis.

a)
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b)

100
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d)
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Compound 11

h)

i)

Compound 14

102

Compound 13

Given our promising results at a 10 µM concentration, we decided to
evaluate time effects as well as the effects of a higher concentration of the
tropolones on the modulation of H4K12Ac in Jurkat cells. We followed up our
12h analysis with a 4h treatment using a higher inhibitor concentration, 25 µM
tropolones, in Jurkat cells (Table 2); histograms for this analysis are in the
Appendix, Section 9. It should be noted that we did not evaluate SAHA at 25
µM due to excessive cell death. However, we did not observe any significant
hyperacetylation by any of the tropolones; for example, compounds 2 and 7
had GMFI values of 5.56 and 5.02 which were less than the untreated control
(5.87). Compound 13 was the only tropolone to have a slightly higher value
(7.78) than the untreated control prompting further investigation after a longer
treatment period. Moreover, SAHA had a GMFI of 4.11 which was within the
same threshold as the untreated control suggesting that a 4h period may not
be sufficient for the accumulation of histones.

Table 2: Modulation of H4K12Ac in Jurkat cells after 4h treatment with HDACi. Note: All HDACi at
25 µM except for SAHA which is at 10 µM.
GMFI in Jurkat cells

Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(H4K12Ac, 4h)

5.87

4.11

5.56

5.18

5.02

3.84

4.56

4.05

7.78

3.69
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We also evaluated the effects of a 25 µM concentration of the
tropolones on H4K12Ac modulation after a 12h treatment period (Table 3);
histograms for this analysis are in the Appendix, Section 10. Assay data
strongly suggest that evaluation of the tropolones at a 25 µM concentration
did not result in more significant hyperacetylation of H4K12 after a 12h
treatment in Jurkat cells; for example, compounds 5, 10 and 13 had GMFI
values of 18.3, 18.6 and 18.8 respectively compared to 18.0 in the untreated
control. We hypothesize that the higher concentration of the tropolones may
result in an arrest of the S-phase (DNA synthesis) in Jurkat cells but we will
further explore this observation via cell cycle analysis in Chapter 6.
Furthermore, a higher concentration of the tropolones may have resulted in
increased cell death thus reducing the percentage of intact cells available for
response to treatment by H4K12Ac antibodies in Jurkat cells. Interestingly,
the methylated tropolone, compound 11, that typically exerts the lowest
activity among the tropolones, exerted the highest propotion of histone
hyperacetylation. Based on our growth inhibition data (Chapter 4), it may be
possible that compound 11 was the least cytotoxic in Jurkat cells thus
resulting in a higher percentage of intact cells to respond to treatment by
H4K12Ac antibodies.
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Table 3: Modulation of H4K12Ac in Jurkat cells after 12h treatment with 25 µM tropolones
GMFI in Jurkat cells
Treatment
(H4K12Ac, 12h)

Control

2

5

7

9

10

11

13

14

18.0

21.0

18.3

17.8

24.3

18.6

46.0

18.8

17.2

Based on our promising results with a 10 µM treatment, we
investigated the ability of 10 µM treatments of the tropolones and SAHA to
hyperacetylate H3K9Ac levels after a 12h incubation period in Jurkat cells
via FACS analysis (Table 4). Corresponding histograms are in Section 11
of the Appendix. 10 µM SAHA induced a 10-fold increase in the
modulation of H3K9Ac antibodies when compared to the untreated
control. Alternatively, compounds 2, 5, 9, and 13 were the only tropolones
that activated a two-fold increase; the rest of the tropolones were within
the same threshold as the untreated control. These observations suggest
that tropolones could be isoform-selective HDACi since they show
selectivity towards promoter-specific histone residues unlike the panHDACi SAHA that exerted a 10-fold increase in hyperacetylation of both
H3K9Ac and H4K12Ac antibodies.
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Table 4: Modulation of H3K9Ac in Jurkat cells after 12h treatment with 10 µM.HDACi
GMFI in Jurkat cells

Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(H3K9Ac, 12h)

5.91

61.70

13.70

14.20

2.12

15.50

8.19

3.23

14.70

7.91

We followed up our assessment of the hyperacetylation of H3K9
levels in Jurkat cells with an evaluation of the modulation of H3K23Ac in
Jurkat cells after a 12h treatment with 10 µM HDACi (Table 5).
Corresponding histograms are in the Appendix, Section 12. With the
exception of SAHA, compounds 2, 7, and 14, the rest of the compounds
had GMFI values lower than the untreated control. SAHA exerted almost a
two-fold increase in hyperacetylation (36.90 vs. 20.20) whereas
compounds 2, 7 and 14 had slightly higher values than the untreated
controls (24.6, 24.0 and 27.2 respectively). Once again, we can deduce
that the tropolones show selectivity towards acetyl-specific histones in
Jurkat cells.
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Table 5: Modulation of H3K23Ac in Jurkat cells after 12h treatment with 10 µM HDACi
GMFI in Jurkat cells

Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(H3K23Ac, 12h)

20.20

36.90

24.60

18.30

24.00

17.20

17.50

17.80

17.80

27.20

D. Investigation of histone modulation in HuT-78 cells
Given our promising results in Jurkat cells, we also evaluated the
modulation of H3K9Ac and H4K12Ac antibodies in HuT-78 cells following a
12h treatment with 10 µM HDACi via FACS analysis (Table 6). Corresponding
histograms are in the Appendix, sections 13 and 14. Similar to our data in
Jurkat cells, the tropolones were more sensitive to H4K12Ac treatment than
H3K9Ac. Compound 9 exerted almost a 2-fold increase in H4K12 (84.40 vs.
51.00 in the untreated control). Alternatively, compound 9 had a lower GMFI
value for H3K9Ac modulation than the untreated control (20.90 vs. 29.20).
SAHA treatment resulted in slightly more than a 2-fold increase in HuT-78
cells that is notably less than the 10-fold increase we observed in Jurkat cells
indicating cell line selectivity towards both H3K9 and H4K12 hyperacetylation.
Concurrently, the tropolones seem to also be more sensitive to both H3K9Ac
and H4K12Ac treatment in Jurkat cells than in HuT-78 cells; this observation
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also matches the cellular data that we have previously obtained on growth
inhibition (Chapter 4).

Table 6: Comparative analysis of histone modulation in HuT-78 cells treated with 10
µM HDACi after a 12h treatment
Treatment

GMFI in HuT-78 cells
H3K9Ac

H4K12Ac

Control

29.20

51.00

SAHA

72.40

111.00

Compound 2

17.40

58.20

Compound 5

16.40

56.00

Compound 7

18.80

56.10

Compound 9

21.00

84.40

Compound 10

18.60

61.20

Compound 11

18.10

47.00

Compound 13

21.50

63.40

Compound 14

20.90

61.90

We also investigated H3K23Ac modulation in HuT-78 cells after a
24h treatment period in order to evaluate if a longer treatment period may
lead to a higher accumulation of histones by the tropolones.
Corresponding histograms are in the Appendix, Section 15. Compound 14
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exerted the most significant hyperacetylation of H3K23 antibodies with
approximately a 1.6 fold increase compared to the untreated control.
While the rest of the tropolones were within close range to the untreated
control, SAHA exerted more than a 5-fold increase in H3K23
hyperacetylation. These results suggest once again that tropolones show
selectivity towards acetyl-specific histone acetylation whereas SAHA is a
broad-spectrum HDACi.

Table 7: Modulation of H3K23Ac in HuT-78 cells after 24h treatment with 10 µM HDACi
GMFI in Jurkat cells

Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(H3K23Ac, 24h)

24.0

133.0

22.1

28.3

28.2

22.4

25.5

25.1

34.7

37.4

E. Investigation of tubulin modulation in Jurkat and HuT-78 cells
HDAC6, a class IIb isozyme, is a unique HDAC with two catalytic
subunits and a C-terminal zinc finger domain (29-32). HDAC6 resides mainly
in the cytoplasm and regulates many important biological processes,
including cell migration and degradation of misfolded proteins (29-32).Many
cell movements are mediated by the microtubule, which is made up of
globular tubulin subunits (α, β, and γ), with the α/β-tubulin heterodimers
forming the tubulin subunit common to all eukaryotic cells (29, 30-32).
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HDAC6, has been shown to deacetylate the structural protein, α-tubulin at
lysine40 (K40), resulting in a modulation of cell motility (16, 29, 32).
Evaluation of inhibition constants (Ki ) obtained for HDAC6 (Chapter 3)
indicate that the tropolones exhibited poor inhibition of this isozyme (Table 8).
In fact, with the exception of compound 2 (Ki = 527 nM), the inhibition
constants for the tropolones were greater than 2500 nM. Hence, we predicted
that the tropolones will weakly modulate the acetyl-specific tubulin, Ac-α-tubK40, in Jurkat and HuT-78 cells and tested our hypothesis after a 12h
treatment with 10 µM HDACi via FACS analysis. We used 10 µM
concentrations because it resulted in significantly low cell death compared to
higher concentrations thus allowing for a more precise evaluation of cellular
effects. We compared our results to published data for tubulin modulation by
our experimental control, SAHA (33). Detailed experimental methods are in
Section G of the Materials and Methods chapter. Corresponding histograms
are in sections 16 and 17 of the Appendix.

We found that SAHA activated about a 10-fold increase in tubulin
hyperacetylation in both Jurkat and HuT-78 cells when compared to the
untreated control (Table 8; Figure 3). On the other hand, our compounds
modulated tubulin within the threshold of the untreated control. In fact, many
of the tropolones, such as compounds 2 and 7, had lower GMFI values for
Ac-α-Tub-K40 modulation than the untreated control. However, selective
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inhibition of class I HDAC enzymes, particularly HDAC8, is also associated
with weak tubulin modulation (34); conversely, pan-HDACi and HDAC6selective HDACi show significant tubulin modulation as a result of HDAC6
hyperacetylation (30, 33, 34). Therefore, these observations support our
biochemical data that shows very poor inhibition of HDAC6 by the tropolones
and lends support to our claim on the isoform-selective nature of HDAC
inhibition by the tropolones.

Table 8: Comparative analysis of tubulin modulation and HDAC6 inhibition. Note:
Not applicable (N.A.); Not determined (N.D.)
Treatment

Tubulin modulation
(10 µM HDACi)
Jurkat, GMFI

HDAC6 enzyme
Inhibition (Ki , nM)

HuT-78, GMFI

Control

5.38

18.20

N.A.

SAHA

54.20

177.00

3.02

Compound 2

2.89

13.40

527

Compound 5

2.75

N.D.

>2500

Compound 7

1.89

13.20

>2500

Compound 9

6.71

17.30

>2500

Compound 10

2.14

9.21

>2500

Compound 11

3.74

12.80

>2500

Compound 13

6.57

2.52

>2500

Compound 14

6.2

11.60

>2500
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Figure 3: Comparative analysis of tubulin modulation and HDAC6 inhibition

F. Conclusions
Accumulation of histones and non-histone proteins such as tubulin are
validated mechanisms of HDAC inhibition. Therefore, we conducted a
comprehensive investigation of the hyperacetylation of a panel of acetylspecific histones and tubulins in HT29, Jurkat and HuT-78 cells. Our
compounds were the most sensitive to treatment in Jurkat cells and activated
hyperacetylation of H4K12Ac; some of our compounds responded to H3K9Ac
and H3K23Ac whereas SAHA responded with at least a 2-fold increase in
hyperacetylation for all the promoter-specific histones. BA, an experimental
control for our HT29 data, showed the same trend indicating that both HDACi
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are pan-HDACi unlike the tropolones which showed selectivity to promoterspecific histones. Furthermore, we conducted a comparative analysis of
tubulin modulation and HDAC6 inhibition and we found that our compounds
did not significantly induce hyperacetylation of Ac-α-tub-K40 unlike SAHA that
activated a ten-fold increase in tubulin hyperacetylation in both HuT-78 and
Jurkat cells. Our cellular data on tubulin hyperacetylation correlates with our
biochemical data that showed weak inhibition of HDAC6. Overall, our
comprehensive analysis of tubulin and histone modulation lends support to
our claim on the isoform nature of HDAC inhibition by the tropolone library.
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Chapter 6
Elucidating the antiproliferative effects of tropolones on cell cycle progression

A. Introduction
The cell cycle is a precisely programmed series of events that enables
a cell to duplicate its contents and generate two daughter cells (1). The
machinery that constitutes the cell cycle clock (2; Figure 1) operates on a
similar level in all cell types throughout the body (1, 2). The cell cycle clock
uses a subfamily of serine/threonine protein kinases, known as the cyclindependent kinases (CDK), to execute the various steps of the cell cycle.

Figure 1: Depiction of cell cycle machinery (2).
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A newly formed cell either retreats to a quiescent stage, G0, or initiates a
new round of active growth and division, collectively termed proliferation. Unlike
the accumulation of RNA and proteins which is initiated immediately, DNA
synthesis is deferred for 12-15 hours resulting in the 1st gap of the cell cycle
known as G1. Following G1, DNA synthesis (the S phase), typically takes 6-8
hours to reach completion. Before cells can proceed to the M phase (mitosis),
there is a second gap, termed G2, typically lasting 3-5 hours, in which cells
further prepare for entry into mitosis into the M phase (mitosis).
Cell cycle deregulation is recognized as the hallmark of cancer
progression in most malignant tumors (3). HDAC inhibitors (HDACi) of various
structural classes have been shown to induce G1, S phase and/or G2/M arrest
and concurrently disrupt mitotic progression in proliferating cells in normal and
malignant tissues (4-25). The natural product, hinokitiol (compound 10), has
been reported to induce arrest of the G1 phase of the cell cycle in malignant
melanomas presumably as a result of association with the CDK inhibitor, p27 (
26). Therefore, the focus of this chapter is to evaluate the antiproliferative
effects of our tropolone library on cell cycle progression in the four cell lines that
were the most sensitive to treatment by tropolones via flow cytometric analyses.
The use of fluorescent activated cell sorting (FACS) in flow cytometry
allows for fast, objective and quantitative measurements on apoptotic cells when
compared to the classic methods of morphological examination by electron
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microscopy or DNA ladder formation by gel electrophoresis (27). The amount of
bound fluorescent dye, typically propidium iodide, in a given cell is correlated
with the DNA content in the cell (27-30); thus, percentages of cell populations in
each cell cycle phase were calculated based on DNA content histograms with
the aid of the FlowJo Analysis Workstation (Tree Star, Inc.). Furthermore, when
represented on frequency histograms, DNA fragmentation in apoptotic cells is
characterized by a distinctive sub-G1 peak which represents oligonucleosomal
DNA fragments and exhibits a fluorescent intensity lower than that of G 1 cells
(27-30). Cell cycle analysis was performed at multiple time points and/or multiple
concentrations when possible. We compared our data with published reports of
cell cycle analysis for the experimental control, SAHA, when possible (22-24).
With the exception of the 12h time-point for the Jurkat cells, corresponding
histograms for cell cycle analyses are in sections 18-22 of the Appendix.

B. Elucidation of antiproliferative effects in HCT116 colon cancer cells
Initial assessment of the antiproliferative effects of tropolones on cell cycle
progression was conducted in HCT116 colon cancer cells at two different
concentrations (10 µM and 50 µM) after a 24h incubation period via flow
cytometric analyses. 10 μM SAHA served as experimental control. It should be
noted that a higher concentration of SAHA could not be evaluated since it
resulted in excessive cell death that significantly altered the cell cycle profiles
and reduced data accuracy. Based on cytotoxicity data, four compounds (2, 7, 12
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and 13) were chosen for FACS analysis (Table 1). An increase in the sub-diploid
peak (<G0/G1) that is indicative of apoptosis was observed for both the 10 µM
and 50 µM treatments for the tropolones. However, the antiproliferative effects of
tropolones on cell cycle progression seem to be concentration-dependent since a
higher percentage of cells in both the sub-G0/G1 phase and the G1 phase were
observed at a concentration of 50 µM compared to a 10 µM concentration. In
fact, treatment with 50 µM of compound 13 resulted in the most significant G1
arrest since 77.3% of cells were observed in the G1 stage compared to 48.3% in
the untreated control, 47.5% in the 10 µM treatment of compound 13, and 51.2%
in the 10 µM SAHA treatment.
G1 arrest is typically associated with increased growth inhibition and
concurrently decreased DNA synthesis (31). G1 arrest is also associated with
increased expression of the cyclin-dependent kinase inhibitor (CDKI), p21,
indicating that the anti-proliferative effects of SAHA and compound 13, may be
arbitrated by changes in the expression of CDKI (23. 24). Correspondingly, a
decrease in the S and G2-M phases was also observed for the treatment with 50
μM compound 13 and SAHA. Conversely, 50 µM of compound 12 was the only
compound that activated an increase in the population of cells in the G2-M phase
since 27.1% of cells were observed in the G2-M phase compared to 21% in the
untreated control, 19.1% in the 10 µM treatment of compound 12, and 17.3% in
the 10 µM SAHA treatment. Increased G2-M arrest is associated with enhanced
apoptosis (31).
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Table 1: Cell-cycle distribution as measured via FACS analysis after a 24h
treatment in HCT116 cells.
Treatment

24h
<G0/G1

%G1

%S

%G2-M

Control

2.06

48.30

24.60

21.00

10 µM SAHA

13.60

51.20

9.90

17.30

10 μM Compound 2

5.15

50.00

23.30

11.40

50 μM Compound 2

6.99

51.50

28.10

6.04

10 μM Compound 3

6.40

51.80

30.50

5.11

50 μM Compound 3

9.64

43.60

32.10

1.43

10 μM Compound 7

3.98

51.00

19.50

18.80

50 μM Compound 7

6.58

55.00

21.10

2.22

10 μM Compound 12

2.80

44.30

15.40

27.10

50 μM Compound 12

2.97

50.30

19.10

19.10

10 μM Compound 13

3.06

47.50

22.70

18.50

50 μM Compound 13

5.72

77.30

9.10

3.99

Compound 2 at a 10 µM concentration and compound 3 at both
concentrations were the only compounds to activate an S-phase arrest.
However, at a 10 μM concentration in HCT116 cells, the tropolones did not
exhibit any notable cellular effects indicating that further modifications to the
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current tropolone scaffold may be needed in order to exert more potent cellular
effects at lower concentrations in these solid tumor cells.

C. Elucidation of cell cycle progression in BXPC3 cells
SAHA induced a more significant cell cycle arrest in BXPC3 pancreatic
cells than the tropolones after a 12h incubation period. Specifically, SAHA
treatment resulted in an increase in the population of cells in the sub-G0/G1
phase and G2/M phase; concurrently, SAHA treatment also decreased the
percentage of cells in the G1 phase and the S phase. Conversely, the distribution
of DNA content by ten tropolones (Compounds 2, 3, 5,7, 9-14) essentially
resembled that of the untreated control; although on average, there was a lower
percentage of cells in the G1 phase and more cells in the S phase and G2-M
phase.
Furthermore, there was no significant arrest of the sub-G0/G1 phase of
the cell cycle by either SAHA or the tropolones. Given that arrest of the subG0/G1 phase of the cell cycle is usually seen as an index for apoptosis (27-30), it
may be deduced that these HDACi may not significantly induce apoptosis in
BXPC-3 cells after a 12h incubation period. However, these observations
correlate with data from the cancer cell line selective cytotoxicity assays (Chapter
5) in which the HDACi showed the most pronounced antiproliferative effects in
the hematological cell lines. In a similar manner to the HCT116 colon cancer
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cells, it may be possible that a higher concentration and/or a longer treatment
period may result in more pronounced effects in the BXPC3 cell line.

Table 2: Elucidation of the antiproliferative effects of tropolones on cell cycle
progression as measured via FACS analysis after a 12h treatment in BXPC3 cells.
Treatment

12h
%<G0/G1

%G1

%S

%G2-M

Control

1.21

67.20

7.44

11.30

10 μM SAHA

3.55

59.60

2.92

15.90

10 μM Compound 2

1.44

58.10

11.00

10.70

10 μM Compound 3

0.81

69.10

7.60

10.50

10 μM Compound 5

0.59

59.70

9.44

12.10

10 μM Compound 7

0.96

60.50

9.89

10.90

10 μM Compound 9

0.99

63.40

8.01

11.70

10 μM Compound 10

1.67

63.20

8.45

11.00

10 μM Compound 11

1.90

60.50

10.30

10.90

10 μM Compound 12

0.59

57.90

11.10

10.70

10 μM Compound 13

0.62

66.80

7.49

11.50

10 μM Compound 14

0.95

65.70

8.55

11.40
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D. Time-dependent analysis of cell cycle progression in Jurkat cells
Given that our compounds, like most HDACi in clinical development
today, showed preferential inhibition to hematological malignancies, we
decided to conduct cell cycle analyses at multiple time points in both Jurkat
and HuT-78 cells (5-7, 9, 10, 15, 16, 19-21, 25). We observed a distinct arrest
of the sub-diploid phase (<G0/G1) of the cell cycle by 10 µM treatments of the
tropolones over multiple time points (Table 3). As previously indicated, an
increase in the subdiploid peak is often seen as an index for apoptosis; thus
this observation will be further evaluated in subsequent chapters where we
will explore the induction as well as mechanisms of apoptosis of tropolones in
Jurkat cells.
There was also a subtle arrest of the G1 phase of the cell cycle followed
by correspondent decreases in both the S-phase and G2-M phase of the cell
cycle following tropolone treatment at all three time-points. On the other hand,
SAHA was able to induce an increase in the population of cells in the subG0/G1, S and G2-M phases of the cell cycle at 12h (Figure 2) but at 24h and
36h, the percentage of apoptotic cells (<G0/G1) was 48.90% and 60.80%
respectively resulting in concurrent decreases in the population of cells in
other phases of the cell cycle. Furthermore, our internal negative control,
compound 11 with a methylated tropolone as the key moiety, essentially
resembled the untreated control. This observation lends support to our
hypothesis on the availability of the alpha-hydroxyl ketone on the tropolone
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ring being essential for metal chelation at the HDAC active site. However, as
previously stated in previous chapters, efforts are currently in place by the
Anderson laboratory to further explore this hypothesis via structural studies of
a tropolone bound to HDAC8.

Table 3: Time-dependent analysis of the antiproliferative effects of tropolones on cell
cycle progression as measured via FACS analysis in Jurkat cells after a 12h
treatment.
Treatment

12h
%<G0/G1

%G1

%S

%G2-M

Control

4.16

65.0

19.5

10.0

10 μM SAHA

20.4

25.9

31.6

19.7

10 μM Compound 2

22.3

64.3

11.1

1.39

10 μM Compound 7

16.3

71.5

10.2

1.25

10 μM Compound 11

3.14

68.4

17.5

9.52

10 μM Compound 13

13.3

67.4

15.2

2.67
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Table 4: Time-dependent analysis of the antiproliferative effects of tropolones on
cell cycle progression as measured via FACS analysis in Jurkat cells after a 24h
treatment.
24h
Treatment

%<G0/G1

%G1

%S

%G2-M

Control

2.39

60.90

20.90

14.30

10 µM SAHA

48.90

7.46

19.90

12.30

10 μM Compound 2

13.90

70.20

13.30

1.81

10 μM Compound 7

13.90

66.50

15.80

2.58

10 μM Compound 11

1.62

63.00

20.60

13.50

10 μM Compound 13

13.00

69.40

14.20

2.32

Table 5: Time-dependent analysis of the antiproliferative effects of tropolones
on cell cycle progression as measured via FACS analysis in Jurkat cells after
a 36h treatment.
Treatment

36h
%<G0/G1

%G1

%S

%G2-M

Control

1.80

59.10

23.00

14.20

10 μM SAHA

60.80

6.90

15.60

14.90

10 μM Compound 2

18.50

64.20

13.30

2.97

10 μM Compound 7

13.40

65.90

14.60

4.35

10 μM Compound 11

1.22

60.70

21.80

14.60

10 μM Compound 13

17.70

64.70

13.10

3.21
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Figure 2: Evaluation of the antiproliferative effects of tropolones on cell cycle
proliferation after a 12h treatment in Jurkat cells.
a.

Control

b.

10 µM SAHA

c.

10 µM Compound 2

d.

10 µM Compound 7
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e.

10 µM Compound 11

f.

10 µM Compound 13

Given our promising results with 10 µM treatments, we also evaluated the
antiproliferative effects of eight tropolones (Compounds 2, 5, 7, 9-11, 13 and 14)
at a higher concentration of 25 µM after a 12h incubation period in Jurkat cells
(Table 4). The tropolones were able to induce a subtle subdiploid phase arrest
but activated a more pronounced increase in the population of cells in the S
phase particularly when compared to the 10 µM treatment. However, it seems
that a 10 µM concentration is sufficient to activate an increase in the subdiploid
phase without excessive cell death which alters cell cycle profiles thus reducing
data accuracy; Therefore, future assays on apoptosis and mechanisms of gene
expression will utilize this 10 µM concentration.
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Table 6: Elucidation of the antiproliferative effects of 25 µM tropolones on cell
cycle progression as measured via FACS analysis after a 12h treatment in
Jurkat cells.
Treatment

12h
%<G0/G1

%G1

%S

%G2-M

Control

3.78

64.20

17.50

13.20

25 μM Compound 2

4.25

59.40

27.10

7.09

25 μM Compound 5

5.20

60.90

27.60

4.94

25 μM Compound 7

3.47

61.10

25.30

7.66

25 μM Compound 9

3.93

60.10

27.90

6.22

25 μM Compound 10

5.17

53.90

33.30

6.00

25 μM Compound 11

3.34

63.10

18.70

13.00

25 μM Compound 13

4.94

57.00

29.10

6.37

10 μM Compound 14

4.06

58.50

27.60

7.27

E. Elucidation of antiproliferative effects of tropolones on HuT-78 cells
In a similar manner to Jurkat cells, 10 µM treatments of tropolones were
used to evaluate antiproliferative effects on cell cycle progression in HuT-78
cells. 5 µM SAHA served as experimental control to allow for more accurate
observation of cell cycle profiles with reduced cell death. After a 12h
treatment, there was no significant increase in the subdiploid population, G1
or S phases by either SAHA or the tropolones. However, all the compounds
were able to activate a G2-M arrest with the most significant effect being
exhibited by compound 7. After a 24h treatment, there was a significant
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increase in the subdiploid phase of the cell cycle and a subtle G1 arrest
followed by a corresponding decrease in the S phase and G2-M phases for all
the compounds except for compound 11 that basically resembled the
untreated control. After 36h, the most significant observation that we saw for
all the treatments was an increase in the subdiploid peak; thus prompting for
future investigations into the induction and execution of apoptosis.
Table 7: Time-dependent analysis of cell cycle progression in HuT-78 cells as
measured via FACS analysis in HuT-78 cells after a 12h treatment.
12h
Treatment
%<G0/G1

%G1

%S

%G2-M

Control

11.20

54.70

16.50

13.80

5 μM SAHA

7.73

46.90

17.10

23.80

10 μM Compound 2

4.78

56.30

15.10

22.40

10 μM Compound 7

5.96

46.70

16.40

29.20

10 μM Compound 11

7.12

51.70

17.70

21.90

10 μM Compound 13

7.44

55.50

16.20

20.40
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Table 8: Time-dependent analysis of cell cycle progression in HuT-78 cells as
measured via FACS analysis in HuT-78 cells after a 24h treatment.
Treatment

24h
%<G0/G1

%G1

%S

%G2-M

Control

4.71

43.40

31.80

15.90

5 μM SAHA

42.80

29.40

12.70

11.50

10 μM Compound 2

19.10

41.60

22.40

14.70

10 μM Compound 7

11.70

46.40

17.50

23.00

10 μM Compound 11

5.33

49.70

25.50

14.90

10 μM Compound 13

10.50

48.00

19.10

21.60

Table 9: Time-dependent analysis of cell cycle progression in HuT-78 cells as
measured via FACS analysis in HuT-78 cells after a 36h treatment.
Treatment

36h
%<G0/G1

%G1

%S

%G2-M

Control

8.98

41.60

24.50

22.70

5 μM SAHA

43.20

34.30

14.00

6.24

10 μM Compound 2

8.24

53.10

21.60

14.70

10 μM Compound 7

16.70

40.40

21.80

18.00

10 μM Compound 11

39.40

20.00

26.50

13.90

10 μM Compound 13

18.00

42.70

20.00

17.00
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F. Conclusions
Cell cycle arrest is well established as a major mechanism of HDAC
inhibition. Analyses of cell cycle distribution in multiple cell lines treated with
tropolones indicate that the tropolones exert antiproliferative effects on cell
cycle progression in a time-dependent manner particularly in the two
hematological cell lines, Jurkat and HuT-78. An increase in the sub-diploid
population of cells treated with tropolones, an index for apoptosis, was the
most evident in Jurkat cells followed by the HuT-78 cells. These observations
prompted further investigation on the induction and mechanisms of apoptosis
that will be discussed in future chapters. The antiproliferative effects of
tropolones on cell cycle progression in hematological cell lines seem to be
time-dependent since more notable events were observed after longer
incubation periods. On the other hand, a high concentration of 50 µM was
required in order to induce significant changes in cell cycle distribution in
HCT116 cells. 10µM concentrations of the tropolones did not result in
significant cellular changes in HCT116 and BXPC3 cells lending support to
earlier observations that we observed in the cytotoxicity assays. Finally,
compound 11, typically exhibited changes in cell cycle distribution that were
essentially the same as the untreated control thus lending support to our
claim on the availability of the alpha-hydroxyl ketone being essential for metal
chelation at the HDAC active site.
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Chapter 7
Investigation of specific gene expression

A. Introduction
Alterations of various cell signaling pathways can result in dysregulation of
apoptosis and lead to cancer and neurodegenerative diseases (1-5). The p53
tumor suppressor gene is a transcription factor that regulates the cell cycle and is
the most widely mutated gene in human tumorigenesis (4-13). The critical role of
p53 is evident by the fact that it is mutated in over 50% of all human cancers (413). In fact, the selective binding of HDACs may involve pathways where p53
mediate repression of transcription (Figure 1; 6, 12, 13). For example, the levels
of cell death by apoptosis that is induced by the fatty acid HDACi, sodium
butyrate, is greatly reduced in the absence of p53 (6); whereas the
hydroxamates, TSA and SAHA, can induce cell death by apoptosis in either a
p53-dependent or a p53-independent manner (5-7, 9). Thus, it will be
enlightening to evaluate if tropolone-mediated growth inhibition involves a p53dependent pathway.
Cyclin-dependent kinases (CDKs) are a family of serine/threonine kinases
that rely on associated cyclin proteins to execute the various steps of the cell
cycle (1, 2, 14). CDK activity is regulated through posttranslational modifications
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and subcellular translocations of specific CDK inhibitors (CDKIs), which are
organized in two families, INK4 and Cip/Kip (1, 2).

Figure 1: Schematic representation of the mechanism of action of HDAC
inhibitors (HDI, HDACi; 6)

The INK4 family (inhibitors of cyclin D-dependent kinases) consists of four
members: p16INK4A, p15INK4B, p18INK4C and p19INK4D, and the Cip/Kip family
(inhibitors of cyclin D-, cyclin E-, and cyclin A-dependent kinases) comprises
p21Cip1 (also known as p21Waf1), p27Kip1 and p57Kip2 (1, 2). The overexpression of
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CDKI such as p21CIP1/WAF1 through histone hyperacetylation is well demonstrated
as one of the molecular mechanisms for anti-cancer effect of HDACi (6, 8, 1133). The natural product, hinokitiol (compound 10), has been reported to arrest
the G1 phase of the cell cycle in malignant melanoma cells presumably as a
result of p27 activation (34). Furthermore, p15 and other INK4 proteins are
implicated in early to mid-stage G1 whereas p21 and p27 act broadly on all
stages of the cell cycle (2). Therefore, we will explore the ability of tropolones to
suppress tumor growth via specific gene expression of p15INK4B, p21CIP1/WAF1 and
p27KIP1in Jurkat and HuT-78 cells, the two cell lines that are the most sensitive to
tropolone-mediated growth inhibition. Results garnered from evaluation of
specific gene expression will lend support to cell cycle analysis data (Chapter 6)
and further illuminate the mechanisms of action of tropolones as HDACi.
We evaluated specific gene expression via FACS analysis by sequentially
incubating treated cells with primary antibodies for p53, p21, or p27 followed by
treatment with secondary antibodies conjugated with a fluorescein isothiocyanate
(34-38). We determined values for geometric mean fluorescence intensities
(GMFI), equivalent to the median cell population response, for each cell
treatment with the aid of the FlowJo Workstation (36-38). Assays were
performed at multiple time points and/or multiple concentrations when possible.
We compared our data with published reports for specific gene expression for the
experimental control, SAHA, when possible (6, 15, 20, 21, 33). Detailed
experimental methods are in Section I of the Materials and Methods chapter.
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With the exception of the 24h time-point for the Jurkat cells, corresponding
histograms for evaluation of specific gene expression are in sections 23-36 of the
Appendix.

B. Elucidation of p53 expression in Jurkat cells
The tumor suppressor p53 belongs to a family of structurally and
functionally related transcription factors, including p73 and p63 (10). Diverse
cellular stresses, genotoxic stresses, and many anticancer agents can activate
p53 activity that consequently stimulates the transcription of many genes that are
involved in cell cycle regulation and apoptosis (2, 10). The mechanisms of action
of many HDACi may either be p53-dependent or p53-independent (6, 12).
Hence, we evaluated activation of p53 in Jurkat cells after a 12h treatment with
10 µM HDACi via flow cytometric analysis (Table 1). We observed that the values
for geometric mean fluorescence intensities (GMFI) for the tropolones and SAHA
were within the same threshold of the untreated control. Given that there was no
significant overexpression of p53 protein levels following treatment, our results
suggest that tropolones may mediate growth inhibition in Jurkat cells in a p53independent manner. However, further investigation at multiple time points and in
multiple cell lines may be needed to validate our data since HDACi have been
reported to act uniquely in different cell lines (6, 7, 11, 12, 15, 23-25, 27-30).
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Table 1: Elucidation of p53 expression in Jurkat cells after a 12h treatment with 10 µM HDACi
GMFI in HuT-78 cells
Treatment
Control

SAHA

2

5

7

9

10

11

13

14

4.22

3.92

4.39

4.34

3.34

3.37

3.48

5.13

3.65

3.92

(p53, 12h)

C. Comparative analysis of p15 expression in Jurkat and HuT-78 cells
The INK4 family of CDKIs consists of four members, p16 INK4A, p15INK4B,
p18INK4C and p19INK4D (2); these CDKI are targeted specifically to the CDK4 and
CDK6 complexes and as a result are active in the early and mid-G1 phase of
the cell cycle (2). Based on our cell cycle analyses data (Chapter 6), we
investigated the activation of p15INK4b primary antibodies in Jurkat and HuT-78
cells following a 24h treatment with 10 µM and 50 µM tropolones
correspondingly via FACS analysis (Table 2). 10 µM SAHA served as
experimental control and we did not evaluate 50 µM SAHA due to excessive cell
death. We observed that activation of p15 antibodies were within the same
range for the tropolones and the untreated control for both the 10 µM and 50 µM
treatments in Jurkat cells. For example, 10 µM and 50 µM treatments of
compound 2 resulted in GMFI values of 2.27 and 2.38 respectively whereas the
untreated control had a GMFI value of 2.21. Concurrently, SAHA treatment

140

resulted in a slightly higher increase in p15 activation in Jurkat cells
(GMFI=3.43).
We also observed similar trends in HuT-78 cells; SAHA treatment resulted
in a slightly higher increase in p15 activation (GMFI of 28.00 vs. 17.00 in the
untreated control). Compound 12 was the only tropolone that showed a notable
increase in p15 activation at a higher concentration resulting in more than twofold increase in p15 activation at 50 µM when compared to the 10 µM treatment
that was essentially the same as the untreated control (GMFI = 17.90). These
results suggest that activation of p15INK4B may not be a mechanism for
tropolone-mediated growth inhibition for Jurkat and HuT-78 cells but it is
possible that other INK4 proteins may be implicated by the tropolones.
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Table 2: Comparative analysis of p15 activation in Jurkat and HuT-78 cells. Note: N.D. = Not
determined.
Jurkat

HuT-78
INK4B

Treatment

p15
10 µM

Control

50 µM

, GMFI (24h)
10 µM

2.21

50 µM
17.00

SAHA

3.43

N.D.

28.00

N.D.

Compound 2

2.27

2.38

19.40

18.20

Compound 3

2.25

2.82

17.50

19.40

Compound 5

2.65

N.D.

15.30

N.D.

Compound 7

2.28

2.68

17.30

20.60

Compound 9

2.65

N.D.

17.30

N.D.

Compound 10

1.90

2.62

17.70

18.60

Compound 11

2.23

2.35

15.60

17.10

Compound 12

2.51

2.46

17.90

38.10

Compound 13

2.34

2.43

14.70

17.10

Compound 14

2.39

2.35

14.30

18.00

D. Elucidation of p27 activation in Jurkat and HuT-78 cells
The three broad-spectrum CDKI, p21CIP1/WAF1, p27KIP1 and p57KIP2 are
known to act at all stages of the cell cycle and inhibit all of the cyclin-CDK
complexes that form at later stages of the cell cycle (2). While relatively little is
known about p57, p21 and p27 function similarly but p27 expression is unique in
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its own way and has been shown to be implicated in HDAC inhibition (20, 34,
40); moreover, p27 is reported to be available in high concentrations in the G0
quiescent stage (2). Given these observations and our cell cycle analyses data,
we conducted an initial assessment of p27 activation in HuT-78 cells after a 12h
treatment with 10 µM HDACi via FACS analysis.
With the exception of compounds 2 and 8, the HDACi activated p27 levels
within the same threshold as the untreated control; compound 2 had a notably
lower GMFI (8.25 vs. 24.40 in the untreated control) whereas compound 9 had
the highest GMFI of all the compounds (31.80). These results suggest that p27
activation may not be implicated in tropolone-mediated cell cycle arrest after a
12h treatment with 10 µM in HuT-78 cells.

Table 3: Initial assessment of p27 activation in HuT-78 cells after a 12h treatment with 10 µM HDACi
GMFI in HuT-78 cells

Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(p27, 12h)

24.40

20.30

8.25

20.60

20.20

31.80

20.10

25.00

22.90

20.80

Alternatively, we evaluated p27 activation in Jurkat cells after 12h and 24h
treatments with the tropolones in Jurkat cells (Table 4). 10 µM treatments of
SAHA, compound 2 and compound 7 did not exert any overexpression of p27
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when compared to the untreated control after a 12h treatment. However, after a
24h treatment period, 10 µM treatments of SAHA, compound 2 and compound 7
resulted in slightly higher expression levels of p27 but still resulting in less than
a two-fold difference when compared to the untreated control.

Table 4: Time-dependent analysis of p27 activation in Jurkat cells treated with
HDACi. Note: ND=Not determined.
Jurkat
Treatment

KiP1

p27

, GMFI

12h

24h

Control

10.10

7.76

10 µM SAHA

5.57

8.64

10 µM Compound 2

6.14

9.18

50 µM Compound 2

ND

12.10

10 µM Compound 7

8.87

9.47

50 µM Compound 7

ND

8.58

Interestingly, treatment with 50 µM of compound 2 resulted in the most
significant overexpression of all treatments (12.10 vs. 7.76 in the untreated
control) whereas 50 µM of compound 7 actually resulted in a lower activation of
p27 when compared to the corresponding 10 µM treatment (8.58 vs. 9.47). This
observation may be due to the fact that compound 7 is more cytotoxic in Jurkat
cells than compound 2 (GI50 of 0.67 µM vs. 3.33 µM) thus the 50 µM treatment
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with compound 7 may have resulted in more cell death leading to a lower
number of intact cells to respond to the p27 treatment.
Given that there was no significant overexpresssion of p27 at either 12h or
24h treatment periods or with either 10 µM or 50 µM treatments of the
tropolones, it may be deduced that p27 may not be implicated in tropolonemediated growth inhibition and cell cycle arrest in Jurkat and HuT-78 cells.
However, studies in human malignant melanoma cells have shown that 80 µM of
the natural product, hinokitiol (compound 10), activated p27 expression after a
24h treatment (34). Therefore, it is possible that a higher concentration of the
tropolones may result in increased p27 expression in Jurkat and HuT-78 cells;
but given the high potency of the tropolones in both cell lines, a higer
concentration may also result in excessive cell death that will result in a
decreased amount of intact cells that respond to antibody treatments.

E. Investigation of p21 overexpression in Jurkat and HuT-78 cells
The p21 gene is a repressor complex, tightly controlled by the tumor
suppressor protein p53, which inhibits cell cycle progression by blocking CDK
activity and arresting the cell cycle in G1 phase (2, 4-6, 8, 11-13, 29).
Expression profiling studies have shown that treatment of HDACi alters the
expression of approximately 2% to 10% of cellular genes including the upregulation of histones, tubulins, and the CDKI, p21CIP1/WAF1 (6, 8, 11-13, 15, 21,
23, 28-30, 41-43). In fact, p21 is one of the most commonly induced genes by
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HDACi and HDACi-mediated expression of p21 is correlated with an increase in
the acetylation of histones associated with the p21 promoter region (15, 20, 28).
For example, the p21 gene promoter has been shown to be a direct target for
SAHA in ARP-1 human multiple myeloma cells but SAHA treatment did not
concurrently alter p27 expression levels once again indicating that both panCDKI have unique functions within cells (15, 20, 28). Therefore, we conducted
comprehensive analyses of p21 overexpression in Jurkat and HuT-78 cells via
FACS studies.
Our initial assessment of p21 activation in Jurkat cells was conducted after
a 12h treatment with 10 µM HDACi (Table 5). We found that SAHA and the
tropolones exerted p21 expression within the same threshold as the untreated
control. For example, the natural product (compound 10) exerted the most
significant expression among all HDACi (GMFI = 5.30 vs. 4.62 in the untreated
control and 5.18 in SAHA). The results of the preliminary assessment warranted
further investigation of p21 activation by the tropolones in Jurkat cells.

Table 5: Initial assessment of p21 activation in Jurkat cells after a 12h treatment with 10 µM HDACi
GMFI in Jurkat cells
Treatment

Control

SAHA

2

5

7

9

10

11

13

14

(p21, 12h)

4.62

5.18

4.75

4.06

4.91

4.09

5.30

2.47

4.72

3.03
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Based on our initial 12h assessment, we hypothesized that a longer
treatment period and/or a higher concentration of the tropolones may be
required in order to induce notable effects in p21 expression in the two
hematological cell lines. Therefore, we conducted an investigation of p21
overexpression at after a 24h treatment with 10 µM and 50 µM concentrations of
the tropolones in Jurkat and HuT-78 cell lines (Table 6; Figure 2). After a 24h
period, SAHA treatment resulted in a three-fold increase in expression levels of
p21 whereas the tropolones were either slightly higher or lower than the
untreated controls at both 10 µM and 50 µM treatments in Jurkat cells. Once
again, compound 10 exerted the most significant effect (2.52 vs. 1.35 in the
untreated control) at a 10 µM concentration whereas compound 2 exerted the
most significant effect (2.53 vs. 1.57 in the untreated control) at a 50 µM
concentration in Jurkat cells.
On the other hand, SAHA treatment resulted in more than a two-fold
increase in p21 expression levels whereas the tropolones were around the
same range as the untreated control in HuT-78 cells. For example, compound
13 induced the most significant effect (32.30 vs. 21.80 in the untreated control)
at a 10 µM concentration whereas compound 2 induced the most significant
effect (2.53 vs.1.57 in the untreated control) at a 50 µM concentration in Jurkat
cells.
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Table 6: Comparative analysis of p21 activation in Jurkat and HuT-78 cells. Note: ND = Not
determined.
Treatment

Jurkat

HuT-78
Cip1/WAF1

p21

,

GMFI (24h)

10 µM

50 µM

10 µM

Control

1.35

1.57

21.8

SAHA

4.03

ND

53.20

ND

Compound 2

2.26

2.53

21.50

39.50

Compound 3

2.42

2.42

ND

34.30

Compound 5

2.41

ND

26.70

ND

Compound 7

1.67

1.87

21.80

26.20

Compound 9

1.44

ND

23.90

ND

Compound 10

2.52

2.03

21.70

29.10

Compound 11

1.16

1.52

22.40

20.40

Compound 12

ND

1.84

ND

26.70

Compound 13

2.01

1.85

32.30

29.60

Compound 14

1.39

1.86

23.20

23.90
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50 µM

Figure 2: Evaluation of p21 expression in Jurkat cells after a 24h treatment with
10 µM HDACi. Note: Untreated control for pertinent HDACi treatments
represented in red and HDACi represented in blue on the corresponding
histograms.

a)

c)

SAHA

b)

Compound 5

d)
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Compound 2

Compound 7

e)

Compound 9

f)

Compound 10

g)

Compound 11

h)

Compound 13
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i)

Compound 14

F. Comparative analysis of gene expression via qRT-PCR analysis in
Jurkat cells
We followed up our FACS studies on p21 expression in Jurkat cells with
quantitative real-time polymerase chain reaction (qRT-PCR). Reversetranscription polymerase chain reaction (RT-PCR) assays are considered the
most common method for characterizing and confirming gene expression
patterns, and also for comparing the levels of mRNA in different sample
populations (44). Quantitative real-time PCR is often used to further validate RTPCR protocols through the use of a standardized primer and internal competitor
template sets for each target gene (44). Therefore, following a 24h treatment with
10 µM concentrations of both SAHA and compound 2 in Jurkat cells, we
conducted RT-PCR and qRT-PCR using methods that are detailed in Section J
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of the Materials and Methods chapter (45-47). Assay was performed in triplicate
and we compared our p21 data to published reports for our experimental control,
SAHA (33). Standard deviation values are reported in the Appendix, section 36.
We evaluated the relative gene expression levels of HDAC2, p21 and the
vitamin D receptor (VDR). Clinical studies have shown a correlation between low
levels of vitamin D in patients with lymphomas and increased mortality thus
prompting our interest in evaluating tropolone-mediated VDR expression (48).
Our results are highlighted in table 7 and in Figure 2.

Table 7: Elucidation of relative expression of specific genes after a 24h treatment with 10
µM HDACi in Jurkat cells
Relative Gene Expression
Treatment
HDAC2

p21

VDR

Control

1.00

1.00

1.00

Compound 2

0.86

0.95

0.58

SAHA

1.10

328.23

82.54
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Figure 3: Elucidation of relative expression of specific genes after a 24h
treatment of compound 2 in Jurkat cells

Similar to our flow cytometric data, we found that compound 2 induced
gene expression levels of p21 around the same threshold as the untreated
control. Even though HDAC2 expression was also around the same range as the
untreated control, there was down-regulation of VDR gene expression levels by
compound 2. Alternatively, SAHA significantly overexpressed p21 and VDR gene
levels but HDAC2 levels were about the same when compared to either
compound 2 or the untreated control. Our data suggests that p21 activation may
not be a mechanism for tropolone-mediated growth inhibition; furthermore,
overexpression of VDR and HDAC2 may not be involved in the mechanisms of
action of tropolones. It may be plausible that the inability of the tropolones to
153

inhibit HDAC1 may hinder p21 activation since it has been reported that SAHA
treatment in multiple myeloma cells resulted in a marked decrease in HDAC1
expression and a significant overexpression of p21 (20, 21, 28). Moreover, gene
knockdown studies in human malignant melanoma cells have shown that p21 is
not required for the induction of cell cycle arrest by hinokitiol, compound 10 (34).
Furthermore, our preliminary assessment of gene expression highly suggests
that there is a distinct need for comprehensive gene studies via microarray
analysis in normal and mutant Jurkat and/or HuT-78 cells or even in animal
models in order to more distinctly appraise genes that are altered as a result of
tropolone treatment (49). Based on our enzyme inhibition data (Chapter 3),
mutant hematological cells may either be deficient of or overexpressed with
HDAC2 or HDAC8 thus serving as further proof of concept for our claim on the
isoform-selective nature of HDAC inhibition by the tropolones.

G. Conclusions
Elucidation of specific gene expression is critical in understanding the
molecular mechanisms of tropolones as HDACi. Selective binding of HDACs may
involve pathways where p53 mediate repression of transcription. Furthermore,
overexpression of CDKIs such as p21CIP1/WAF1 is well demonstrated as one of the
molecular mechanisms for anti-cancer effects of HDACi. Our results indicate that
tropolone-mediated growth inhibition may involve a p53-independent pathway in
Jurkat cells. Furthermore, preliminary evaluation of the overexpression of CDKIs
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that play active roles at early to mid-stage G1 (p15INK4B), as well as broadspectrum CDKIs (p21CIP1/WAF1 and p27KIP1) did not reveal any significant
activation of these proteins at the assayed concentrations and timepoints in
Jurkat and HuT-78 cells. However, compound 13 at a 50 µM concentration was
able to activate a two-fold increase of p15 after a 24h treatment in HuT-78 cells.
qRT-PCR analysis of p21 expression in Jurkat cells was also used to validate our
flow cytometric data. Based on published studies, we hypothesize that the
inability of the tropolones to overexpress p21 in may be due to lack of HDAC1
inhibition. These preliminary assessments highly suggest that there is a need for
a more comprehensive analysis of tropolone-mediated gene expression in
normal and mutant Jurkat or HuT-78 cells via microarray analysis in order to
more precisely determine altered genes.

H. References
1. Currais, A., Hortobágyi, T., & Salvador, S. The neuronal cell cycle as a
mechanism of pathogenesis in Alzheimer’s disease. Aging (Albany NY)
2009; 1(4): 363–371.
2. Weinberg, R. The Biology of Cancer. New York, NY: Garland Science, Taylor
& Francis Group, LLC., 2007.
3. Elmore, S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol.
2007: 35 (4): 495-516.
4. Wang X.W., & Harris, C.C. p53 tumor-suppressor gene: clues to molecular
carcinogenesis. J Cell Physiol. 1997;173 (2):247-55.
5. Davies, C., Hogarth, L.A., Dietrich, P.A., et. al. p53-independent epigenetic
repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. J
Biol Chem. 2011; 286(43): 37639–37650.
6. Ouaissi, M., & Ouaissi, A. Histone deacetylase enzymes as potential drug
targets in cancer and parasitic diseases.J Biomed Biotechnol. 2006;
2006(2):13474.
155

7. Knutson, A.K., Welsh, J., Taylor, T., et.al. Comparative effects of histone
deacetylase inhibitors on p53 target gene expression, cell cycle and
apoptosis in MCF-7 breast cancer cells. Oncol Rep. 2012; 27(3):849-53.
8. Ouaissi, M., Giger, U., Sielezneff, I., et al. Rationale for possible targeting of
histone deacetylase signaling in cancer diseases with a special reference to
pancreatic cancer. J Biomed Biotechnol. 2011: 315939.
9. Bajbouj, K., Mawrin, C., Hartig, R., et.al. P53-dependent antiproliferative and
pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J
Neurooncol. 2012; 107(3):503-16.
10. Nieto-Rementería, N., Pérez-Yarza, G., Boyano, M.D., et. al. Bexarotene
activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J
Dermatol. 2009; 160(3):519-26.
11. Ouaissi, M., Cabral, S., Tavares, J., et al. Histone deacetylase (HDAC)
encoding gene expression in pancreatic cancer cell lines and cell sensitivity
to HDAC inhibitors. Cancer Biol Ther. 2008; 7(4): 523-531.
12. Singh, B.N., Zhang, G., Hwa, Y.L., et. al. Nonhistone protein acetylation as
cancer therapy targets. Expert Rev Anticancer Ther. 2010; 10(6): 935–954.
13. Dickinson, M., Johnstone, R.W., & Prince, H.M. Histone deacetylase
inhibitors: potential targets responsible for their anti-cancer effect. Invest
New Drugs. 2010; 28 Suppl 1:S3-20.
14. Xiong, Y., Hannon, G.J., & Zhang, H. p21 is a universal inhibitor of cyclin
kinases. Nature. 1993; 366(6456):701-4.
15. Wozniak, M.B., Villuendas, R., Bischoff, J.R., et.al. Vorinostat interferes with
the signaling transduction pathway of T-cell receptor and synergizes with
phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
16. Schrump, D.S. Cytotoxicity Mediated by Histone Deacetylase Inhibitors in
Cancer Cells: Mechanisms and Potential Clinical Implications. Clin. Cancer.
Res 2009; 15: 3947-3957.
17. Han, J., Ahn, S., Park, S. et. al. Apicidin, a histone deacetylase inhibitor,
inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and
gelsolin. Cancer Res. 2000; 60 (21): 6068–6074.
18. Han, J.W., Ahn, S.H., Kim, Y.K., et. al. Activation of p21(WAF1/Cip1)
transcription through Sp1 sites by histone deacetylase inhibitor apicidin:
involvement of protein kinase C. J Biol Chem. 2001 ;276(45):42084-90.
19. Hrzenjak, A., Moinfar, F., Kremser, M.L., et al. Histone deacetylase inhibitor
vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Mol Cancer. 2010; 9: 49.
20. Gui, C-Y., Ngo, L., Xu, W.S., et. al. Histone deacetylase (HDAC) inhibitor
activation of p21WAF1 involves changes in promoter-associated proteins,
including HDAC1. Proc. Natl. Acad. Sci. USA 2004; 101:1241-1246.
21. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., et. al. Histone deacetylase
inhibitor selectively induces p21WAF1 expression and gene-associated histone
acetylation.
156

Proc Natl Acad Sci U S A. 2000; 97(18): 10014–10019.
22. Vinodhkumar, R., Song, Y-S., & Devaki, T. Romidepsin (depsipeptide)
induced cell cycle arrest, apoptosis and histone hyperacetylation in lung
carcinoma cells (A549) are associated with increase in p21 and
hypophosphorylated retinoblastoma proteins expression. Biomed
Pharmacother. 2008; 62(2):85-93.
23. Marks, P., Rifkind, R.A., Richon, V.M., et. al. Histone deacetylases and
cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194-202.
24. Noureen, N., H. Rashid, & Kalsoom, S. Identification of type-specific
anticancer histone deacetylase inhibitors: road to success. Cancer
Chemother Pharmacol. 2010; 66(4):625-33.
25. Paris, M., Porcelloni, M., Binaschi, M., et al. Histone deacetylase inhibitors:
from bench to clinic. J Med Chem 2008; 51(6): 1505-29.
26. Zhou, Q., Dalgard, C.L., Wynder, C., et. al. Histone deacetylase inhibitors
SAHA and sodium butyrate block G1-to-S cell cycle progression in
neurosphere formation by adult subventricular cells. BMC Neurosci.
2011;12:50.
27. Blagosklonny, M., Robey, R., Sackett, D., et al. Histone deacetylase
inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic
arrest and cytotoxicity. Mol. Cancer Ther. 2002; 1 (11): 937–941.
28. Marks, P.A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and
development as anticancer agents. Expert Opin Investig Drugs 2005; 14(12):
1497-511.
29. Kim, N.H., Kim, S.N., & Kim, Y.K. Involvement of HDAC1 in E-cadherin
expression in prostate cancer cells; its implication for cell motility and
invasion. Biochem Biophys Res Commun. 2011; 404(4):915-21.
30. Cao, Z.A., Bass, K.E., Balasubramanian, S., et al. CRA-026440: a potent,
broad-spectrum, hydroxamic histone deacetylase inhibitor with
antiproliferative and antiangiogenic activity in vitro and in vivo. Mol Cancer
Ther, 2006; 5(7): 1693-701.
31. Hagelkruys, A., Sawicka, A., Rennmayr, M., et.al. The biology of HDAC in
cancer: the nuclear and epigenetic components. Handb Exp. Pharmacol.
2011; 206: 13-37.
32. Butler, L.M., Agus, D.B., Scher, H.I., et al. Suberoylanilide hydroxamic acid,
an inhibitor of histone deacetylase, suppresses the growth of prostate cancer
cells in vitro and in vivo. Cancer Res, 2000; 60(18): 5165-70.
33. Almenara J, Rosato R, & Grant S. Synergistic induction of mitochondrial
damage and apoptosis in human leukemia cells by flavopiridol and the
histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Leukemia. 2002; 16(7):1331-43.
34. Liu, S., & Yamauchi, H. p27-Associated G1 arrest induced by hinokitiol in
human malignant melanoma cells is mediated via down-regulation of pRb,
157

Skp2 ubiquitin ligase, and impairment of Cdk2 function. Cancer Lett 2009;
286(2): 240-9.
35. Morales, J.C., Ruiz-Magana, M.J., Carranza, D., et. al. HDAC inhibitors with
different gene regulation activities depend on the mitochondrial pathway for
the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer
Lett. 2010 ;297(1):91-100.
36. Verma, R., Rigatti, M.J., Belinsky, G.S., et. al. DNA damage response to the
Mdm2 inhibitor nutlin-3. Biochem Pharmacol. 2010 ;79(4):565-74.
37. Yale School of Medicine. Introduction to Flow Cytometry: A Learning Guide.
Retrieved from:
http://medicine.yale.edu/labmed/cellsorter/start/411_66019_Introduction.pdf
38. Herzenberg, L.A., Tung, J., Moore, W.A., et. al. Interpreting flow cytometry
data: a guide for the perplexed. Nat Immunol. 2006; 7(7):681-5.
39. Qu, C.X., Wang, J.Z., Wan, W.H., et.al. Establishment of a flow cytometric
assay for determination of human platelet glycoprotein VI based on a mouse
polyclonal antibody. J Clin Lab Anal. 2006; 20(6):250-4.
40. Noonan, E.J., Place, R.F., Pookot, D., et al. miR-449a targets HDAC-1 and
induces growth arrest in prostate cancer. Oncogene, 2009; 28(14): 1714-24.
41. Furumai, R., Matsuyama, A., Kobashi, N., et al. FK228 (depsipeptide) as a
natural prodrug that inhibits class I histone deacetylases. Cancer Res, 2002;
62(17): 4916-21.
42. Vigushin, D.M., Ali, S., Pace, P.E., et al. Trichostatin A is a histone
deacetylase inhibitor with potent antitumor activity against breast cancer in
vivo. Clin Cancer Res, 2001; 7(4): 971-6.
43. Tong, X., Joshi, S., Rosenberg, D.W., et.al. Cyclooxygenase-2 regulation in
colon cancer cells: modulation of RNA polymerase II elongation by histone
deacetylase inhibitors. J Biol Chem. 2005; 280(16):15503-9.
44. Bustin, S.A. Quantification of mRNA using real-time reverse transcription
PCR (RT-PCR): trends and problems. Journal of Molecular Endocrinology
2002; 29: 23–39.
45. Lee, J-H., Jeong, E-G., Choi, M-C., et.al. Inhibition of Histone Deacetylase
10 Induces Thioredoxin-Interaction Protein and Causes Accumulation of
Reactive Oxygen Species in SNU-620 Human Gastric Cancer Cells, 2010;
Mol. Cells 30: 107-112.
46. Spurling, C.C., Godman, C.A., Noonan, E.J., et. al. HDAC3 Overexpression
and Colon Cancer Cell Proliferation and Differentiation, Mol. Carc. 2008; 43:
137-147.
47. Godman, C.A., Joshi, R., Tierney, B.R., et.al. HDAC3 impacts multiple
oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D
signaling. Cancer Biol. & Ther. 2008; 7 (10): 1570-1580.
48. Miller, K. Vitamin D may boost lymphoma survival. Retrieved from
http://www.webmd.com/cancer/non-hodgkinslymphoma/news/20091207/vitamin-d-may-boost-lymhoma-survival
158

49. Khleif, S.N., & Curt, G.A. Animal Models in Developmental Therapeutics. In:
Bast R.C. Jr., Kufe, D.W., Pollock, R.E., et al., editors. Holland-Frei Cancer
Medicine. 5th edition. Hamilton (ON): B.C. Decker; 2000. Chapter 42.
Retrieved from: http://www.ncbi.nlm.nih.gov/books/NBK20822/

159

Chapter 8
Investigation of the induction and mechanisms of cell death by apoptosis

A. Introduction
The process of apoptosis, otherwise known as programmed cell death, is
an important component of several physiological processes including normal cell
turnover that involves the genetically determined elimination of cells (1-3).
Defects in the regulation of apoptosis are implicated in many diseases including
neurodegenerative diseases, ischemic damage, autoimmune disorders and
many types of cancer (2, 3). In the last decade, significant attention has been
focused on the exploitation of apoptosis as a novel and promising strategy for
cancer chemoprevention and chemotherapy (1-3). Structurally diverse HDAC
inhibitors have been shown to induce apoptosis in several human malignant cells
(4-60). The natural product, hinokitiol (compound 10), has also been shown to
induce apoptosis in human prostate cancer cells (61). The induction of apoptosis
is distinguished by specific morphological and biochemical events, including
exposure of phosphatidylserine (PS) on the outer leaflet of the plasma
membrane as well as the activation of cysteine aspartic acid-specific protease
(caspases) (1-7, 62-65).
There are two major mechanisms of apoptosis that are highly complex
and involve an energy-dependent cascade of molecular events (2, 3, 9-12).
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These two pathways are the extrinsic or death receptor pathway and the
intrinsic or mitochondrial pathway; both pathways are linked and influence each
other (Figure 1). Recent evidence shows that there is an additional pathway that
involves T-cell mediated cytotoxicity and perforin-granzyme dependent killing of
the cell (2, 3). The extrinsic, intrinsic, and granzyme B pathways converge on
the same terminal, or execution pathway that is initiated by the cleavage of
caspase-3 resulting in significant apoptotic events such as DNA fragmentation
(2).

Figure 1: Schematic representation of apoptotic events (2)

HDAC inhibition has been shown to upregulate the intrinsic apoptosis
pathway via both the upregulation of proapoptotic proteins and downregulation
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of anti-apoptotic proteins in the B-cell lymphoma 2 (Bcl-2) family (9-14, 16, 22,
24, 26- 28, 37, 40, 43, 49, 54, 57- 59). HDAC inhibition also induces elements of
the extrinsic apoptotic pathway by increasing expression of death receptors,
including Fas, tumor necrosis factor-α (TNF-α), and TNF-related apoptosisinducing ligand (TRAIL) receptors (9, 14, 15, 17, 19, 22- 24, 26, 27, 49, 54, 57,
58). In fact, it has been reported that treatments with vorinostat results in
upregulation of caspase-7 and caspase-9, key players in the intrinsic pathway of
apoptosis, and downregulation of caspase-8, a key player in the extrinsic
pathway (14, 37). Therefore, the purpose of this chapter is to investigate the
ability of the tropolones to induce apoptosis and to explore the mechanisms of
execution of apoptosis by the tropolones.

B. Elucidation of the induction of cell death by apoptosis
It is well established that cells lose their membrane phospholipids in the
early stages of apoptosis and expose phosphatidylserine (PS) on the outer leaflet
of the plasma membrane (2, 3, 5, 63-65). Conversely, an alternative to cell death
by apoptosis is necrosis, which is a toxic process where cells passively follow an
energy-independent mode of death resulting in interference with the energy
supply of the cell as well as direct damage to cell membranes (1). Annexin V is a
calcium-dependent phospholipid-binding protein with a high affinity for PS that is
often used in conjugation with a fluorescein isothiocynanate (FITC) to label PS
externalization (2, 60, 63-65). Given that AnnexinV complexed with FITC can
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also label premature cell death by necrosis following the loss of membrane
integrity, the simultaneous addition of propidium iodide that does not permeate
cells with intact plasma cells allows for discrimination between intact cells and
early apoptotic cells (60, 63, 65).
Based on cell line selective cytotoxicity data, the induction of cell death by
apoptosis was evaluated by analyzing membrane phosphatidyl-serine (PS)
exposure via flow cytometric analyses in Jurkat and HuT-78 cells because they
were the two cell lines that are the most sensitive to inhibition by tropolones.
Treated cells were analyzed for apoptosis with the aid of Annexin V and
propidium iodide via flow cytometric analysis. Assays were performed at multiple
time points and/or multiple concentrations when possible. We compared our
results to published data on the induction of apoptosis by our experimental
control, SAHA, lines when possible (59). Detailed methods for flow cytometric
analysis are described in Section K of the Materials and Methods chapter. With
the exception of the 24h time-point for the Jurkat cells, corresponding histograms
for evaluation of specific gene expression are in sections 37 and 38 of the
Appendix. With the aid of the FlowJo Workstation (Treestar Inc., USA), cells were
identified as early apoptotic cells if they were Annexin V positive and PI negative;
late apoptotic or necrotic cells were both Annexin V positive and PI positive
whereas surviving cells were Annexin V negative and PI negative (5, 60, 63-65).
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C. Initial assessment of the induction of apoptosis in Jurkat cells
Given our observations that an increase in the sub-diploid population of
cells treated with tropolones, an index for apoptosis, was the most evident in
Jurkat cells followed by the HuT-78 cells, our initial assessment of the induction
of apoptosis was conducted in Jurkat cells. After a 20h treatment, 48.3% of
SAHA-treated cells were undergoing early apoptosis compared to 25.6% in the
untreated control. Both the alpha-substituted and the beta-substituted
tropolones were able to induce an equivalent proportion of apoptosis in Jurkat
cells (Table 1; Figure 2). For example, compound 2 and compound 7 with a
phenyl at the alpha and beta positions respectively, induced early apoptosis in
34.6% and 35.8% of the Jurkat cells correspondingly. Similarly, compound 2
and compound 7 induced equivalent percentages of late stage
apoptotic/necrotic cells (12.7% and 14.0% respectively).
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Table 1: Analysis of the induction of apoptosis in Jurkat cells after a 20h treatment with 10
µM HDACi
Treatment
% Intact cells
% Early Apoptotic
% Late
cells
Apoptotic/Necrotic
cells
25.6
Control
63.4
11.0
SAHA

36.8

48.3

14.8

Compound 2

52.6

34.6

12.7

Compound 5

48.1

36.8

15.0

Compound 7

50.0

35.8

14.0

Compound 9

56.7

30.6

12.6

Compound 10

49.9

35.0

15.0

Compound 11

52.5

31.4

15.9

Compound 13

48.4

35.8

14.1
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Figure 2: Analysis of the induction of apoptosis in Jurkat cells after a 20h
incubation: y axis represents PI response whereas x axis represents Annexin V
(AV) response. Quadrant 1 (bottom left) represents intact (live) cells (AV -, PI-);
Quadrant 2 (bottom right) represents early apoptotic cells (AV+, PI-); Quadrant 3
(top right) represents late apoptotic/necrotic cells ((AV+, PI+).

a)

Control

b)
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Compound 7
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Compound 9
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Compound 10

h)
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Compound 13
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Compound 11

D. Time-dependent analysis of the induction of apoptosis in Jurkat cells
Following our 20h assessment of the induction of apoptosis in Jurkat cells,
we evaluated multiple time-points to more accurately elucidate the ability of
tropolones to induce apoptosis in a time-dependent manner. Based on cell line
cytotoxicity and the 20h data on the induction of apoptosis, we chose compound
2 for comparative analysis (Table 2; Figure 3). Induction of early-stage apoptosis
by both compound 2 and SAHA peaked at 24h even though SAHA activated a
higher percentage of cells in early stage apoptosis than compound 2 (36.20%
vs. 11.70%). However, after a 48h incubation, there were a significantly higher
number of necrotic cells in the SAHA-treated cells (25.30%) than for those
treated with compound 2 (3.51%).

Table 2: Elucidation of the induction of apoptosis in Jurkat cells after a 20h treatment with 10 µM HDACi
Treatment 6h

12h

24h

48h

Control

%
%
%
Apoptotic Necrotic Apoptotic
6.91
9.57
16.6

%
Necrotic
7.61

%
Apoptotic
8.02

%
Necrotic
5.37

%
Apoptotic
3.17

%
Necrotic
1.66

SAHA

4.35

9.29

22.50

8.49

36.20

1.94

4.63

25.3

2

5.00

8.21

11.50

8.32

11.70

2.07

9.63

3.51

This observation may be attributed to an accumulation of hyperacetylated
histones that trigger different genes involved in the regulation of apoptosis and
tumor growth in SAHA-treated cells when compared to compound 2 suggesting
that the mechanisms of apoptosis by these two compounds may be executed by
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different pathways (14, 22, 24, 26, 27, 44, 49, 54-58). Therefore, we will discuss
the mechanisms of apoptosis by SAHA and the tropolones subsequently.

Figure 3: Time-dependent analysis of the induction of apoptosis in Jurkat cells
treated with 10 µM HDACi. Histograms indicate: a) % apoptotic cells; b) %
necrotic cells
a)

b)
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E. Elucidation of the induction of apoptosis in HuT-78 cells
Given that HuT-78 cells were also sensitive to tropolone-mediated growth
inhibition, we evaluated the induction of apoptosis at two time-points, 12h and
20h. At the 12h time-point, there was very little apoptotic activity since the
majority of the cells were still intact (Table 3). However, this observation is not
surprising since an evaluation of a panel of cutaneous T-cell lymphoma (CTCL)
cell lines showed that HuT-78 cells were the least sensitive to induction by
apoptosis by HDACi including SAHA (14).

Table 3: Time-dependent analysis of the induction of apoptosis in HuT-78 cells treated
with 10 µM HDACi
% Intact cells
% Early Apoptotic Cells
Treatment
12h
20h
12h
20h
Control
SAHA

96.10
93.80

91.30
73.70

3.46
5.71

6.12
16.50

Compound 2
Compound 7
Compound 10

96.00
94.70
92.60

89.30
90.60
88.70

3.36
5.06
7.11

7.96
6.60
8.22

Compound 11

95.70

91.10

3.95

5.90

However, after a 20h incubation, SAHA was able to activate more than a
2-fold increase in the percentage of early apoptotic cells (16.5%) when
compared to either the untreated control (6.12%) or compound 2 (7.96%). The
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natural product, compound 10, induced the highest percentage of early
apoptotic cells (8.22) among all tropolones; whereas the methylated tropolone,
compound 11, resembled the untreated control thus lending support to our
hypothesis about the availability of the alpha-hydroxyl ketone being essential for
tropolone-mediated activity.

F. Investigation of the mechanisms of activation of the extrinsic apoptotic
pathway in Jurkat cells
The extrinsic apoptotic pathway, also known as the receptor-activated
apoptotic pathway and the death receptor pathway, is triggered by external
cellular events and involves the activation of pro-apoptotic cell surface receptors
(2, 3). The extrinsic apoptotic pathway functions through binding of death
receptors such as Fas, TNF, or TRAIL to their corresponding ligands (2, 3, 9, 14).
Activation of caspases often indicates an irreversible commitment towards cell
death (2). There are ten major caspases (2, 66, 67) categorized into initiators
(caspase-2, -8, -9, -10), effectors or executioners (caspase-3, -6, -7), and
inflammatory caspases (caspase-1, -4, -5). In fact, interactions between death
receptors and their corresponding ligands results in the release of caspase-8 and
caspase-10, which in turn results in the activation of effector caspases (Figure 1;
2, 14, 66, 67). Moreover, HDACi such as SAHA alone and/or in combination with
other anticancer agents have been shown to induce apoptosis in a caspase-8
dependent manner in several malignant cells (11, 12, 14, 16, 17, 37 58).
172

Therefore, we monitored the activation of caspase-8 by tropolones and SAHA
after a 24h incubation in Jurkat cells with the aid of a fluorescent inhibitor of
caspases (FLICA) reagent via flow cytometic analysis (66). Detailed experimental
methods are in Section L of the Materials and Methods chapter.
We observed that SAHA activated over a 100-fold increase in caspase-8
activation in Jurkat cells when compared to either the untreated control or the
tropolones (Table 4; Figure 5). Our data strengthens our earlier hypothesis that
the mechanisms of apoptosis may involve different pathways since SAHA
activated caspase-8 levels significantly higher than the untreated control whereas
the tropolones, compound 2 and compound 7, activated caspase-8 at the same
levels as the untreated control. This observation indicates that tropolones induce
apoptosis in a caspase-8 independent manner, suggesting that the extrinsic
apoptotic pathway may not be involved in the initiation of apoptosis by
tropolones.
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Table 4: Elucidation of Caspase 8 activation in Jurkat cells after a 24h treatment
with 10 µM HDACi
Treatment

% Intact cells

% Caspase-8 responsive cells

Control

99.30

0.32

SAHA

62.60

35.90

Compound 2

98.90

0.43

Compound 7

99.40

0.40

Figure 5: Evaluation of Caspase 8 activation in Jurkat cells after a 24h
treatment with 10 µM HDACi: y axis represents PI response whereas x axis
represents caspase-8-carboxyfluorescein (FAM) response. Quadrant 1 (bottom
left) represents intact (live) cells (FAM-, PI-); Quadrant 2 (bottom right)
represents caspases-8 responsive cells (FAM+, PI-).

a) Control

b) SAHA
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c)

Compound 2

d)

Compound 7

G. Investigation of the mechanisms of execution of the intrinsic apoptotic
pathway in Jurkat cells
The intrinsic apoptotic pathway, also known as the stress-activated and
the mitochondrial apoptotic pathway, is triggered by a diverse array of nonreceptor-mediated stimuli that give rise to intracellular signals that act directly on
targets within the cell (2, 3, 9, 14). The intrinsic apoptotic pathway, which is
regulated by pro- and antiapoptotic proteins of the Bcl-family, are mitochondrialinitiated events that release proteins such as cytochrome c resulting in the
activation of caspases (2, 3, 9, 14, 58, 62). Both the extrinsic and intrinsic
pathways converge at the final pathway of apoptosis (2, 11, 12, 14, 58, 62, 6668), the execution phase, as a result of activation of the execution caspases
(caspase-3, -6, -7). Execution caspases activate cytoplasmic endonucleases
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that degrade nuclear material as well as proteases that degrade the nuclear and
cytoskeletal proteins (2, 3, 58, 62, 66-68).
Caspase-3, also known as CPP-32, Yama or Apopain, is an intracellular
cysteine protease that exists as a proenzyme, becoming activated during the
cascade of events associated with apoptosis (16, 25). Caspase-3 is considered
to be the most important of the executioner caspases (2, 11, 12, 62, 66-68) and
is activated by the other initiator caspases (caspase-8, -9, -10). Furthermore,
direct activation of caspase-3 is critical for granzyme B-induced killing in the
third apoptotic pathway, the perforin/granzyme pathway (2).
Based on the essential nature of caspase-3 in the execution of apoptosis,
we conducted an investigation of caspase-3/7 activation in Jurkat cells. Our
initial assessment of caspase-3/7 activation was conducted in Jurkat cells after a
12h treatment using a 96-well luminescent assay that correlates luminescence
with caspase-3 activity (68-70). Detailed experimental methods are highlighted
in Section M of the Materials and Methods chapter. Standard deviation values
for all treatments are reported in the Appendix, Section 39.
After a 12h treatment, SAHA activated more than a 2-fold increase in
caspase-3/7 activity when compared to the untreated control (Table 5; Figure 6).
The tropolones were also able to activate an increase in caspase activity when
compared to the untreated control albeit lower than SAHA-treated cells.
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Table 5: Activation of caspase-3/7 after a 12h treatment with 10 µM HDACi
Treatment

Caspase 3/7 Activity (Mean RLU)
*RLU= relative luminescent units

Control

69,935

SAHA

157,988

Compound 2

97,513

Compound 7

110,650

Figure 6: Evaluation of Caspase-3/7 activation after a 12h treatment with 10 µM
HDACi
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H. Time-dependent analysis of Caspase-3 activation in Jurkat cells
Given the promising data garnered from the 12h analysis, we conducted a
comprehensive, time-point analyses of caspase-3 activation in Jurkat cells
(Table 6; Figure 7). After a 6h treatment, compound 2 and compound 7
activated a higher proportion of caspase-3 activity than either the untreated
control or SAHA. Caspase-3 activity dropped after 24h and increased again
after a 48h treatment by the tropolones but at both time-points, tropolonemediated caspase-3 activity was lower than the untreated control. On the other
hand, caspase-3 activity increased in SAHA-treated cells after 24h and dropped
after 48h but SAHA-mediated caspase-3 activity was lower than the untreated
control for both time-points. However, our comprehensive analysis (Figure 7d)
highly suggests that caspase-3/7 activation by both the tropolones and SAHA
peak at 12h indicating that caspase-3 activation may be one of the mechanisms
for the execution of apoptosis in Jurkat cells by both the tropolones and SAHA.
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Table 6: Time-dependent analysis of caspases-3/7 activation in Jurkat cells
Caspase-3/7 Activity (Mean RLU)
Treatment

6h

24h

48h

Control

59,417

136,627

109,510

SAHA

53,518

125,484

95,463

Compound 2

88,661

76,948

105,357

Compound 7

73,949

80,438

71,048

Figure 7: Time-dependent analysis of Caspase-3 activation in Jurkat cells

a) Activation of Caspase-3 after a 6h treatment in Jurkat cells
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b)

c)

Activation of Caspase-3 after a 24h treatment in Jurkat cells

Activation of Caspase-3 after a 48h treatment in Jurkat cells
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d)

Time-dependent analysis of Caspase-3 activation in Jurkat cells

I. Evaluation of the ability of tropolones to enhance differentiation of
perforin in Jurkat cells
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells play a critical
role in the immune system by recognizing and directly destroying virally infected
tumorigenic cells (2, 3, 71-77). NK cells are critical to the innate immune system
whereas CTLs play important roles in adaptive immunity (2, 3, 73). Both types of
cells kill their cellular targets by either secreting membrane-disrupting proteins
known as perforin and a family of structurally related serine proteases known as
granzymes that work together to induce apoptosis of the target cell (2, 71-77);
alternatively, a second pathway involves the engagement and aggregation of
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target-cell death receptors such as Fas (2, 3, 71-77). Studies in gene-disrupted
mice have shown that the perforin pathway is closely involved in defense
against viral pathogens and tumorigenic cells (73). Furthermore, HDACi have
been reported to modify the immune system via various effects on regulatory T
cells and lysis of tumor targets by T cells and natural killer cells (11, 12, 75-77).
Interestingly, lower numbers of CTLs has been correlated with less favorable
prognosis in patients with mycosis fungoides (MF), the most common form of
CTCL (72).
Therefore, we conducted a time-dependent analysis to evaluate the ability
of the tropolones to differentiate perforin in Jurkat cells (Table 7; Figure 8). We
used FACS analysis to monitor fluorescence intensities at multiple time points in
Jurkat cells treated with 10 µM HDACi by sequentially incubating treated cells
with primary antibodies for perforin followed by treatment with secondary
antibodies conjugated with a fluorescein isothiocyanate (FITC; 58, 78-81 ). We
determined values for geometric mean fluorescence intensities (GMFI),
equivalent to the median cell population response, with the aid of the FlowJo
Workstation. Detailed methods for experimental analysis are in Section G of the
Materials and Methods chapter. Additional histograms are in the Appendix,
section 40.
After 6h and 12h treatments, both SAHA and compound 2 enhanced
differentiation of perforin in Jurkat cells around the threshold of the untreated
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control; but differentiation of perforin peaked after 48h by both SAHA and
compound 2 resulting in an approximate two-fold increase in the differentiation
of perforin. We hypothesize that the differentiation of perforin by the tropolones
may lead to the cascade of events that we observed in our time-dependent
analysis in Jurkat cells. Hence, our observations suggest that tropolones may be
able to execute cell death by apoptosis via the perforin/granzyme pathway.
Moreover, HDAC inhibitors such as valproic acid have been shown to
improve sensitivity of Jurkat and humanhepatoma cells to NK cell-mediated
killing (75, 76). Furthermore, studies in genetically identical murine tumor
models of mammary, renal, prostate, and colorectal carcinomas have shown
robust and prolonged eradication of solid tumors using SAHA combined with
immune-stimulating antibodies, CD8(+) CTL that used perforin as the key
immune effector molecule (77). These observations combined with our data for
perforin differentiation suggest promising therapeutic applications and warrant
further investigation of tropolones in combination with immune-activating
antibodies for treatment of both solid tumors and hematological malignancies.
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Table 7: Time-dependent analysis of the differentiation of perforin in Jurkat cells treated
with 10 µM HDACi
Treatment

Perforin/Granzyme, GMFI
GMFI = geometric mean fluorescence intensities

6h

24h

48h

Control

1.28

1.57

3.15

SAHA

1.52

2.32

6.29

Compound 2

1.39

1.40

6.15

Figure 8: Time-dependent analysis of the differentiation of perforin in Jurkat
cells. Note that histograms represent the untreated control superimposed with
the HDACi treatment for comparative analysis.

a)

6h analysis of SAHA

b)
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6h analysis of compound 2

c)

24h analysis of SAHA

e)

48h analysis of SAHA

d) 24h analysis of compound 2

f)
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48h analysis of compound 2

J. Preliminary studies on the synergistic effects of tropolones in breast
cancer cells
It has been previously reported that co-treatment of breast cancer cell
lines including MCF-7 cells with HDACi such as SAHA resulted in synergistic
anti-tumor activity presumably with a depletion of both the estrogen receptor (ER)
and progesterone receptor (PR) (82). In clinical studies, a combination treatment
of vorinostat and tamoxifen resulted in a reduction in the resistance of tamoxifen
in breast cancer patients (83). In both preclinical and clinical studies, histone
acetylation and HDAC2 expression were used as biomarkers to monitor the
efficacy of the combination treatment. Given these observations, we conducted a
preliminary assessment of the co-treatment of 10 µM compound 2 with the antiestrogen, tamoxifen, after 48h treatment in MCF-7 cells via FACS analysis (Table
8). 10 µM served as the experimental control and we compared our data to
published reports on synergistic effects in MCF-7 cells by SAHA (82). Detailed
experimental methods are in Section K of the Materials and Methods chapter.
As expected, combination of SAHA with tamoxifen resulted in some
increase in the induction of apoptosis when compared to either the untreated
control (30.30% vs. 3.12%), SAHA treatment alone (21.50%), or even tamoxifen
treatment alone (4.24%); however, a combination of compound 2 with tamoxifen
did not result in significant increase when compared to compound 2 alone
(6.68%% vs. 3.15%). Our preliminary assessment of synergisitic effects in
breast cancer cells warrants further investigation in multiple breast cancer cell
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lines at multiple concentrations and time-points in addition to gene expression
studies, gene knockdown studies and even cell cycle analyses in order to garner
a more precise evaluation of the synergistic effects of tropolones in breast
cancers.
Table 8: Elucidation of synergistic effects in MCF-7 cells after a 48h treatment
period
Treatment

% Apoptotic cells

Control

3.12

10 µM SAHA only

21.5

10 µM Compound 2 only

6.68

10 µM Tamoxifen only

4.24

10 µM SAHA + 10 µM Tamoxifen

30.3

10 µM Compound 2 + 10 µM Tamoxifen

3.15
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Figure 9: Preliminary assessment of synergistic effects of 10 µM HDACi and 10
µM tamoxifen after a 48h treatment in MCF-7 cells. y axis represents PI
response whereas x axis represents Annexin V (AV) response. Quadrant 1
(bottom left) represents intact (live) cells (AV-, PI-); Quadrant 2 (bottom right)
represents early apoptotic cells (AV+, PI-); Quadrant 3 (top right) represents late
apoptotic/necrotic cells ((AV+, PI+).

a)

Control

b)

SAHA only

c)

Compound 2 only

d)

Tamoxifen only
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e)

Tamoxifen + SAHA

f)

Tamoxifen + Compound 2

K. Conclusions
Apoptosis is a highly complex process that is implicated in many disease
areas including cancers and neurological disorders. The induction of apoptosis
is marked by specific biochemical events such as the exposure of phosphatidyl
serine on the outer leaflet of the plasma membrane as well as the activation of
caspases. There are three major mechanisms of apoptosis and these apoptotic
pathways include: extrinsic (death receptor or receptor-activated), intrinsic
(mitochondrial or stress-activated), and the granzyme/perforin pathway. HDACi,
including SAHA, have been reported to alter both the intrinsic and extrinsic
apoptotic pathways. Our comprehensive analysis of the induction of apoptosis
shows that tropolones induce apoptosis in a time-dependent manner in both
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Jurkat and HuT-78 cells. Our preliminary assessment of the synergistic effects
of tropolones in MCF-7 cells indicates that a more comprehensive analysis in
multiple breast cancer cell lines, at multiple concentrations, and an inclusion of
gene expression studies will be required for a more precise analysis of
synergistic effects. We also showed that tropolones initiate apoptosis in a
caspase-8 independent manner but the activation of caspase-3 may be
essential for the execution of apoptosis by tropolones. Finally, we discovered
that tropolones are able to enhance differentiation of perforin in Jurkat cells in a
time-dependent manner. Our observations suggest that tropolones may be able
to execute cell death by apoptosis via the perforin/granzyme pathway and
warrant further investigation particularly with regards to combining tropolones
with immune-activating antibodies for robust and prolonged treatment of solid
tumors and hematological malignancies.
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Chapter 9
Characterizing other natural product derivatives as anticancer agents: viridin
analogs

A. Introduction
Collaborations between the Wright and Anderson laboratories have led
to the development of tropolones as well as furanosteroidal natural product
derivatives as potential therapeutic agents for the treatment of infectious
diseases, cancer and neurodegenerative diseases (1, 2). The furanosteroidal
natural products (Figure 1), wortmannin and viridin, are potent antifungal
metabolites isolated from Penicillium wortmannii and Gliocladium virens
respectively (1, 3-5). We have recently reported our efforts to characterize
these viridin analogs as inhibitors of phosphoinositide 3-kinase (PI3K)
enzymes (1). Our interest in these viridin analogs as PI3K inhibitors stems
from several studies that indicate that small molecules capable of inhibiting
PI3K signaling show promising applications in a diverse number of
therapeutic areas including autoimmune disorders, cardiovascular diseases
and cancer (1, 3-11).
Both wortmannin and viridin are potent, irreversible, pan-PI3K inhibitors
with IC50 values of 2-10 nM (1). However, wortmannin has significant stability,
solubility and toxicity issues that limit its therapeutic uses (1, 3-5). Therefore,
the purpose of this chapter is to discuss the biological activities of viridin
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analogs that were synthesized by the Wright laboratories with the goal of
improving PI3K enzyme selectivity as well as antiproliferative activities in
multiple cell lines.

a)

b)

Figure 1: Structures of a) wortmannin and b) viridin

B. Biological and clinical significance of the PI3K signaling pathway
Cancer is a complex disease and there are multiple pathways that play
important roles in carcinogenesis and mutagenesis (12). Since the discovery
of the tyrosine kinase inhibitor Gleevec in 2001, there has been growing
interest in protein and lipid kinases for the treatment of cancer and many
other diseases (13-17). The PI3K signaling pathway is presumably the most
commonly altered in human cancers (10, 18, 19). PI3Ks are a ubiquitously
expressed family of enzymes that through the generation of phospholipids
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serve as secondary messengers by modulating the levels of
phosphotidylinasitol (PIs) in cells (1, 5, 10, 12, 17-20). PI3Ks influence many
cellular functions including cell signaling, cell growth, cell‐cycle progression,
cell survival, motility, cell development and differentiation (7, 12, 17-20).
PI3Ks catalyze the phosphorylation of phosphoinositides from ATP to
3’-OH of the inositol ring for three different substrates: phosphotidylinasitol
(PI), phosphatidyl inositol 4 phosphate (PI4P), and phosphatidyl inositol 4, 5bisphosphate (PI(4, 5)P2). Based on substrate specificity, PI3Ks are classified
into three groups: I, II, III. (1, 5, 5, 19, 20). Class I PI3Ks are the most studied
and consist of heterodimeric proteins with a smaller 85 kDa regulatory domain
and a larger 110 kDa catalytic subunit (10). Class I PI3Ks occur in four
isoforms subdivided into Class 1a (p110α, p110β, & p110σ) and Ib (p110γ).
Studies in gene-targeted mice have shown that class 1A PI3Ks, particularly
p110α, are important for vascular development & angiogenesis (7-9). The
constitutive activation of PI3K signaling usually seen in many cancers is
presumably as a result of the simultaneous promotion of proliferation and
inhibition of cell death (6). However, the cross inhibition that is often
observed with protein kinases has also made it very difficult to develop
selective PI3K inhibitors (1, 5, 8, 10, 11). Yet, many natural products and
corresponding derivatives are currently being explored for the development of
more effective lipid and protein kinase inhibitors that selectively target these
kinases while maintaining therapeutic efficiency (1, 3, 5, 8-11, 17, 21-27).
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C. Evaluation of biological activity
Key enzyme kinetic parameters values for the class I PI3K enzyme,
p110α and the PI substrate were obtained via a luminescent assay that
correlates kinase activity to luminescence. Detailed experimental methods are
reported in Section N of the Materials and Methods Chapter. Assay data were
analyzed via non-linear regression analysis (GraphPad Prism Software, Inc.,
CA; 28). Best fit values are highlighted in Table 1 and Figure 1. Standard
error values are reported in the Appendix, Section 41.

Table 1: Elucidation of key enzyme parameters for the class I PI3K enzyme,
p110α and the PI substrate

KM (μM)

Vmax (μM)

kcat (s-1)

kcat /KM (M-1 s-1)

p110α
9.64 ± 1.93

3453.00 ± 90.94
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Figure 2: Non-linear regression analysis of p110-alpha activity.

We recently reported our evaluation of PI3K-alpha inhibition IC50 values
for the three viridin analogs (compounds 1a, 2a, & 3a) using a luminescent assay
that correlates kinase activity to luminescence (Table 2; 1). Detailed experimental
methods are reported in Section O of the Materials and Methods Chapter. We
converted IC50 values to Ki values, using methods described by Cheng and
Prusoff (29). We also evaluated the antiproliferative effects in three cell lines:
HCT116 colon cancer cell line, U87 glioblastoma cell line, and MCF-7 breast
cancer cell line (Table 2; 1). All three viridin analogs exhibited submicromolar
inhibition of PI3K-α even though the IC50 values obtained were not as low as that
of wortmannin (IC50 = 11.9 nM).
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Table 2: Elucidation of biological activity for viridin analogs[1].
Compound Structure
IC50,
Ki
GI50 (µM)
p110α/p85α
(nM)
(nM)
PI substrate
HCT116 U87
MCF-7
1a
338.9

284.1

>100

>100

22.9

270.5

226.8

>100

>100

37.7

177.5

148.8

>100

>100

>100

11.9

9.99

>100

>100

>100

2a

3a

Wortmannin

None of the compounds were able to inhibit the growth of the colon cancer
cell line, HCT116; however, compound 1a and 2a inhibited growth of the MCF-7
breast cancer cell line with GI50 values of 22.9 µM and 37.7 µM respectively.
Interestingly, a higher potency for PI3K-α inhibition resulted in reduced growth
inhibition of the MCF-7 cells since compound 1a and 2a had higher IC50 values
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for the PI3K-α relative to compound 3a and wortmannin respectively. Hence, our
results are promising and show potential for further development of viridin
analogs as targeted therapies for the treatment of cancer.

D. Conclusions and future directions
Natural products and corresponding derivatives have found diverse
applications in the treatment of neurodegenerative diseases as well as in the
treatment of various microbial diseases and cancer. Since the discovery of
Gleevec in 2001, there has been a growing interest in the development of other
kinase inhibitors for the treatment of many cancers. Small molecule inhibitors of
the PI3K pathway show promise as anticancer agents but cross-inhibition that is
often observed with protein kinases has also made it very difficult to develop
selective PI3K inhibitors. Our viridin analogs are highly promising PI3K inhibitors
that exhibit submicromolar inhibition of the class I PI3K enzyme, p110α. Unlike
wortmannin, two of our analogs, 1a and 2a, also inhibited the growth of the MCF7 breast cancer cell line. Future investigations will also explore the synthesis of
structurally diverse viridin analogs as well as the inhibition of other PI3K isoforms
and multiple cell lines for the evaluation of isozyme selectivity and cancer cell line
selective cytotoxicity respectively by our current library.
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Chapter 10
Comprehensive Analysis and Future Directions

A. Research summary and emerging directions
Cancer is the second leading cause of death in the United States and
a major cause of death worldwide (1-5). The development of natural product
derivatives for the treatment of cancer and many other diseases has been a
trend in medicinal chemistry for over 25 years (6-19). Given that the PI3K
signaling pathway is presumably the most commonly altered in human
cancers (20-22), a biological analysis was performed on three furanosteroidal
natural product derivatives synthesized by the Wright laboratory in order to
evaluate enzyme inhibition and cytotoxicity in cultured human cancer cell
lines. Evaluation of the three viridin analogs as PI3K inhibitors showed great
promise particularly given submicromolar inhibition of a class I PI3K, p110α
(23) . Unlike the well known, pan-PI3K inhibitor, wortmannin, two of the viridin
analogs, 1a and 2a, also inhibited the growth of the MCF-7 breast cancer cell
line (23). Future investigations will explore the synthesis of structurally diverse
viridin analogs as well as the inhibition of other PI3K isoforms and multiple
cell lines for the evaluation of isozyme selectivity and cancer cell line selective
cytotoxicity respectively by our current library.
Alternatively, inhibitors that target major enzymes involved in
epigenetic alterations, particularly HDACs, are also growing more popular in
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cancer research because of the ability of these inhibitors to reversibly induce
terminal differentiation of transformed cells presumably as a result of
chromatin modulation (24-60). To date, two HDACi, Zolinza (vorinostat;
SAHA) and Istodax (romidepsin) have been approved by the FDA for the
treatment of cutaneous T-cell lymphoma (CTCL). Through an in-house
collaborative effort, derivatives of hinokitiol (β-thujaplicin), a troplone-derived
natural product are being developed by the Wright and Anderson laboratories
as HDAC inhibitors (HDACi). Thujaplicins are a family of small tropolonederived natural products that are associated with a wide range of biological
effects (62-66).There are fourteen compounds currently in the tropolone
library and the studies presented in this dissertation are the the first reported
comprehensive analysis of tropolones as HDAC inhibitors.
Functional and biochemical studies were employed in this dissertation
research to elucidate the mechanisms of action of fourteen tropolones as
HDACi. Experimental data indicate that tropolones selectively target HDAC2
and HDAC8 in a competitive manner and at nanomolar potency. Mode of
binding studies for compound 2 in HDAC8 suggest that tropolones inhibit
HDACs in a competitive manner. Moreover, efforts are currently in place by
the Anderson laboratory to gain further structural insights on HDAC8 binding
by solving the three-dimensional crystal structure of the ACA-HDAC8 protein
bound to a tropolone using preliminary methods for expression and
purification described in this dissertation.
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Furthermore, the tropolones show greater potency for HDAC2
inhibition relative to HDAC8. For example, compound 9 exhibits greater than
500-fold selectivity towards HDAC2 relative to HDAC8. This observation is
highly promising and shows that it is possible to develop these tropolones as
HDAC2-selective inhibitors particularly given that there are no reported
HDAC2-selective inhibitors in pre-clinical and clinical development because of
high degree of similarity in class I HDACs especially HDAC-1, -2, and -3 (33).
Besides, it is well established that HDACi have multiple therapeutic purposes
and have found success in the treatment of cancer, neurological disorders
and neurodegenerative diseases (24-60).
Moreover, the natural product, hinokitiol (compound 10), has been
shown to possess in vitro neuroprotective activity in HT22 cells, a neuronal
cell line derived from mouse hippocampus that lack glutamate receptors (62).
It is believed that the presence of the tropolone scaffold results in compounds
with high potency against oxidative stress-induced cell death of HT22 cells
that is typically implicated in Alzheimer’s disease and many
neurodegenerative disorders (62). Concurrently, HDAC2 inhibition has been
shown to facilitate learning and memory in wild-type mice as well as in mouse
models of neurodegeneration (26, 60). Our studies may have shown that the
reported neuroprotective effects of hinokitiol may be as a result of HDAC2
inhibition but we cannot rule out the fact that other HDAC family members
and nonhistone substrates may also be modulated by treatment with the
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tropolones (62). Nevertheless, our preliminary assessments indicate that it is
possible to explore the use of tropolones in the treatment of
neurodegenerative diseases.
Tropolones also display cancer cell line selective cytotoxicity as
evidenced by preferential inhibition to the two hematological cell lines, Jurkat
and HuT-78. It can be deduced that selective HDAC inhibition may result in
reduced toxicity profiles (25, 32-37, 41, 43-46, 49, 55, 57, 58, 67, 68) as
further evidenced by biochemical data that shows that with the exception of
compound 7, none of the tropolones exerted significant inhibition of the
normal dermal fibroblasts unlike the pan-HDACi, SAHA. Tropolones also
arrested the subdiploid phase of the cell cycle, usually viewed as an apoptotic
index, in Jurkat and HuT-78 cells in a time-dependent manner. Furthermore,
preliminary assessment of the extrinsic apoptotic pathway via caspase-8
activation by the tropolones did not show significant overexpression of
caspase-8 in Jurkat cells when compared to the untreated control. However,
the tropolones were shown to induce apoptosis via the intrinsic pathway of
caspase-3/7 activation in Jurkat cells in a time-dependent manner
In a similar manner to SAHA, compound 2 was able to activate the
differentiation of perforin in a time-dependent manner in Jurkat cells
suggesting that tropolones may be able to execute cell death by apoptosis via
the perforin/granzyme pathway (69-73). Moreover, HDAC inhibitors such as
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valproic acid have been shown to improve sensitivity of Jurkat and
humanhepatoma cells to natural killer (NK) cell-mediated killing (73, 74).
Furthermore, studies in genetically identical murine tumor models of
mammary, renal, prostate, and colorectal carcinomas have shown robust and
prolonged eradication of solid tumors using SAHA combined with immunestimulating antibodies, CD8(+) cytolytic T lymphocytes (CTL) that used
perforin as the key immune effector molecule (75). These studies combined
with the data on perforin differentiation by compound 2 suggest promising
therapeutic applications and warrant further investigation of tropolones in
combination with immune-activating antibodies for treatment of both solid
tumors and hematological malignancies.
Histone acetylation is considered to be the most studied
posttranslational modification (24, 51, 76); in addition to histones, HDACs
modulate over 1700 nonhistone substrates including the structural protein,
tubulin (77). Hyperacetylation of key lysine residues on histone H4 (H4K12)
were observed in Jurkat cells and to a lesser extent in HuT-78 cells as a
result of tropolone treatment (78). Interestingly, tropolone treatments in Jurkat
and HuT-78 cells did not result in significant modulation of lysine residues on
acetylated alpha-tubulins (Ac-α-tub-Lys40) typically indicative of HDAC6
inhibition (28, 68, 79-82). However, selective inhibition of class I HDAC
enzymes, particularly HDAC8, is also associated with weak tubulin
modulation (67); conversely, pan-HDACi and HDAC6-selective HDACi show
211

significant tubulin modulation as a result of HDAC6 hyperacetylation (28, 68).
Hence, this observation supports our biochemical data that shows very poor
inhibition of HDAC6 by the tropolones and further strengthens our claim on
the isoform-selective nature of HDAC inhibition by the tropolones.

B. Distinct need for further evaluation of gene expression and analysis
of drug-like properties
Elucidation of specific gene expression in both Jurkat and HuT-78 cells did
not reveal any significant overexpression of the tumor-suppressor gene, p53,
or CDKIs such as p15, p21 and p27. It may be possible that the inability of the
tropolones to inhibit HDAC1 may hinder p21 activation since it has been
reported that SAHA treatment in multiple myeloma cells resulted in a marked
decrease in HDAC1 expression and a significant overexpression of p21 (83,
84). However, a more comprehensive analysis of tropolone-mediated gene
expression via microarray analysis in normal and mutant Jurkat and/or HuT-78
cells as possibly in animal models will be required for a more precise
evaluation of genes that are altered as a result of tropolone treatment (85).
Moreover, gene expression analysis in mutant hematological cells that are
deficient of or overexpressed with HDAC2 or HDAC8 may serve as further
proof of concept for our claim on the isoform-selective nature of HDAC
inhibition by the tropolones.
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Elucidation of drug-like properties is an integral constituent of any drug
discovery project (86). Preliminary assessment of toxicity in adult human
dermal fibroblasts (hDF) indicates that selective HDAC inhibition by the
tropolones may result in reduced toxicity profiles as evidenced by the fact that
with the exception of compound 7, none of the tropolones showed significant
inhibition of hDF unlike the pan HDAC inhibitor, SAHA (GI50 = 18.95 µM).
However, despite the high potencies displayed against HDAC2 and HDAC8 in
enzyme inhibition studies, the activities of tropolones within cell lines and
possibly in future in vivo studies may be hindered by poor physicochemical
properties such as permeability and chemical stability issues (86). Hence,
current knowledge on the mechanisms of action of tropolones as HDACi will
be strengthened by a better knowledge on the biochemical properties of the
tropolones, particularly metabolism, as well as in vitro, and possibly in vivo,
studies on pharmacokinetics and toxicity.

C. Proposed modification of the tropolone scaffold
Efforts are currently in place to develop a second generation library of
tropolones using methods described in this dissertation that will potentially
maintain isoform selectivity in HDAC inhibition while exerting a more robust
therapeutic application particularly for the treatment of solid tumors and
hematological malignancies. The proposed scaffold for second-generation
tropolones (Figure 1) will now include a linker domain (the alkyl chain) that is
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presumed to mimic the natural HDAC substrate and occupy the active site
channel thus allowing for exploration for isozyme selectivity (24, 87).

Figure 1: Proposed scaffold for 2nd generation tropolones

R groups will either be hydrogen atoms, alkyl groups, or aryl groups.
The same substitutions will also be evaluated in the alpha and possibly
gamma positions in order to elucidate SAR. Moreover, virtually all HDACi
currently in clinical development for the treatment of cancer share this
common pharmacophore pattern consisting of: a metal binding domain which
complexes zinc; a linker domain and a surface domain or cap group, which
makes contact with the rim of the catalytic pocket (24, 33, 87). Accordingly,
the tropolone ring with the alpha-hydroxyl ketone will serve as the metalbinding domain, the alkyl chain will serve as the linker domain and the
secondary aryl moiety will serve as the cap group. It is expected that
modification of the tropolone scaffold may also lead to improvements in
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pharmacokinetic properties that may improve in vitro potency & possibly in
vivo efficacy (58).

D. Conclusions
Given the high incidence of cancer worldwide and growing interest in
research on epigenetic alterations, a comprehensive investigation on the
mechanisms of action of tropolones as HDACi was conducted via biochemical
and functional studies. As a result of this dissertation research, several
techniques that are relatively new to the Anderson laboratory have been
developed for biochemical and functional analysis of HDAC inhibition by the
tropolone library: 1) Evaluation of HDAC enzymatic activity and inhibition, 2)
Investigation of antiproliferative effects via cytotoxicity assays and cell cycle
analyses, 3) Elucidation of the induction and mechanisms of cell death by
apoptosis, 4) Assessment of specific gene expression. The incorporation of
these methods in present studies have improved understanding on the
mechanisms of action of tropolones as isoform-selective HDACi and will also
guide development of future tropolone libraries.
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Chapter 11
Materials and Methods

A. Expression and purification of HDAC8
HDAC8 expression and purification was performed essentially as
described by in reference 1. Briefly, mid-log phase BL21 DE3 E. coli cells were
induced with one millimolar isopropyl-1-thio-β-D-galactopyranoside (IPTG) (3h,
225 rpm, 37°C) in LB media. Harvested bacteria were resuspended in the
lysis buffer, BugBuster 10X Protein Extraction Reagent (EMD4 Biosciences,
USA), incubated with DNase I (5 units/mL) and clarified by centrifugation at
35,000 × g for 1 h. The supernatant was then loaded into a Ni-NTA resin
column preequilibrated in the wash buffer (50 mM Tris•HCl, pH 8.0/3 mM
MgCl2/300 mM KCl/20 mM imidazole/5% glycerol/1 mM 2mercaptoethanol/PMSF). HDAC8 was eluted with 250 mM imidazole, then
dialyzed against the final buffer (50 mM Tris•HCl, pH 8.0/50 mM KCl /5%
glycerol/10 μM ZnCl2/1 mM DTT). The HDAC8 protein (ACA-HDAC8) was
then loaded onto a G75 26/60 gel filtration column (GE Healthcare Life
Sciences, USA), equilibrated in the gel filtration buffer (50 mM Tris•HCl pH
8.0/150 mM KCl/5% glycerol/1 mM DTT) and stored at -80oC.
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B. HDAC Activity Assays for the elucidation of enzyme kinetic
parameters
KM and Vmax values for one class I HDAC enzyme (HDAC8), two class
IIa HDAC enzymes (HDAC4, HDAC5) and one class IIb HDAC (HDAC6) were
determined using commercially available human recombinant HDAC enzymes
(BPS Bioscience, San Diego, CA) and fluorogenic HDAC assay kits (BPS
Bioscience). Kinetic parameters for two class I HDAC enzymes (HDAC1,
HDAC2) were obtained using human recombinant HDAC enzymes (BPS
Bioscience) and a fluorogenic HDAC assay kit (Active Motif, Carlsbad CA).
Both fluorogenic assays work by utilizing a short, patented, peptide substrate
containing an acetylated lysine residue that upon deacetylation by a HDAC
enzyme results in the production of a fluorescent product with an excitation
wavelength of 360 nm and an emission wavelength of 460 nm. Assay was
performed at substrate concentrations of 25-400 µM according to the
manufacturer’s protocol. Best-fit values for KM and Vmax were determined via
non-linear regression analysis (GraphPad Software, Inc., CA) and compared
to published HDAC enzyme kinetics data (2, 3). Values for kcat and kcat /KM
were determined from the KM and Vmax values obtained for each HDAC
isozyme using methods described in references 2 and 4.
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C. HDAC Inhibition Assays for the determination of IC50 and Ki values
HDAC inhibition assays measured the half maximal inhibitory
concentration, IC50, for tropolones for or one class I HDAC enzyme (HDAC8),
two class IIa HDAC enzymes (HDAC4, HDAC5) and one class IIb HDAC
(HDAC6) using commercially available human recombinant HDAC enzymes
(BPS Bioscience, San Diego, CA) and fluorogenic HDAC assay kits (BPS
Bioscience). IC50 values for two class I HDAC enzymes (HDAC1, HDAC2)
were obtained using human recombinant HDAC enzymes (BPS Bioscience)
and a fluorogenic HDAC assay kit (Active Motif, Carlsbad CA). Both
fluorogenic assays work by utilizing a short, patented, peptide substrate
containing an acetylated lysine residue that upon deacetylation by a HDAC
enzyme results in the production of a fluorescent product with an excitation
wavelength of 360 nm and an emission wavelength of 460 nm. Assay was
performed in replicates essentially as described in the manufacturer’s protocol.
The potent hydroxamic acid HDACi, Trichostatin A (TSA), provided in the
assay kit, served as a control for the assays. DMSO, at the same percentage
as is present in the compounds, showed no significant inhibition of HDAC
enzymes. Assay data were analyzed via non-linear regression (GraphPad
Software, Inc., CA). Best-fit values for IC50 were determined via non-linear
regression analysis (GraphPad Software, Inc., CA) and compared to published
IC50 data (2, 3, 5). The IC50 of the tropolones were converted to the inhibition
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constant, Ki, for each of the inhibitors using the KM value in accordance to
techniques previously described by Cheng and Prusoff (6).

D. Mode of binding studies in HDAC8
The mechanism of action of compound 2 in HDAC8 (BPS Bioscience)
was determined using four concentrations of the fluorogenic class IIa HDAC
substrate (BPS Bioscience; 10 μM, 20 μM, 40 μM and 80 μM) against four
inhibitor concentrations (0.5 nM, 1 nM, 2 nM, 4 nM). Enzyme parameters were
analyzed via non-linear regression analysis (GraphPad Prism); the mixed
model inhibition module on the GraphPad Prism software was used to
determine the best fit value for the Ki, the alpha value, and concurrently
determine the mode of binding of compound 2 in HDAC8 (7, 8). The
parameter, alpha, (Ki‘/Ki) is used to determine the degree to which binding of
an inhibitor changes the affinity of the enzyme for the substrate (7, 8).

E. Cell culture
All ten human cell lines were obtained from the American Type Culture
Collection (ATCC; Manassas, VA) and maintained in a humidified incubator
(37oC, 5% CO2) using ATCC recommendations and pertinent methods
required for culturing human solid tumor and hematological cells (9). With the
exception of HuT-78 and MCF-10A, all cell lines were supplemented with 10%
fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA). BXPC-3 and
Jurkat cells were cultured in RPMI 1640 (ATCC) supplemented with 1%
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penicillin/streptomycin (PEN-STREP; Mediatech Inc., Manassas, VA) and 1%
L-Glutamine (L-Glut; Mediatech Inc.). HuT-78 cells were cultured in IMDM
(ATCC) supplemented with 20 % FBS, 1% PEN-STREP (Mediatech Inc.) and
1% L-Glut (Mediatech Inc.). HT-29 and HCT116 were cultured in McCoy’s
media (Life Technologies, Carlsbad CA) supplemented with 1% non-essential
amino acids (NEAA; Mediatech Inc.) and 1 % PEN-STREP (Mediatech Inc.).
MCF-7 cells were maintained in DMEM/F12 supplemented with 1% L-Glut and
1% PEN-STREP. MCF-10A cells were cultured with the MEGM kit (Lonza
Biologics, Basel, Switzerland) supplemented with cholera toxins (Sigma
Aldrich). MCF-10A cells were grown with the MEGM kit (Lonza, Switzerland)
supplemented with 50 µg/mL cholera toxin (Sigma Aldrich, St. Louis, MO). U87
cells were cultured in MEM supplemented with 10% FBS. A549 were cultured
in F-12 media supplemented with 10% FBS. Normal human adult dermal
fibroblasts (hDF) were maintained in DMEM supplemented with 10% FBS.
Vorinostat (SAHA), (Z)-4-hydroxytamoxifen, and wortmannin were obtained
from Sigma Aldrich.

F. Cell viability assay
Confluent Jurkat and HuT-78 cells were seeded in triplicate at a density
of 5 x104 cells/well in 96-well culture plates (Corning Inc., Corning, NY). MCF7 and MCF-10A cell lines were seeded in triplicate at a density of 1 x 10 4
cells/well in 96-well culture plates (Corning Inc.). HCT116, HT-29, BXPC-3,
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U87, A549, and hDF cells were seeded in triplicate at a density of 5 x 103
cells/well in 96-well culture plates (Corning Inc.). Cells were treated
accordingly at varying concentrations (1 μM-100 μM) of a tropolone, a
furanosteroid, SAHA or wortmannin. DMSO served as a vehicle control. After
a 72h exposure, cytotoxicity was evaluated using the Cell Titer 96 Aqueous
One kit (Promega, Madison, WI) according to the instructions of the
manufacturer. Formazan content was determined by measuring the
absorbance at 490 nm on an Infinite M200 microplate reader (Tecan Group
Ltd., Switzerland). Assay data were analyzed via nonlinear regression analysis
(GraphPad Software, Inc.) and best fit values for growth inhibition was
compared to published data for the experimental controls (SAHA or
wortmannin) when possible (10-17).

G. Analysis of histone and tubulin modification
Approximately 1 x106 logarithmic-phase Jurkat and HuT-78 cells were
treated with either a tropolone or SAHA for the applicable treatment period in
6-well culture plates (Corning Inc.). Control wells contained no HDACi. After
pertinent exposure, cells were harvested using applicable methods described
in reference 9. Harvested cells were chilled on ice for 10 min, washed with
phosphate-buffered saline (PBS) and fixed with 4 % (w/v) paraformaldehyde
(PFA) for 20 min. Fixed cells were resuspended in 5 % BSA/PBS and stored
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overnight at 4oC. Cells were permeabilized with PBS plus 0.5 % (v/v) Triton-X100, washed and blocked with 10 % normal goat serum.
Cells were then incubated with either H3K9Ac, H3K23Ac, H4K12Ac or
Ac-α-Tub-K40 using primary antibodies purchased from Cell Signaling
Technology ( Beverly, MA) at a 1:100 dilution in 5 % BSA/PBS and a
fluorescein isothiocyanate (FITC) conjugated secondary antibody
(Millipore,Billerica, MA) at a 1:1000 dilution in 5 % BSA/PBS. Flow cytometric
analysis has been shown to be a reliable method for evaluating epigenetic
alterations including histone acetylation (18-20). Hence, following staining,
cells were evaluated for fluorescence in-house at the at the UConn Flow
Cytometry and Confocal Microscopy (FCCM) Facility using the Becton
Dickinson (BD) FACSCalibur Flow Cytometer (San Jose, CA). Values for the
geometric mean fluorescence intensities (GMFI), equivalent to the median cell
population response, were obtained via analysis on the FlowJo Workstation
(Treestar Inc., Ashland OR; 21-23).

H. Cell cycle Analyses
Approximately 1 x 106 logarithmic-phase HCT116, BXPC3, Jurkat and
HuT-78 cells were treated with either a tropolone or SAHA for the relevant time
period in 6-well culture plates (Corning Inc.). Control wells contained no
HDACi. After pertinent exposure, cells were harvested using applicable
methods described in reference 9. Harvested cells were washed with cold
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phosphate-buffered saline (PBS). Cells were fixed with ice-cold 70 % ethanol,
incubated at 4oC for several hours and incubated overnight at -20oC. Fixed
cells were stained with 50 μg/mL of propidium iodide (Life Technologies) and
200 μg/mL of DNA-free RNAse A (Sigma Aldrich) and incubated in the dark for
several minutes (24-26). Following staining, cells were analyzed for the
distribution of DNA content in-house at the UConn FCCM Facility using the BD
FACSCalibur Flow Cytometer. Percentages of cell populations in each cell
cycle phase were calculated based on DNA content histograms with the aid of
the FlowJo Workstation. Assay results were compared to published reports on
cell cycle analysis for the experimental control, SAHA when possible (27-29).

I. Evaluation of specific gene expression
Approximately 1 x 106 logarithmic-phase Jurkat and/or HuT-78 cells
were treated with either a tropolone or vorinostat for either 12h or 24h in 6-well
culture plates (Corning Inc.). Control wells contained no HDACi. After pertinent
exposure, cells were harvested using applicable methods described in
reference 9. Harvested cells were chilled on ice for 10 min, washed with PBS
and fixed with 4 % (w/v) paraformaldehyde (PFA) for 20 min. Fixed cells were
resuspended in 5 % BSA/PBS and stored overnight at 4oC. Cells were
permeabilized with PBS plus 0.5 % (v/v) Triton-X-100, washed and blocked
with 10 % normal goat serum. Cells were then incubated with either perforin,
p15, p21, p27, or p53 using primary antibodies purchased from Cell Signaling
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Technology ( Beverly, MA) at a 1:100 dilution in 5 % BSA/PBS and a FITC
conjugated secondary antibody (Millipore,Billerica, MA) at a 1:1000 dilution in
5 % BSA/PBS. Following staining, cells were evaluated for fluorescence inhouse at the UConn FCCM Facility using a BD FACSCalibur flow cytometer
(21-23). Values for the geometric mean fluorescence intensities (GMFI),
equivalent to the median cell population, were obtained via analysis on the
FlowJo Workstation. Assay results were compared to published data when
possible (30-32).

J. Reverse-transcription PCR and quantitative real-time PCR analysis
A quantitative real-time polymerase chain reaction (qRT-PCR) analysis
was further used to validate p21 expression in Jurkat cells after a 24h
treatment with compound 2 and SAHA (33-36). Briefly, 5 x106 treated Jurkat
cells were harvested and washed with ice-cold PBS. RNA was isolated using
the Trizol reagent (Life Technologies) according to the instructions of the
manufacturer. Two micrograms of extracted RNA was subjected to reverse
transcription using the Applied Biosystems High Capacity cDNA kit according
to the manufacturer’s instructions. Following the PCR reaction, Taqman gene
expression systems (Applied Biosystems) for p21, HDAC2, vitamin D receptor
(VDR) and beta-actin were prepared and added in triplicate to optical 96-well
micro-titer plates (Applied Bioystems) containing one microliter of cDNA
according to the instructions of the manufacturer. All cDNA samples were
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synthesized in parallel and qRT-PCR was performed in triplicate on an Applied
Biosystem’s 7500 Fast Real-Time PCR system and software. Relative mRNA
expression for p21, VDR and HDAC2 were normalized to β-actin levels.
K. Evaluation of induction of apoptosis
Approximately 1 x106 logarithmic-phase Jurkat and HuT-78 cells were
treated with either a tropolone or SAHA for the pertinent time period in 6-well
culture plates (Corning Inc.). Approximately 5 x105 MCF-7 cells were treated
alone with either compound 2 or SAHA and/or in combination with (Z)-4Hydroxytamoxifen, the active metabolite of the antiestrogen tamoxifen in 6-well
culture plates (Corning Inc.) for 48h (37). Control wells contained no HDACi or
4-OH-tamoxifen. After exposure, cells were harvested using relevant
technique for each cell line (9). Harvested cells were washed with cold PBS,
and resuspended in Annexin-binding buffer [10 mM HEPES, 140 mM NaCl
and 2.5 mM CaCl2, pH 7.4]. Cells were stained with Annexin V conjugated with
a fluorescein molecule (Life Technologies) according to the instructions of the
manufacturer. Propidium iodide (PI; Life Technologies) was also added to the
cell suspension as a dead cell indicator. Following staining, cells were
analyzed for fluorescence in-house at the UConn FCCM Facility using a BD
FACSCalibur flow cytometer (24, 33, 38, 39). Populations of cells were sorted
with the aid of the FlowJo Workstation as follows: live cells [Annexin V (-), PI ()]; early apoptotic cells [Annexin V (+), PI (-)]; late apoptotic/necrotic cells
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[Annexin V (+), PI (+)]. Assay data were compared to published reports for the
experimental control, SAHA when possible (37, 40).

L. Evaluation of Caspase-8 activation
Approximately 1 x106 logarithmic phase Jurkat cells were treated with
either a tropolone or SAHA for 24h in 6-well culture plates (Corning Inc.).
Untreated wells served as negative controls for the assay. Cells were
harvested, washed with cold PBS and evaluated for caspase-8 activation via
FACS analysis with the aid of a fluorescent inhibitor of caspases (FLICA)
reagent (Vybrant FAM Caspase-8 assay kit, Life Technologies) according to
the instructions of the manufacturer (41). Assay data were collected at the
UConn FCCM using a FACSCalibur and data were analyzed on the FlowJo
Workstation.

M. Caspase-3/7 Analysis
Approximately 2 x104 logarithmic phase Jurkat cells were treated in
triplicate in 96-well culture plates with 10 μM of either tropolone or SAHA for
the applicable time period. Untreated wells served as experimental controls for
the assay. Following treatment, Caspase-3/7 activity was measured in Jurkat
cells using the luminescent Caspase-Glo 3/7 assay (Promega) according to
the manufacturer’s instructions (42-44). The luminescent signal generated
from the assay is correlated with caspase-3/7 activity and luminescence was
measured using a Veritas Microplate reader (Promega).
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N. PI3K enzyme activity assays
Key enzyme kinetic parameters (KM, Vmax, kcat, kcat /KM ) for the class Ia
PI3K enzyme, p110α, was determined using a commercially available human
recombinant enzyme (Sigma Aldrich) phosphatidyl inositol substrate (PI;
Sigma Aldrich), and the luminescent ADP-Glo Kinase assay kit (Promega).
Assay was performed in a black, flat bottom 96-well plate essentially as
described by the manufacturer’s protocol. Briefly, twenty five microliters of a
reaction mixture containing 50 ng of PI3K enzyme, 25-400 μM of PI and 10 μM
ATP (provided in the assay kit) was incubated for 1 hour at 37oC. The reaction
mixture was cooled and incubated sequentially at room temperature with the
ADP-Glo and Kinase Detection reagents in order to simultaneously convert
ADP to ATP and allow the newly synthesized ATP to be measured using a
luciferase/luciferin reaction. The luminescent signal generated from the assay
is correlated with kinase activity and luminescence was measured using a
Veritas Microplate reader (Promega). Assay data were subjected to non-linear
regression analysis (GraphPad Software); kcat /KM values were calculated from
best fit values for KM and Vmax using methods described in reference 4.

O. PI3K enzyme inhibition assays
Enzyme inhibition assays were performed using a commercially
available human recombinant Class I PI3K enzyme (p110α/p85α, Sigma
Aldrich, St. Louis, MO), phosphatidyl inositol substrate (PI; Sigma Aldrich), and
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the luminescent ADP-Glo Kinase assay kit (Promega, Fitchburg, WI).
Wortmannin served as an experimental control. Assay was performed in
replicates in a black, flat bottom 96-well plate essentially as described by the
manufacturer’s protocol. Briefly, twenty five microliters of a reaction mixture
containing 0.5 nM to 25,000 nM concentrations of the compounds, 50 ng of
PI3K enzyme, 50 μM of PI and 10 μM ATP (provided in the assay kit) was
incubated for 1 hour at 37oC. The reaction mixture was cooled and incubated
sequentially at room temperature with the ADP-Glo and Kinase Detection
reagents in order to simultaneously convert ADP to ATP and allow the newly
synthesized ATP to be measured using a luciferase/luciferin reaction. The
luminescent signal generated from the assay is correlated with kinase activity
and luminescence was measured using a Veritas Microplate reader
(Promega). Assay data were subjected to non-linear regression analysis
(GraphPad Software). Best fit values for IC50 values have been reported (16);
IC50 values were also converted to Ki values using methods described in
reference 6.
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Appendix
1. Standard error values for elucidation of KM and Vmax values (Chapter 3, Table 2)

Class I HDAC

Class IIa HDAC

Class IIb
HDAC

Kinetic
Parameter

HDAC1

HDAC2

HDAC8

HDAC4

HDAC5

HDAC6

KM (μM)

7.97

7.07

6.61

17.35

72.88

4.91

Vmax (μM)

33.94

35.56

184.5

1130.00

242.4

340.60

2. Graphs for Enzyme Kinetics (Chapter 3)

HDAC1 Kinetics

Enzyme Activity

500
400
300
200
100
0
0

50

100

150

[Substrate]

239

200

250

HDAC2 Kinetics

Enzyme Activity

600

400

200

0
0

50

100

150

200

250

[Substrate]

HDAC8 Kinetics

Enzyme Activity

6000

4000

2000

0
0

100

200

300

[Substrate]

240

400

500

HDAC4 Kinetics

Enzyme Activity

5000
4000
3000
2000
1000
0
0

20

40

60

80

100

[Substrate]

HDAC5 Kinetics

Enzyme Activity

600

400

200

0
0

50

100

150

[Substrate]

241

200

250

HDAC6 Kinetics

Enzyme Activity

4000
3000
2000
1000
0
0

20

40

60

80

100

[Substrate]

3. Standard error values for HDAC2 inhibition (Chapter 3,
Figure 5a & 5b)
Single time-point analysis

Comprehensive analysis

1.40

1.57
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4. Standard error values for IC50 analysis of HDAC2 and
HDAC8 (Chapter 3, Table 3)
Compound

HDAC2

HDAC8
1.40

1.58

1.41

2.78

1.65

3.24

1.66

2.27

2.07

3.03

2.75

2.74

2.03

3.27

1.60

4.11

1.58

2.34

1.53

3.91

1.39

2.81

1.73

2.96

1.38

3.41

1.68

2.40

2.17

2.26

TSA
1
2
3
4
5
6
7
8
9
10
11
12
13
14
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5. Standard error values for elucidation of calculated
Ki and Alpha values for Compound 2 (Chapter 3,
Figure 6)
Ki
Alpha
0.52

6.46

6. Standard error values for determination of GI50 values for solid tumor cell lines
(Chapter 4, Table 1)
Compound HCT116
HT-29
BXPC-3 A549
U87
MCF-7
MCF-10A
SAHA

1.19

1.18

1.19

1.49

1.27

1.28

1.20

1

1.24

1.00

1.75

1.00

1.66

1.24

1.23

2

1.16

1.46

1.32

1.47

1.44

1.24

1.16

3

1.25

1.42

1.27

1.62

1.00

1.78

1.21

4

1.26

1.26

1.20

1.30

1.65

1.49

1.19

5

1.22

1.22

1.39

1.44

1.00

1.48

1.13

6

1.19

1.19

1.36

1.45

1.69

1.17

1.27

7

1.21

1.41

1.29

1.40

1.27

1.38

1.37

8

1.28

1.28

1.42

1.62

1.00

1.51

1.13

9

1.34

1.34

1.67

3.03

1.00

1.00

1.22

10

1.19

1.15

1.27

1.36

1.00

1.46

1.40

11

2.23

1.51

1.00

1.00

2.06

1.00

1.19

12

1.19

1.40

1.39

1.23

2.54

2.27

1.19

13

1.16

1.31

1.52

1.29

1.78

1.16

1.29

14

1.29

1.29

1.60

1.30

1.91

1.45

1.20
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7. Standard error values for determination of GI50 values for
Jurkat, HuT-78 and hDF cells (Chapter 4, Table 2).

Compound

Jurkat

HuT-78

hDF

SAHA

1.35

1.16

1.35

1

1.21

1.22

5.07

2

1.25

1.17

1.38

3

1.39

1.23

1.22

4

1.48

1.26

3.91

5

1.35

1.25

1.00

6

1.23

1.16

1.58

7

1.44

1.20

1.32

8

1.46

1.31

1.00

9

1.21

1.29

1.63

10

1.34

1.19

1.00

11

7.63

1.38

1.00

12

1.42

1.19

1.76

13

1.86

1.24

1.37

14

1.40

1.18

1.69
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8. Modulation of histone H4 antibodies in Jurkat cells after a 12h treatment
with HDACi (Chapter 5. Table 1). Note that histograms for the HDACi
treatments represent the untreated control (red) superimposed with the
HDACi treatment (blue) for comparative analysis.

a) Experimental/compensation controls [unlabeled cells (red); 2 o antibody
(green); untreated control (blue)].

b)

SAHA treatment

c)
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Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10
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h)

Compound 11

i)

k)

Compound 14

248

Compound 12

9. Comparative analysis of unlabeled cells (green), secondary (2o) antibody
treatment only (blue) and the untreated control (primary (1o) + 2o antibody;
red) for evaluation of H4K12Ac modulation in Jurkat cells treated with 10
µM HDACi for 12h (Chapter 5, Table 2).

Modulation of histone H4K12Ac antibodies in Jurkat cells after a 4h treatment
with HDACi (Chapter 5). Note: Untreated control for pertinent HDACi treatments
represented in red and HDACi represented in blue on the corresponding
histograms.

a)

Experimental/compensation controls [unlabeled cells (green); 2 o antibody
(blue); untreated control (red)].
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b)

10 µM SAHA

c)

25 µM Compound 2

d)

25 µM Compound 5

e)

25 µM Compound 7
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f)

25 µM Compound 9

g)

25 µM Compound 10

h)

25 µM Compound 11

i)

25 µM Compound 13
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j)

25 µM Compound 14

10. Modulation of histone H4K12Ac antibodies in Jurkat cells after a 12h
treatment with 25 µM tropolones (Chapter 5, Table 3). Note: Untreated
control for pertinent tropolone treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [unlabeled cells (red); 2 o antibody
(blue); untreated control (green)].
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b)

SAHA

c)

Compound 2

d)

Compound 5

e)

Compound 7
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f)

Compound 9

g)

Compound 10

h)

Compound 11

i)

Compound 13
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j)

Compound 14

11. Modulation of histone H3K9Ac antibodies in Jurkat cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 4). Note: Untreated control
for pertinent HDACi treatments represented in red and HDACi represented
in blue on the corresponding histograms.
a) Experimental/compensation controls [2o antibody (blue); untreated control
(red)].
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b)

SAHA

d)

Compound 5

c)

Compound 2

e)

256

Compound 7

f)

Compound 9

g)

Compound 10

h)

i)

Compound 13

Compound 11
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j)

Compound 14

12. Modulation of histone H3K23Ac antibodies in Jurkat cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 5). Note: Untreated
control for pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (green); 2o antibody
(blue); untreated control (red)].
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b)

SAHA

d)

Compound 5

c)

e)
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Compound 2

Compound 7

f)

Compound 10

g)

Compound 11

h)

Compound 13

i)

Compound 14
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13. Modulation of histone H4K12Ac antibodies in HuT-78 cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 6). Note: Untreated control
for pertinent HDACi treatments represented in red and HDACi represented
in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (red); 2 o antibody
(blue); untreated control (green)].

b)

SAHA

c)
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Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10
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h)

Compound 11

i)

j)

Compound 14
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Compound 13

14. Modulation of histone H3K9Ac antibodies in HuT-78 cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 6). Note: Untreated control
for pertinent HDACi treatments represented in red and HDACi represented
in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (green); 2 o antibody
(blue); untreated control (red)].

b)

SAHA

c)

264

Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10

265

h)

Compound 11

i)

j)

Compound 14

266

Compound 13

15. Modulation of histone H3K23Ac antibodies in HuT-78 cells after a 24h
treatment with 10 µM HDACi (Chapter 5, Table 7). Note: Untreated
control for pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (green); 2 o antibody
(blue); untreated control (red)].

b)

SAHA

c)

267

Compound 2

d)

Compound 3

f)
11

Compound 10

e)

Compound 7

g)

268

Compound

h)

Compound 12

i)

j)

Compound 14

269

Compound 13

16. Modulation of tubulin (Ac-α-tub-K40) antibodies in Jurkat cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 8). Note: Untreated
control for pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (green); 2 o antibody
(blue); untreated control (red)].

b)

SAHA

c)

270

Compound 2

d)

Compound 5

f)

Compound 9

e)

Compound 7

g)

271

Compound 10

h)

Compound 11

i)

j)

Compound 14

272

Compound 13

17. Modulation of tubulin (Ac-α-tub-K40) antibodies in HuT-78 cells after a 12h
treatment with 10 µM HDACi (Chapter 5, Table 8). Note: Untreated control
for pertinent HDACi treatments represented in red and HDACi represented
in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (green); 2 o antibody
(blue); untreated control (red)].

b)

SAHA

c)

273

Compound 2

d)

f)

Compound 7

e)

Compound 10

g)

274

Compound 9

Compound 11

h)

Compound 13

i)

275

Compound 14

18. Analysis of Cell Cycle Progression in HCT116 cells after a 24
treatment (Chapter 6, Table 1)
a.

Control

c.

10 µM Compound 2

b.

10 µM SAHA

d. 50 µM Compound 2

276

e.

10 µM Compound 3

g.

10 µM Compound 7

f.

50 µM Compound 3

h. 50 µM Compound 7

277

i.

10 µM Compound 12

j.

k.

10 µM Compound 13

l.

278

50 µM Compound 12

50 µM Compound 13

19. Analysis of Cell Cycle Progression in BXPC3 cells after a 12h
treatment (Chapter 6, Table 2)
a.

Control

c.

10 µM Compound 2

b. 10 µM SAHA

d.

279

10 µM Compound 3

e.

10 µM Compound 5

g.

10 µM Compound 9

f. 10 µM Compound 7

h. 10 µM Compound 10

280

i.

k.

10 µM Compound 11

j.

10 µM Compound 13

l. 10 µM Compound 14

281

10 µM Compound 12

20. Time Dependent Analysis of Cell Cycle Progression in Jurkat Cells
(Chapter 6, Tables 4 & 5)
24h
Control

c.

10 µM Compound 2

b.

d.

282

10 µM SAHA

10 µM Compound 7

e. 10 µM Compound 11

f.

10 µM Compound 13

36h
g.

Control

h.

283

10 µM SAHA

i.

10 µM Compound 2

j. 10 µM Compound 7

k. 10 µM Compound 11

l. 10 µM Compound 13

284

21. Analysis of Cell Cycle Progression in Jurkat cells after a 24h treatment
with 25 µM HDACi (Chapter 6, Table 6)
a.

Control

b.

25 µM Compound 2

c.

25 µM Compound 5

d.

25 µM Compound 7

285

e.

25 µM Compound 9

f.

25 µM Compound 10

g.

25 µM Compound 11

h.

25 µM Compound 13

286

i.

25 µM Compound 14

22. Time-dependent analysis of cell cycle progression in HuT-78 cells
(Chapter 6, Tables 7-9)
12h
a.

Control

b.

287

5 µM SAHA

c.

10 µM Compound 2

d.

10 µM Compound 7

e.

10 µM Compound 11

f.

10 µM Compound 13

288

24h
g.

i.

Control

h.

10 µM Compound 2

j.

289

5 µM SAHA

10 µM Compound 7

k.

10 µM Compound 11

l.

10 µM Compound 13

Control

n.

5 µM SAHA

36h
m.

290

o.

10 µM Compound 2

p.

q.

10 µM Compound 11

r.

291

10 µM Compound 7

10 µM Compound 13

23. Evaluation of p53 expression in Jurkat cells after a 12h treatment with
10 µM HDACi (Chapter 7, Table 1). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.
a)

Experimental/compensation controls [unlabeled cells (red); 2 o antibody
(blue); untreated control (green)].

b)

SAHA

c)

292

Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10

293

h)

Compound 11

i)

j)

Compound 14

294

Compound 13

24. Evaluation of p15 expression in Jurkat cells after a 24h treatment with
10 µM HDACi (Chapter 7, Table 2). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue) and untreated
control (red)].

b)

SAHA

c)

295

Compound 2

d)

Compound 5

f)

Compound 9

e)

g)

296

Compound 7

Compound 10

h)

Compound 11

i)

j)

Compound 14

297

Compound 13

25. Evaluation of p15 expression in Jurkat cells after a 24h treatment with
50 µM HDACi (Chapter 7, Table 2). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue) and untreated
control (red)].

b)

Compound 2

c)

298

Compound 3

d)

Compound 7

e)

Compound 10

f)

Compound 11

g)

Compound 12

299

h)

Compound 13

i)

Compound 14

26. Evaluation of p15 expression in HuT-78 cells after a 24h treatment with
10 µM HDACi (Chapter 7, Table 2). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue) and untreated
control (red)].
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b)

SAHA

c)

Compound 2

d)

Compound 3

e)

Compound 5

301

f)

Compound 7

g)

Compound 9

h)

Compound 10

i)

Compound 12

302

j)

Compound 13

k)

Compound 14

27. Evaluation of p15 expression in HuT-78 cells after a 24h treatment with
50 µM HDACi (Chapter 7, Table 2). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue) and untreated
control (red)].

303

b)

Compound 2

d)

Compound 7

c)

e)

304

Compound 3

Compound 10

f)

Compound 11

g)

Compound 12

h)

Compound 13

i)

Compound 14

305

28. Evaluation of p27 expression in Jurkat cells after a 24h treatment with
HDACi (Chapter 7, Table 3). Note: Untreated control for pertinent
HDACi treatments represented in red and HDACi represented in blue
on the corresponding histograms.
a)

Experimental/compensation controls [Unlabeled cells (red); 2 o antibody
(blue) and untreated control (green)].

b)

SAHA

c)

306

Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10

307

h)

Compound 11

i)

j)

Compound 14

308

Compound 13

29. Evaluation of p27 expression in Jurkat cells after a 24h treatment with
HDACi (Chapter 7, Table 4). Note: Untreated control for pertinent
HDACi treatments represented in red and HDACi represented in blue
on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue) and untreated
control (red)].

b)

10 µM SAHA

c)

309

10 µM Compound 2

d)

50 µM Compound 2

e)

e)

10 µM Compound 7

310

10 µM Compound 7

30. Evaluation of p27 expression in HuT-78 cells after a 12h treatment with
10 µM HDACi (Chapter 7, Table 4). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.
a)
Experimental/compensation controls [2o antibody (blue); untreated control
(red)]

b)

Compound 2

c)

311

Compound 5

d)

Compound 7

e)

Compound 9

f)

Compound 10

g)

Compound 11

312

h)

Compound 13

i)

Compound 14

31. Evaluation of p21 expression in Jurkat cells after a 12h treatment with
10 µM HDACi (Chapter 7, Table 5). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [unlabeled cells (red); 2o antibody
(blue); untreated control (green)].

313

b)

SAHA

c)

Compound 2

d)

Compound 5

e)

Compound 7

314

f)

Compound 9

g)

Compound 10

h)

Compound 11

i)

Compound 13
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j)

Compound 14

32. Comparative analysis of secondary (2o) antibody treatment only (blue)
and the untreated control (primary (1o) + 2o antibody; red) for
evaluation of p21 expression in Jurkat cells after a 24h treatment with
10 µM HDACi (Chapter 7, Table 6).

316

33. Evaluation of p21 expression in Jurkat cells after a 24h treatment with
50 µM HDACi (Chapter 7, Table 6). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [2o antibody (blue); untreated control
(red)].

b)

Compound 2

c)

317

Compound 3

d)

e)

Compound 7

Compound 10

f)

318

Compound11

g)

h)

Compound 12

Compound 13

i)

319

Compound 14

34. Evaluation of p21 expression in HuT-78 cells after a 24h treatment with
10 µM HDACi (Chapter 7, Table 6). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [ 2o antibody (blue) and untreated
control (red)].

b)

SAHA

c)

320

Compound 2

d)

Compound 5

e)

Compound 7

f)

Compound 9

g)

Compound 10

321

h)

Compound 11

i)

j)

Compound 14

322

Compound 13

35. Evaluation of p21 expression in HuT-78 cells after a 24h treatment with
50 µM HDACi (Chapter 7, Table 6). Note: Untreated control for
pertinent HDACi treatments represented in red and HDACi
represented in blue on the corresponding histograms.

a)

Experimental/compensation controls [ 2o antibody (blue) and untreated
control (red)].

b)

Compound 2

c)

323

Compound 3

d)

Compound 7

e)

Compound 10

f)

Compound 11

g)

Compound 12

324

h)

Compound 13

i)

Compound 14

36. Elucidation of standard error values for gene expression
analyses (Chapter 7, Table 7).
HDAC2

p21

VDR

Compound 2

0.16

0.01

0.04

SAHA

0.11

36.74

8.59

325

37. Time-dependent analysis of the induction of apoptosis in Jurkat cells
(Chapter 8, Table 2): y axis represents PI response whereas x axis
represents Annexin V (AV) response. Quadrant 1 (bottom left)
represents intact (live) cells (AV-, PI-); Quadrant 2 (bottom right)
represents early apoptotic cells (AV+, PI-); Quadrant 3 (top right)
represents late apoptotic/necrotic cells ((AV+, PI+).
6h
a)

Control

b)

c)

10 µM Compound 2

326

10 µM SAHA

12h
a)

Control

b)

c)

10 µM Compound 2

327

10 µM SAHA

24h
a)

Control

b)

c)

10 µM Compound 2

328

10 µM SAHA

48h
a)

Control

b)

c)

10 µM Compound 2

329

10 µM SAHA

38. Time-dependent analysis of the induction of apoptosis in HuT-78 cells
(Chapter 8, Table 3): y axis represents PI response whereas x axis
represents Annexin V (AV) response. Quadrant 1 (bottom left)
represents intact (live) cells (AV-, PI-); Quadrant 2 (bottom right)
represents early apoptotic cells (AV+, PI-); Quadrant 3 (top right)
represents late apoptotic/necrotic cells ((AV+, PI+).
12h
a)

Control

c)

10 µM Compound 2

b)

10 µM SAHA

d)

330

10 µM Compound 7

e)

Compound 10

f)

Compound 11

b)

10 µM SAHA

20h
a)

Control
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c)

10 µM Compound 2

d)

e) 10 µM Compound 10

f)

332

10 µM Compound 7

10 µM Compound 11

39. Standard deviation values for Caspase-3/7 analysis in Jurkat cells
(Chapter 8, Tables 5 & 6)
Treatment

6h

12h

24h

48h

Control
10002.74

7003.63

31846.96

4710.453

7939.778

8869.66

20509.97

10357.53

11860.49

6312.14

5292.832

7390.019

21813.73

10670.77

8117.586

6650.594

SAHA

Compound 2

Compound 7
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a)

40. Comparative analysis of unlabeled cells (green), secondary (2o)
antibody treatment only (blue) and the untreated control (primary (1 o) +
2o antibody; red) for evaluation of perforin differentiation in Jurkat cells
(Chapter 8, Table 4).
6h analysis
b)
24h analysis

c)

48h analysis
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41. Standard error values for elucidation of key enzyme parameters
for the class I PI3K enzyme, p110α and the PI substrate
(Chapter 9, Table 1).

KM (μM)
p110α

Vmax (μM)

1.93

90.94
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